Tirzepatide Clinical Protocol

Purpose. This is the Module 5 (Weight Loss & Metabolic) clinical protocol for tirzepatide (Eli Lilly; FDA-approved for marketing claims as Mounjaro for type 2 diabetes 2022, Zepbound for chronic weight management 2023, and Zepbound OSA for moderate-to-severe obstructive sleep apnea with obesity December 2024), produced under the Protocol Template v1.0 (post-patch state at commit 20e66bd; §10 verbatim-anchor aligned). The protocol’s evidence base is the v1.0-final tirzepatide canonical at /Peptides/Tirzepatide.md (2026-05-12) plus the Bibliography at /Process/Tirzepatide/. The structural authority is the Protocol Template; the content authority is the canonical and its verified primary sources.

FDA-approved for marketing claims — load-bearing precision (Editorial Framework §1.2.1; Pattern AA.marketing-claims). The phrase “FDA-approved” throughout this protocol is shorthand for “FDA-approved for marketing claims for [indication X].” FDA approval is indication-specific, not drug-specific; off-label use of an FDA-approved-for-marketing-claims drug remains use of an FDA-approved drug. The protocol uses the convention “FDA-approved for marketing claims for [X]; off-label for [Y]” wherever both registers apply.

Compound-class framing — tirzepatide is a peptide, not a small molecule. Tirzepatide is a 39-amino-acid synthetic peptide engineered as a long-acting dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor (Coskun et al 2018 Mol Metab PMID 30473097). Pattern N.1 enforcement at file-system placement: this protocol lives at /Protocols/ under the peptides folder structure, not at /Small-Molecules/. The structural Module 5 small-molecule path (Orforglipron, Aleniglipron) belongs to non-peptide oral GLP-1R agonists, not to tirzepatide.

Compound-class framing — tirzepatide is a dual-receptor coagonist, not a single-receptor agonist. The section architecture below reflects dual GIP/GLP-1 receptor pharmacology throughout: §1.5 indication scope frames the dual mechanism; §3.7 organ-baseline panels reflect GIP-axis-specific considerations; §6 AE-class management algorithms reflect dual-mechanism AE profile (including the class-differentiated NAION finding at §6.5); §10.5 comparator conversation carries multi-dimensional fact-based comparison with semaglutide including ophthalmologic class-differentiation precision per Pattern AA / Pattern Z anchor 4. The protocol’s structural and content decisions are mechanism-precision-driven, not single-receptor-template-borrowed.

Tirzepatide-specific calibration notes (load-bearing for the production agent and the verification gate).

Dual GIP/GLP-1 mechanism — every receptor-pharmacology reference in this protocol is dual-receptor framed. Single-receptor framing is a Pattern V direction-of-effect drift that would misrepresent the molecule’s mechanism class. The biased-affinity profile (Coskun 2018 PMID 30473097: GIPR at native-GIP-like affinity; GLP-1R at ~5-fold lower affinity than native GLP-1) is the load-bearing pharmacology fact.
NAION class-differentiation precision — Lawrenson 2025 PMID 40383360 (Lakhani M et al Am J Ophthalmol, 180-country FAERS + WHO VigiBase pharmacovigilance) documents ION (with NAION as the primary clinical subtype) signal-presence for semaglutide and signal-absence for tirzepatide at the same analytical threshold. Pattern AA enforcement: this is a class-differentiation finding, not a class-wide finding. §3.7 ophthalmology pre-screen and §6.5 AE class and §10.5 comparator conversation each carry the precision: tirzepatide signal absent at the same threshold as semaglutide’s significant signal; post-approval exposure-window asymmetry caveat (semaglutide ~82 months vs tirzepatide ~28 months at study cutoff September 2024) applies; absent-signal-at-threshold does not equal absent-signal-in-population; mechanism question is research-state-incomplete and hypothesis-generating only.
MASH and CV development pipeline — Pattern AA precision — tirzepatide MASH approval has NOT occurred as of 2026-05-13. SYNERGY-NASH Phase 2 (PMID 38856224) showed 62% MASH resolution at 15 mg vs 10% placebo; Phase 3 program is in development. SURMOUNT-MMO (NCT05556512) is Phase 3 ACTIVE_NOT_RECRUITING with primary completion 2027-10. Counseling beats and indication-scope language throughout this protocol read “in development” / “investigational” / “Phase 3 readout pending” — NOT “approved” or “FDA-approved-pending.” HFpEF + obesity (SUMMIT Phase 3 PMID 39555826 reported HR 0.62 for CV death or worsening HF events) is similarly not yet FDA-labeled; regulatory pathway in active discussion.
Compounding ecosystem — current regulatory state, not the semaglutide-shortage framing — tirzepatide compounding had a brief 503A/503B window during the 2022–2024 FDA-declared shortage; FDA removed tirzepatide from the shortage list in October 2024, effectively ending the broader 503A compounding pathway. 503B outsourcing facilities operate within a narrower scope post-shortage. FDA enforcement actions against 503A and 503B compounding of products that copy FDA-approved drugs in the absence of a shortage have continued; litigation between compounding pharmacy interests and FDA has continued into 2026. Pattern Z compounded-formulation counseling beats at §10.3 (Anchors 1 + 2) reflect this current regulatory state — narrower than the semaglutide compounding ecosystem at the equivalent point in protocol history, but still a real-world clinical option for a subset of patients. Salt-form differentiation (tirzepatide base vs tirzepatide sodium) is a tirzepatide-specific quality-criteria addition the semaglutide protocol does not carry.
Route — SC injection only as of 2026-05-13 — both approved formulations (Mounjaro for T2D, Zepbound for CWM and OSA with obesity) are subcutaneous weekly injection. There is no approved oral tirzepatide platform. Oral development is early-stage and would require either an absorption-enhancement formulation (analogous to SNAC for oral semaglutide) or a non-peptide small-molecule structure (analogous to orforglipron / aleniglipron). Counseling beats and comparator conversations at §10.5 carry this route precision — semaglutide has both SC and oral platforms (Rybelsus; oral Wegovy 25 mg approved 2025); tirzepatide does not.

Indication scope and patient phenotypes
Selection criteria (inclusion / exclusion / contraindications)
Pre-treatment workup
Initiation protocol
Maintenance protocol
Side-effect management
Plateau and non-response algorithm
Discontinuation and tapering
Combination rules
Patient counseling beats (Pattern Z calibration-anchor-compliant)
Source citations
Clinical decision tree

Appendices

A. Verification gate self-audit findings
B. Pattern discipline summary
C. Items deferred to Dr. Gross verification gate

Methodology cross-references

/Methodology/Protocol Template.md — structural authority; 12-section template; post-patch state 20e66bd
/Methodology/Synergy Editorial Framework.md — voice, framing discipline, length-by-evidence-density
/Methodology/Voice Profile - Dr. Jeff Gross MD.md — clinician-voice calibration
/Methodology/AC2-26 - System Observations.md — Pattern R / R.1 / R.2 / V / W / Z / AA / AB.1 / AB.2 / AB.4 / N.1
/Peptides/Tirzepatide.md — v1.0-final canonical reference (evidence source)
/Process/Tirzepatide/ — production artifacts: Bibliography, PSV iterations 1+2, Adversarial Reviews iterations 1+2, Dr. Gross Verification Review
/Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md — Pattern Z verbatim anchors (Anchors 1–5)
/obsidian-peptides/Peptides/Semaglutide.md — sibling protocol’s canonical source (Pattern Z anchor source; comparator framing reference at §10.5)
/obsidian-peptides/Protocols/Semaglutide Protocol.md — Wave 1 lead exemplar (parallel-production sibling for tirzepatide; Wave-1 comparator framing source)

1. Indication scope and patient phenotypes

1.1 Purpose

Define where tirzepatide applies — the indication scope — and which patient phenotypes within that scope are the protocol’s primary, secondary, and tertiary targets. Section 1 is the protocol’s applicability gate. The downstream sections (Section 2 selection criteria, Section 3 pre-treatment workup, Section 4 initiation, Section 5 maintenance, Section 6 AE management, Section 9 combination rules, Section 10 counseling beats) are each read through the indication scope established here.

Pattern R.1 enforcement at this section: open with what tirzepatide does and for whom, not with what it does not do, who it excludes, or what regulatory limits constrain it. Exclusions, contraindications, and regulatory framing live in Section 2 and Section 11 respectively. Section 1 leads with research-state content — the FDA-approved indications and their pivotal trial program evidence, plus the active development pipeline framed precisely per Pattern AA.

Pattern R.2 enforcement at this section: the indication scope is locked at the section-architecture-design step — before content generation. Tirzepatide has, as of 2026-05-13, three FDA-approved indications (T2D — Mounjaro May 2022; chronic weight management in adults — Zepbound November 2023; moderate-to-severe OSA with obesity — Zepbound December 2024) plus multiple active investigational extensions (HFpEF + obesity — SUMMIT Phase 3 reported, regulatory pathway in discussion; MASH F2/F3 — Phase 2 reported, Phase 3 in development; CV outcomes in obesity — SURMOUNT-MMO active, readout pending 2027-10; CKD subgroup within SURMOUNT-MMO; pediatric T2D — SURPASS-PEDS Phase 3 reported, regulatory pathway pending). The protocol does not drift indication scope mid-draft — every section below is read against this scope-lock.

1.2 Indication categories — applied to tirzepatide

Within the Module 5 indication taxonomy established by the Protocol Template §1.2, the indication categories tirzepatide populates:

Type 2 diabetes mellitus (T2D) — glycemic control. FDA-approved indication via Mounjaro (May 13, 2022). Pivotal program: SURPASS-1 through SURPASS-6 plus SURPASS J-mono, SURPASS-AP-Combo, and SURPASS-PEDS (pediatric). Endpoint: HbA1c reduction.
Chronic weight management (CWM) — non-diabetic obesity or overweight with weight-related comorbidity. FDA-approved indication via Zepbound (November 8, 2023). Pivotal program: SURMOUNT-1 through SURMOUNT-5. Endpoint: percent weight loss from baseline.
Moderate-to-severe obstructive sleep apnea (OSA) with obesity. FDA-approved indication via Zepbound (December 20, 2024) — the first FDA approval of a pharmacological agent for OSA with obesity. Pivotal program: SURMOUNT-OSA dual-trial design (PMID 38912654). Endpoint: AHI reduction.
Heart failure with preserved ejection fraction (HFpEF) — obesity-related. Investigational extension; Phase 3 SUMMIT (PMID 39555826) reported HR 0.62 for CV death or worsening HF events. Regulatory pathway in active discussion; not yet FDA-labeled as of 2026-05-13.
Metabolic dysfunction-associated steatohepatitis (MASH). Investigational extension; Phase 2 SYNERGY-NASH (PMID 38856224) reported 62% MASH resolution at 15 mg vs 10% placebo. Phase 3 program in development; FDA submission anticipated post-Phase 3 completion. Not yet FDA-labeled.
Cardiovascular risk reduction in obesity. Investigational extension; SURMOUNT-MMO (NCT05556512) Phase 3 ACTIVE_NOT_RECRUITING with primary completion 2027-10. Readout pending; not yet FDA-labeled.
Chronic kidney disease (CKD) — subgroup analyses. Investigational extension within SURMOUNT-MMO (kidney composite as secondary endpoint, sometimes referred to as SURMOUNT-CKD as a sub-protocol). Class-context anchor for the kidney-protective hypothesis is semaglutide FLOW (PMID 38785209). Tirzepatide-specific CKD evidence pending SURMOUNT-MMO readout.
Pediatric T2D (ages 10–17). SURPASS-PEDS (Hannon et al 2025 Lancet PMID 40975112; n=99; HbA1c −2.23% vs +0.05% placebo at week 30) supports the FDA pediatric T2D indication pathway. Pediatric CWM Phase 3 program is under development; not yet published. Adolescent T2D indication pathway pending as of 2026-05-13.

Pattern AA enforcement at this section: every indication is labeled precisely as “FDA-approved” (with the specific brand and approval date) or “investigational extension” (with the trial phase, readout status, and any regulatory-pathway language verified against the canonical’s Section 10 regulatory status content). The protocol does not use “approved-pending,” “FDA-approval-pending,” or “emerging” / “next-generation” promotional characterization. The three approved indications are labeled with their specific Mounjaro / Zepbound brand and the indication-specific FDA label date; the investigational extensions are labeled with Phase 2 / Phase 3 status, trial readout disposition, and regulatory pathway state.

1.3 Phenotype-targeting taxonomy applied to tirzepatide

Within each tirzepatide indication, the phenotype-targeting refines selection. The dimensions per Protocol Template §1.3 are populated for tirzepatide as follows:

Metabolic phenotype. Insulin-resistant phenotypes (the dominant SURPASS / SURMOUNT enrollment) are the primary phenotype. The dual-incretin mechanism — additive β-cell glucose-dependent insulin secretion via parallel GLP-1R + GIPR engagement on pancreatic β-cells (Coskun 2018 PMID 30473097; mechanism for SURPASS-2 HbA1c superiority over semaglutide 1 mg at PMID 34170647) — produces robust glycemic response across the IR-dominant T2D phenotype. Beta-cell-failure-advanced phenotypes (long-duration T2D with attenuated endogenous insulin reserve) may show attenuated response despite the dual-mechanism augmentation; clinician judgment with C-peptide and diabetes duration as anchors (§3.3 diabetes-specific panel).
Adiposity distribution. Visceral-adiposity-dominant phenotype (waist circumference ≥102 cm men / ≥88 cm women, with hepatic steatosis frequently co-present) is heavily represented in the SURMOUNT enrollment. SURMOUNT-1 body composition sub-analysis (PMID 35658024) — proportional lean-fat mass loss similar to historical caloric-restriction-only data. SURMOUNT-5 (PMID 40353578) head-to-head waist circumference reduction: −18.4 cm tirzepatide vs −13.0 cm semaglutide — favoring tirzepatide.
Appetite phenotype. Hyperphagia-dominant and slow-satiety-dominant phenotypes are represented across SURMOUNT enrollment. The mechanism (Section 2.3 of the canonical) frames the dual-incretin central appetite-suppression contribution: GIPR engagement adds to GLP-1R-mediated satiety via distinct hypothalamic and brainstem populations (mechanistic hypothesis with partial preclinical support; not yet established as independent clinical claim per Pattern AA discipline). Hedonic-eating-dominant phenotype (reward-pathway-driven) is supported by mechanism rationale across GLP-1 RA + dual-incretin class; tirzepatide-specific Phase 3 data on hedonic-eating sub-phenotype is sparse and clinician-judgment is appropriate.
Energy-expenditure phenotype. Adaptive-thermogenesis-prone phenotype (post-prior-weight-loss with regained weight; the typical CWM-enrollment pattern) is represented across SURMOUNT-1, SURMOUNT-4 (PMID 38078870 randomized withdrawal), and SURMOUNT-3 (intensive lifestyle bridge). Low-REE-for-mass phenotype may benefit from REE measurement at baseline (§3.8 body composition baseline) if practice has indirect calorimetry capability.
Comorbidity load. Tirzepatide’s polycondition phenotype fit is broad — the molecule has indication-anchoring support across T2D + obesity (SURMOUNT-2 PMID 37385275), obesity + HFpEF (SUMMIT), obesity + OSA (SURMOUNT-OSA), and obesity-only (SURMOUNT-1, SURMOUNT-5). T2D + ASCVD-only is the indication-anchor gap as of 2026-05-13 — SURMOUNT-MMO addresses the obesity + CV-risk population but readout is pending. T2D + CKD is similarly pending via the SURMOUNT-CKD sub-protocol within SURMOUNT-MMO. Polycondition phenotypes (T2D + obesity + ASCVD + CKD) are clinical-judgment-supported by class-level mechanism plus tirzepatide’s approved-and-investigational indication coverage; the protocol does not generalize tirzepatide effect from one indication to another (Pattern V direction-of-effect discipline).
Pharmacologic history. Prior GLP-1 RA exposure phenotypes: response-attenuation on semaglutide is a Section 7 non-response algorithm trigger and the typical SURPASS-2 / SURMOUNT-5 / SURPASS-J-mono head-to-head context — tirzepatide’s higher effect-size is the Pattern V direction-of-effect-anchored transition rationale. Prior bariatric surgery with weight regain phenotype: limited dedicated trial evidence; clinician judgment within indication.
Life-stage modifier. Reproductive-age female phenotype: §8.4 pre-conception washout arithmetic for tirzepatide applies (half-life ~5 days; ~5 half-lives = ~25 days for substantial clearance; ~35 days for complete clearance; label-recommended discontinuation at least 2 months before planned pregnancy). Older-adult (≥65) phenotype: SURMOUNT and SURPASS enrolled older adults but sarcopenia-during-weight-loss risk is the lean-mass concern (§3.8 body composition baseline; §9.3 cross-Module lean-mass combinations). Adolescent T2D (ages 10–17): SURPASS-PEDS-supported; FDA pediatric T2D indication pathway pending. Adolescent obesity: tirzepatide pediatric obesity Phase 3 is under development; not yet trial-published as of 2026-05-13.

A phenotype is primary target when the indication-defining Phase 3 trial(s) enrolled that phenotype; secondary target when supporting evidence (Phase 2, observational, subgroup) is positive but the phenotype is outside the registration label; tertiary / off-target when phenotypes were excluded from trials, the signal direction is uncertain, or evidence is sparse (Pattern V direction-of-effect applies). Section 2 (selection criteria) operationalizes the phenotype-target distinction into screening criteria.

1.4 Cross-reference to case construction

Every tirzepatide clinical case presented in Sections 4, 5, 6, 7, 8 examples and in any standalone case files at /Conditions/ is constructed against the phenotype taxonomy in §1.3 above, using M5.10 Case Study — Patient Questions case-construction conventions. A case that presents a phenotype without anchoring that phenotype to a §1.3 dimension is a Pattern R.2 design-step failure — the case is generating phenotype categories rather than instantiating them. The §1.3 dimensions are the structural lock against drift.

1.5 Worked clinical scope — tirzepatide indication detail

Tirzepatide’s indication scope as of 2026-05-13 — five FDA-approved indications across two formulations (Mounjaro for T2D; Zepbound for CWM and OSA-with-obesity), counting the CWM and OSA-with-obesity indications as separate FDA approvals on the same Zepbound formulation — plus multiple investigational extensions. The protocol’s Section 1 documents the scope with primary-source anchoring.

Indication 1 — T2D glycemic control (FDA-approved May 13, 2022, Mounjaro). Label: as adjunct to diet and exercise to improve glycemic control in adults with T2D. Pivotal program: SURPASS-1 through SURPASS-6 plus SURPASS J-mono, SURPASS-AP-Combo. Primary endpoint: HbA1c change from baseline. Effect-size anchor: SURPASS-2 head-to-head vs semaglutide 1 mg in T2D inadequately controlled on metformin (Frias et al 2021 NEJM PMID 34170647; n=1,879; 40 weeks) demonstrated tirzepatide HbA1c reductions of −2.01% / −2.24% / −2.30% (5 / 10 / 15 mg) vs semaglutide 1 mg −1.86% — superior at all three tirzepatide doses. Weight reductions superior at all three doses. SURPASS-2 is the load-bearing head-to-head trial against semaglutide 1 mg in T2D; the obesity-dose head-to-head is SURMOUNT-5 (separate trial, see Indication 2). Phenotype primary targets: T2D adults with HbA1c above individualized target (typically 7.0–10.5% trial-enrollment range), metformin-treated or metformin-intolerant, BMI typically ≥27. Pattern AA precision: “FDA-approved for glycemic control in T2D” is the Mounjaro label claim; weight loss in T2D patients is a documented secondary endpoint across SURPASS, not a separate Mounjaro-formulation indication (the obesity-specific indication is on Zepbound — Indication 2).

Indication 2 — Chronic weight management in adults (FDA-approved November 8, 2023, Zepbound). Label: as adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with initial BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, T2D, OSA, CVD). Pivotal program: SURMOUNT-1 (Jastreboff et al 2022 NEJM PMID 35658024) through SURMOUNT-5 (Aronne et al 2025 NEJM PMID 40353578). Primary endpoint: percent change in body weight from baseline at week 72.

Effect-size anchors:

SURMOUNT-1 — non-diabetic obesity, n=2,539, randomized 1:1:1:1 to tirzepatide 5 / 10 / 15 mg / placebo. Two estimands reported per primary publication: treatment-regimen estimand (the primary registration ITT result) — −15.0% / −19.5% / −20.9% (5 / 10 / 15 mg) vs −3.1% placebo; efficacy estimand (per-protocol-style adherent-population sub-analysis) — −22.5% at 15 mg vs −2.4% placebo. The efficacy estimand is the figure most commonly cited in cross-trial weight-management comparisons; the treatment-regimen estimand is the primary registration result. 91% achieved ≥5% weight loss at 15 mg; 57% ≥20%; 36% ≥25%. Supported November 2023 Zepbound CWM approval.
SURMOUNT-2 — obesity + T2D, n=938 — −12.8% (10 mg) / −14.7% (15 mg) vs −3.2% placebo at 72 weeks (Garvey et al 2023 Lancet PMID 37385275). Lower weight-loss magnitude in T2D population consistent with the cross-program GLP-1 RA class pattern.
SURMOUNT-3 — intensive lifestyle bridge protocol; n=579 — 12-week intensive lifestyle lead-in (~6.9% weight loss) then randomization to tirzepatide max-tolerated dose vs placebo for 72 weeks. Additional weight loss −18.4% on tirzepatide vs +2.5% on placebo (treatment-policy from randomization). Total weight loss from baseline ~25%.
SURMOUNT-4 — randomized-withdrawal / maintenance design; participants completed 36-week tirzepatide titration (achieving ~−20.9%) then randomized to continue tirzepatide vs switch to placebo for 52 additional weeks (Aronne et al 2024 JAMA PMID 38078870). Continued tirzepatide: additional −5.5% weight loss; switched to placebo: +14% regain through week 88 — two-thirds of run-in weight loss regained on placebo switch. This is the load-bearing chronic-therapy anchor for the protocol (§5.4 dose-adjustment / §7.3 set-point reset framing / §8.5 post-discontinuation weight-regain framing / §10.7 discontinuation conversation).
SURMOUNT-5 — direct head-to-head vs semaglutide in obesity without T2D, n=751, max-tolerated-dose comparison at week 72 (Aronne et al 2025 NEJM PMID 40353578). Tirzepatide −20.2% vs semaglutide −13.7% (P<0.001) — ~6.5 percentage-point difference favoring tirzepatide. Waist circumference reduction also favored tirzepatide (−18.4 cm vs −13.0 cm). SURMOUNT-5 is the single load-bearing head-to-head trial against semaglutide at obesity doses. Cross-trial context: SURMOUNT-1 tirzepatide 15 mg achieved −22.5% (efficacy estimand); STEP UP semaglutide 7.2 mg (Wegovy HD, FDA-approved March 19, 2026, Wharton et al 2025 Lancet Diabetes Endocrinol PMID 40961952) achieved −18.7% — closes the gap with tirzepatide max-dose in cross-trial comparison but is not head-to-head. No head-to-head Wegovy 7.2 mg vs Zepbound 15 mg trial exists as of 2026-05-13.

Phenotype primary targets across the SURMOUNT program: non-diabetic obesity (SURMOUNT-1, SURMOUNT-5), obesity with T2D (SURMOUNT-2, with smaller effect size), intensive-lifestyle-bridge-eligible patients (SURMOUNT-3), maintenance-stable-on-target-dose patients (SURMOUNT-4). Pattern AA precision: the Zepbound CWM label is “adults with BMI ≥30, or BMI ≥27 with weight-related comorbidity”; the indication is not extended off-label to BMI <27 absent comorbidity in this protocol (Section 2 selection criteria carries the threshold).

Indication 3 — Moderate-to-severe OSA with obesity (FDA-approved December 20, 2024, Zepbound). Label: as adjunct to a reduced-calorie diet and increased physical activity for moderate-to-severe OSA in adults with obesity. First FDA approval of a pharmacological agent for OSA with obesity. Pivotal program: SURMOUNT-OSA dual-trial design — Trial 1 (CPAP-naive, n=469) and Trial 2 (CPAP-current, n=234) — in adults with moderate-to-severe OSA (AHI ≥15 events/hour) plus obesity (BMI ≥30) (Malhotra et al 2024 NEJM PMID 38912654). Primary endpoint: change in AHI from baseline. Effect-size anchors:

Trial 1 (CPAP-naive): AHI reduction −25.3 events/hour on tirzepatide vs −5.3 events/hour on placebo; mean baseline AHI ~50; ~50% of tirzepatide-treated patients achieved AHI <5 (clinically meaningful threshold). Mean weight reduction −18.1% on tirzepatide vs −1.3% placebo. ESS improved significantly.
Trial 2 (CPAP-current): AHI reduction −29.3 events/hour on tirzepatide vs −5.5 events/hour placebo. Mean weight reduction −20.1% vs −2.3% placebo. CPAP-discontinuation decision at end-of-study based on follow-up sleep study + clinical assessment.

Phenotype primary targets: moderate-to-severe OSA (AHI ≥15) plus obesity (BMI ≥30); secondary phenotype splits by CPAP-naive vs CPAP-current with somewhat different positioning (§4.5 OSA detail in canonical). Pattern AA precision: tirzepatide does not replace CPAP for all patients; the OSA indication is co-management with sleep medicine specialist, and patients with persistent OSA on tirzepatide should continue CPAP. The Section 10 counseling beat for OSA patients carries this co-management framing.

Investigational extension 1 — HFpEF + obesity (under regulatory discussion). SUMMIT (Packer et al 2025 NEJM PMID 39555826) — Phase 3 RCT in adults with HFpEF (LVEF ≥50%) plus obesity (BMI ≥30); tirzepatide max-tolerated dose (10 or 15 mg weekly) vs placebo; ≥52-week follow-up; composite primary endpoint CV death or worsening HF events. Primary result: HR 0.62 (favoring tirzepatide). KCCQ-CSS improvement substantial; 6-minute walk distance improvement; weight reduction consistent with SURMOUNT-1 magnitude. Class-context: SUMMIT HR 0.62 is in the same envelope as the semaglutide 4-trial pooled HF analysis (Kosiborod et al 2024 Lancet PMID 39222642; HR 0.69 for CV death or worsening HF across SELECT + FLOW + STEP-HFpEF + STEP-HFpEF DM, n=3,743). Regulatory pathway in active discussion as of 2026-05-13. Pattern AA: not yet FDA-labeled for HFpEF; counseling beats state “Phase 3 data supports the HFpEF + obesity indication; FDA label expansion not yet granted as of 2026-05-13.”

Investigational extension 2 — MASH F2/F3 (Phase 3 in development). SYNERGY-NASH Phase 2 (Loomba, Sanyal et al 2024 NEJM PMID 38856224) — Phase 2 RCT in adults with biopsy-proven MASH F2 or F3 fibrosis; n=190 randomized to tirzepatide 5 / 10 / 15 mg vs placebo; 52-week follow-up with paired liver biopsy. MASH resolution without worsening fibrosis: 44% / 56% / 62% (5 / 10 / 15 mg) vs 10% placebo — dose-responsive. Fibrosis improvement (≥1 stage) without worsening MASH: 55% / 51% / 51% vs 30% placebo — significant benefit; less dose-responsive pattern. Class-context: semaglutide ESSENCE Phase 3 (Sanyal, Newsome et al 2025 NEJM PMID 40305708) achieved comparable MASH resolution magnitudes (62.9%) and was FDA-approved August 15, 2025 for F2/F3 MASH. Tirzepatide Phase 3 program continuation under SYNERGY-NASH branding per ClinicalTrials.gov + Lilly investor materials; FDA submission anticipated post-Phase 3 completion. Pattern AA: tirzepatide not yet FDA-labeled for MASH as of 2026-05-13. Counseling beats state “Phase 2 data supports MASH resolution; Phase 3 program in development; FDA approval not yet granted as of 2026-05-13.”

Investigational extension 3 — Cardiovascular outcomes in obesity (SURMOUNT-MMO active). SURMOUNT-MMO (NCT05556512) — Phase 3 ACTIVE_NOT_RECRUITING; adults with obesity (BMI ≥27) with established CVD or CV risk factors; tirzepatide max-tolerated dose vs placebo; mortality-and-morbidity composite endpoint. Primary completion: 2027-10. Class-context: semaglutide SELECT (PMID 37952131; HR 0.80 for 3-point MACE in BMI ≥27 + established CVD without T2D) is the comparable class-level CVOT anchor. The empirical question of whether tirzepatide’s CV benefit matches, exceeds, or falls below the SELECT envelope is what SURMOUNT-MMO will answer. Pattern AA: readout pending; the protocol does NOT use “promising” / “emerging” / “next-generation” language for SURMOUNT-MMO. Counseling beats state “SURMOUNT-MMO is Phase 3 active with readout pending 2027-10; cardiovascular outcomes evidence for tirzepatide is pending.”

Investigational extension 4 — CKD (SURMOUNT-CKD sub-protocol within SURMOUNT-MMO). Kidney composite endpoint as a secondary outcome within NCT05556512. Class-context: semaglutide FLOW (PMID 38785209; T2D + CKD; primary kidney composite HR 0.76 at median 3.4 years) is the kidney-protective class anchor. Tirzepatide-specific CKD outcomes pending SURMOUNT-MMO completion.

Investigational extension 5 — Pediatric T2D (SURPASS-PEDS Phase 3 published; pathway pending). SURPASS-PEDS (Hannon et al 2025 Lancet PMID 40975112; Phase 3 in youth-onset T2D ages 10–17 inadequately controlled on metformin and/or basal insulin; n=99) — HbA1c −2.23% (tirzepatide) vs +0.05% (placebo) at week 30. Dose-responsive BMI reduction. Safety profile consistent with adult SURPASS program (predominantly GI). FDA pediatric T2D indication expansion pending. Pediatric CWM Phase 3 program under development; comparable trajectory to semaglutide STEP-TEENS pathway (PMID 36322838 — semaglutide adolescent CWM approval December 2022). Tirzepatide adolescent CWM Phase 3 not yet published as of 2026-05-13.

Phenotype primary targets across the indication portfolio. The phenotype-taxonomy dimensions from §1.3 that the tirzepatide trial program populated heavily: BMI ≥27 with comorbidity, BMI ≥30 non-diabetic obesity (SURMOUNT), T2D with HbA1c above target across the SURPASS spectrum, moderate-to-severe OSA with obesity (SURMOUNT-OSA), HFpEF with obesity (SUMMIT), MASH F2–F3 (SYNERGY-NASH Phase 2). Phenotypes under-represented in the tirzepatide trial program (and thus phenotype-tertiary in this protocol): F1 MASH (excluded from Phase 2), F4 cirrhosis (no dedicated trial; semaglutide directional finding toward placebo in F4 — Loomba 2023 PMID 36934740 — is a Pattern V flag for the class; tirzepatide F4 not yet trial-tested), CKD without T2D, eGFR <25, BMI <27 absent comorbidity (Zepbound label excludes), adolescent CWM (pediatric obesity Phase 3 not yet published), pregnancy (contraindicated). Each under-represented phenotype is documented in Section 2 (exclusion criteria) and Section 10 (counseling beats anchored to direct-quote-from-trial-population precision per Pattern Z calibration anchor 5 — off-label / extrapolation transparency).

Pattern V applied to §1.5. Effect-size anchors above are quoted at their trial-enrolled population. The protocol does not generalize SURMOUNT-1 −22.5% efficacy estimand to non-trial-enrolled phenotypes; the protocol does not generalize SURMOUNT-5 −20.2% from non-diabetic obesity to T2D + obesity (where SURMOUNT-2 effect-size of −14.7% at 15 mg is the indication-anchored figure); the protocol does not generalize SUMMIT HR 0.62 from HFpEF + obesity to non-obese HFpEF (where the indication-anchor is absent and Pattern V flags caution). Counseling beats at §10.5 (comparator conversation) and §10.6 (off-label / extrapolation conversation) carry the trial-population qualification.

Pattern AB.4 standing scan applied to §1.5. Every PMID and NCT above has been content-verified by abstract retrieval (PMID) or ClinicalTrials.gov entry retrieval (NCT) at the canonical’s PSV iteration 1 and 2 (canonical at /Peptides/Tirzepatide.md carries the verified-identifier table; Section 11 of this protocol carries the protocol-specific Bibliography subset with the same verification chain). The cascade-failure pattern (NCT05608252 mis-attributed as TRIUMPH-1 in the AC2-26 system-observations log) is the failure mode this verification prevents; the protocol’s Section 11 passes Pattern AB.4 verification.

2. Selection criteria (inclusion / exclusion / contraindications)

2.1 Purpose

Define who tirzepatide is for, who it is not for, and who it must not be given to. Section 2 operationalizes the Section 1 indication scope into actionable clinical screening criteria. The section is structured per Protocol Template §2 into three sub-blocks: inclusion criteria (positive — the patient phenotype the SURPASS / SURMOUNT / SURMOUNT-OSA / SUMMIT / SYNERGY-NASH / SURPASS-PEDS programs enrolled and the FDA labels permit), relative exclusion criteria (clinician-judgment — patients in whom benefit is uncertain or risk is elevated), and hard contraindications (absolute — patients in whom tirzepatide must not be used).

Pattern R.1 enforcement at this section: the section opens with inclusion criteria — who tirzepatide is for — before relative exclusions and contraindications. The §2.2 → §2.3 → §2.4 architectural ordering is the Pattern R.1 design-time enforcement; reversing the order (contraindications first) is a structural framing failure that steers clinicians away from tirzepatide before they have read the inclusion case.

Pattern AA enforcement at this section: every contraindication is anchored to its source — FDA boxed warning (class-level for GLP-1 RAs including tirzepatide), FDA labeled contraindication (specific to the Mounjaro / Zepbound product labels), or post-marketing signal under evaluation with primary-source citation. “Avoid in pancreatitis history” without a source distinction (boxed warning vs labeled contraindication vs precaution vs clinician-discretion) is Pattern AA-imprecise; the protocol does not produce that imprecision.

2.2 Inclusion criteria — the trial-enrolled and label-permitted phenotype

Inclusion criteria are stated per indication, anchored to the population the pivotal Phase 3 trials enrolled and the FDA label permits.

T2D glycemic control (Mounjaro):

Adults age ≥18 (adult T2D label).
HbA1c above individualized target — typically 7.0–10.5% trial-enrollment range across SURPASS; clinician judgment for individualized target per ADA / EASD framework.
Adjunct to diet and exercise; on metformin or metformin-intolerant per SURPASS-2 and SURPASS-3 enrollment context; alternative background regimens (insulin, sulfonylurea, SGLT-2) compatible per SURPASS-4 / SURPASS-5 / SURPASS-6 enrollment.
Trial-enrollment baseline labs within standard SURPASS criteria — typically eGFR ≥30 (lower bounds vary by trial); LFT within standard ranges.

Chronic weight management (Zepbound):

Adults age ≥18.
BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, T2D, OSA, CVD).
Adjunct to a reduced-calorie diet and increased physical activity.
Trial-enrollment baseline: SURMOUNT-1 enrolled non-diabetic obesity BMI ≥30 (or ≥27 with weight-related comorbidity, excluding T2D); SURMOUNT-2 enrolled obesity + T2D; SURMOUNT-3 enrolled with intensive-lifestyle-bridge lead-in; SURMOUNT-4 enrolled at the maintenance-stable phase; SURMOUNT-5 enrolled non-diabetic obesity at max-tolerated-dose comparison.

Moderate-to-severe OSA with obesity (Zepbound):

Adults age ≥18 (adult label).
Moderate-to-severe OSA (AHI ≥15 events/hour) confirmed by polysomnography or home sleep test.
Obesity (BMI ≥30).
CPAP-naive or CPAP-current phenotype per SURMOUNT-OSA Trial 1 / Trial 2 enrollment; clinical positioning differs per CPAP status (§4.5 OSA detail) but inclusion criterion is the AHI + BMI combination.
Sleep medicine specialist co-management baseline.

Investigational extension inclusion (off-label, primary-source-supported):

HFpEF + obesity per SUMMIT enrollment (LVEF ≥50%, BMI ≥30); off-label inclusion criterion is mechanism-rationale + Phase 3 trial-program-supported; clinician judgment within informed-consent framework per §10.6.
MASH F2/F3 per SYNERGY-NASH Phase 2 enrollment (biopsy-proven MASH with F2 or F3 fibrosis); off-label; hepatology co-management.
CV risk in obesity per SURMOUNT-MMO enrollment (BMI ≥27 with established CVD or CV risk factors); off-label pending readout 2027-10.
Pediatric T2D ages 10–17 per SURPASS-PEDS enrollment (youth-onset T2D inadequately controlled on metformin and/or basal insulin); off-label until pediatric T2D indication is FDA-approved.

2.3 Relative exclusion criteria — clinician-judgment phenotype

Relative exclusion criteria identify phenotypes where tirzepatide is not contraindicated but where benefit is uncertain, risk is elevated, or trial data are sparse. The protocol’s structure for each: state the criterion; state the underlying concern; state the magnitude of trial evidence (positive, negative, or absent); state the recommended clinician-judgment posture.

Severe gastroparesis or gastroparesis-predisposing comorbidity. Tirzepatide mechanism includes delayed gastric emptying (GLP-1R-dominant; §6.10 drug interaction context); in established gastroparesis, anatomical and symptomatic worsening risk is elevated. SURPASS / SURMOUNT trial programs typically excluded severe gastroparesis. Clinician judgment for mild-to-moderate gastroparesis with gastroenterology co-management; severe gastroparesis is functionally a hard contraindication per the Lilly product labels (§2.4 — verify against current label language).
Active or recent (within 12 months) acute pancreatitis. Distinct from prior single-episode pancreatitis history (a §2.4 relative-precaution); recent acute pancreatitis is a relative exclusion with clinician-judgment posture pending at least 12 months stable post-event. Wen 2025 SR (PMID 40988099; 62 RCTs n=66,232 including tirzepatide) — pooled RR 1.44 (95% CI 1.09–1.89, P=0.009) for acute pancreatitis across the GLP-1 RA + GLP-1/GIP coagonist class. Modest signal; absolute event rates <1–2%/year. Authors frame as “slightly increased risk, likely minimal.” Pattern V direction-of-effect: the pooled signal is present and modestly elevated; the protocol does not characterize Wen 2025 as null/protective.
Severe gastrointestinal disease (active IBD flare, severe GERD with esophagitis). Relative — GLP-1/GIP coagonist GI AE profile (§6.3 GI class management) may exacerbate. Gastroenterology co-management; clinician judgment within informed-consent.
Diabetic retinopathy with rapid-HbA1c-improvement risk (T2D indication). Baseline-status-stratified RWE finding per Buckley et al 2025 Diabetologia PMID 40637847 (retrospective matched cohort, n=6,869; 3,435 tirzepatide-exposed matched 1:1 with 3,434 tirzepatide-unexposed): overall multivariate analysis OR 2.15 (95% CI 1.24–3.74) for new-onset proliferative diabetic retinopathy on tirzepatide adjusted for established risk factors; authors qualitatively interpret signal as “particularly evident” in R1M1 (mild non-proliferative DR + maculopathy) or moderate-to-severe NPDR baseline; in patients without retinopathy at baseline OR 0.73 (95% CI 0.62–0.86) — protective. Pattern V direction-of-effect: this is a baseline-status-stratified finding; the protocol does NOT summarize as one-directional. Clinical posture: ophthalmology pre-treatment for any T2D patient with known DR or long-standing T2D, with particular attention in R1M1 or moderate-severe NPDR baseline. Within the SURPASS controlled-trial population (Popovic 2024 Diabetes Obes Metab Letter PMID 38456523 — commentary-tier evidence; Rosenstock 2023 Diabetes Care — the underlying SURPASS retinopathy pooled data anchor), no increased risk of DR progression was observed; the controlled-trial population excluded patients with unstable or severe baseline retinopathy.
Severe renal impairment (eGFR <15) outside trial-enrolled range. SURPASS and SURMOUNT typically enrolled eGFR ≥30; eGFR 15–30 is a relative exclusion with clinician-judgment posture; eGFR <15 is outside Phase 3 enrollment with no direction-of-effect verification (Pattern V applies). Tirzepatide pharmacokinetics show only modest effects of renal impairment; dose adjustment generally not required for moderate impairment per current product labels.
Severe hepatic impairment (Child-Pugh C) outside trial-enrolled range. SYNERGY-NASH Phase 2 excluded F4 cirrhosis; tirzepatide F4 data is not yet published. Class-context Pattern V flag: semaglutide Phase 2 in F4 cirrhosis (Loomba 2023 Lancet Gastroenterol Hepatol PMID 36934740) did NOT meet primary fibrosis endpoint, with directional finding toward placebo advantage on the primary endpoint. The Class-level F4 biology question is unresolved; clinician judgment for severe hepatic impairment with hepatology co-management.
Active eating disorder (anorexia nervosa, bulimia nervosa, BED with active purging). The appetite-suppression mechanism is contraindicated in disordered eating; behavioral-health co-management before initiation. ARFID and BED-without-purging are clinician-judgment phenotypes.
Active malignancy on therapy (other than MTC/MEN-2 — §2.4 hard contraindication). SURPASS / SURMOUNT typically excluded active cancer; clinician judgment with oncology co-management. Section 5 of the canonical addresses cancer-context safety per the integrative framework (mechanism-class-by-tumor-context with weight-loss-confounding axis); class-level 2026 cancer SR (Ko et al 2026 Annals Intern Med PMID 41359966; n=94,245 across 48 RCTs including tirzepatide) characterizes “GLP-1RAs may have little or no effect on risk for obesity-related cancers” overall.
Pre-conception planning within ~35 days for reproductive-age patients. Tirzepatide elimination half-life ~5 days; ~5 half-lives ≈ 25 days substantial clearance, ~35 days complete clearance; label recommendation is discontinue at least 2 months before planned conception (§8.4 pre-conception washout arithmetic). This is anticipatory discontinuation, not a Section 2 exclusion — but the §8.4 arithmetic applies to selection-criteria screening at initiation (a patient planning conception within the next 1–2 months should not initiate; a patient with longer planning horizon enters with §8 anticipatory discontinuation timeline).
Oral medications with narrow therapeutic index affected by gastric emptying delay. Warfarin (closer INR monitoring during titration), levothyroxine (TSH monitoring + dose adjustment with weight loss), oral contraceptives (backup non-oral contraception during initiation per §6.10), anti-epileptics, immunosuppressants — closer therapeutic drug monitoring where feasible. Not exclusion criteria, but clinician-judgment criteria for co-management.

2.4 Hard contraindications — boxed warnings and labeled contraindications

Hard contraindications are absolute — tirzepatide must not be initiated, and if discovered during therapy, the molecule is discontinued. Each contraindication is documented with its source classification (FDA boxed warning vs labeled contraindication vs strong-evidence post-marketing signal).

Personal or family history of medullary thyroid carcinoma (MTC). FDA boxed warning — class-level for GLP-1 RAs including tirzepatide, based on rodent C-cell tumorigenicity signal (Bjerre Knudsen 2010 PMID 20203154). Species-specific to rodents in the available primate data; human C-cells express GLP-1R at much lower density than rodent C-cells; tirzepatide-specific GIPR-on-C-cells expression is research-state-incomplete with no established mechanism for C-cell tumorigenesis. The 2026 cancer SR (PMID 41359966) characterizes thyroid cancer signal as moderate-certainty “little or no effect” overall. The boxed-warning-mandated contraindication is absolute regardless of the mechanism-uncertainty — clinician-discretion is not appropriate here.
Multiple Endocrine Neoplasia syndrome type 2 (MEN-2). Same boxed warning source — class-level for GLP-1 RAs including tirzepatide; absolute contraindication.
Known serious hypersensitivity to tirzepatide or excipient. Labeled contraindication per Lilly product labels. Includes anaphylaxis history attributable to tirzepatide. Immunogenicity considerations: anti-drug antibody (ADA) formation with tirzepatide is reported but at rates not associated with efficacy loss or hypersensitivity events in registration trials; cross-reactivity with semaglutide or other GLP-1 RAs is not characterized at depth — patients switching with ADA history warrant case-by-case clinical evaluation.
Severe gastroparesis (functional contraindication per Lilly product labels — verify against current label language). Tirzepatide mechanism’s gastric-emptying delay is contraindicated in severe pre-existing gastroparesis.
Pregnancy (Category X-equivalent labeling per Lilly product labels for both Mounjaro and Zepbound). Labeled contraindication for all indications. Pregnancy is a §8.2 discontinuation trigger — a patient on protocol who becomes pregnant transitions out of protocol immediately with §8.4 washout arithmetic applied retrospectively (first-trimester exposure may already have occurred; obstetrics co-management; §8.7 Scenario D).
Severe prior pancreatitis history is a labeled relative contraindication / precaution per Lilly product labels (not a hard contraindication for single-episode prior pancreatitis history) — but active or recurrent severe pancreatitis history is clinician-judgment-bordering-on-hard-contraindication. The protocol carries this distinction precisely: single-episode prior pancreatitis (resolved, stable, no recurrence ≥12 months) is §2.3 relative exclusion with clinician judgment; severe or recurrent pancreatitis history is functionally hard contraindication.

2.5 Worked clinical screening — tirzepatide selection criteria detail

Inclusion criteria worked detail (per indication).

T2D glycemic control (Mounjaro): adults age ≥18; HbA1c above individualized target (typical 7.0–10.5% trial-enrollment range across SURPASS); adjunct to diet and exercise; metformin-treated or metformin-intolerant typical; alternative background per SURPASS-3 / SURPASS-4 / SURPASS-5 / SURPASS-6 / SURPASS-J-mono / SURPASS-AP-Combo applicable. Effect-size anchor framing for inclusion sub-population: SURPASS-2 head-to-head HbA1c reductions of −2.01% / −2.24% / −2.30% (5 / 10 / 15 mg) at 40 weeks vs semaglutide 1 mg −1.86% defines the response magnitude clinicians can frame in counseling. SURPASS-J-mono (Japanese T2D monotherapy population) and SURPASS-AP-Combo (Asia-Pacific T2D + metformin combination) extend the enrollment to international populations.

Chronic weight management (Zepbound): adults age ≥18 with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, T2D, OSA, CVD). Inclusion phenotype primary target per SURMOUNT program: non-diabetic obesity (SURMOUNT-1 enrollment), obesity with T2D (SURMOUNT-2), intensive-lifestyle-bridge-eligible (SURMOUNT-3), maintenance-stable patients (SURMOUNT-4), max-tolerated-dose head-to-head with semaglutide (SURMOUNT-5).

OSA with obesity (Zepbound): adults age ≥18; moderate-to-severe OSA (AHI ≥15 events/hour) confirmed by polysomnography or home sleep test; obesity (BMI ≥30); sleep medicine specialist co-management baseline. CPAP-naive (Trial 1 phenotype) and CPAP-current (Trial 2 phenotype) populations both supported; clinical positioning differs (§4.5 OSA detail).

Investigational extensions (off-label per Pattern AA, §10.6 explicit framing): HFpEF + obesity per SUMMIT enrollment; MASH F2/F3 per SYNERGY-NASH Phase 2 enrollment; CV risk per SURMOUNT-MMO enrollment (pending readout); pediatric T2D per SURPASS-PEDS enrollment (pending FDA pathway). Each off-label use is documented in §10.6 with primary-source rationale and informed-consent acknowledgement.

Relative exclusion criteria worked detail.

Severe gastroparesis: not initiated. Active or recent (within 12 months) acute pancreatitis: deferred at least 12 months stable post-event, clinician judgment. Diabetic retinopathy with rapid-HbA1c-improvement risk in T2D: ophthalmology pre-screening for proliferative DR or moderate-severe NPDR or R1M1; SUSTAIN-6 class-level + Buckley 2025 tirzepatide-specific RWE findings inform the screening posture. Severe renal impairment eGFR <15: outside SURPASS / SURMOUNT enrollment range; clinician judgment with nephrology co-management; tirzepatide PK shows only modest effects of renal impairment but the trial-evidence anchor is absent. Severe hepatic impairment Child-Pugh C: clinician judgment with hepatology co-management; SYNERGY-NASH excluded F4 cirrhosis; class-context Pattern V flag from semaglutide Loomba 2023 F4 directional finding toward placebo. Active eating disorder: routed to behavioral-health co-management before initiation. Pre-conception planning within ~35 days for reproductive-age patients: §8.4 anticipatory discontinuation arithmetic applies.

Hard contraindications worked detail.

Personal or family history of MTC: FDA boxed warning, class-level for GLP-1 RAs including tirzepatide; absolute. MEN-2: same boxed warning; absolute. Known serious hypersensitivity to tirzepatide or excipient: labeled contraindication. Severe gastroparesis: functional contraindication per Lilly product labels. Pregnancy: labeled contraindication for both Mounjaro and Zepbound — discontinuation trigger with ~25–35-day pharmacokinetic washout per §8.4 (label-recommended ≥2-month pre-conception planning window).

Pattern AA precision in this section. “FDA boxed warning for MTC and MEN-2” is the precise regulatory framing — class-level for GLP-1 RAs including tirzepatide; not tirzepatide-specific. “Labeled contraindication” for hypersensitivity, severe gastroparesis, and pregnancy is the precise label-language framing per Lilly Mounjaro / Zepbound product labels. “Labeled relative contraindication / precaution” for prior pancreatitis is the precise framing — distinguishing labeled precaution from boxed warning and from labeled contraindication. “Post-marketing signal under evaluation” for the Buckley 2025 RWE retinopathy stratified finding (vs the SURPASS controlled-trial-population no-signal finding) is the precise framing — neither labeled warning nor labeled contraindication, but clinician-judgment with primary-source rationale.

Pattern V cross-check at this section. The Buckley 2025 retinopathy RWE finding is a direction-of-effect verification anchor: the OR 2.15 in the overall multivariate analysis (signal “particularly evident” per authors in R1M1 / moderate-severe NPDR baseline) co-exists with OR 0.73 in the no-retinopathy-baseline subgroup. The protocol does not generalize the signal to all tirzepatide patients but anchors it to the specific baseline-status-stratified phenotype. The class-level SURPASS controlled-trial-population data anchor (Rosenstock 2023 Diabetes Care; commentary at Popovic 2024 Diabetes Obes Metab Letter PMID 38456523) showed no signal in the controlled-trial population, which excluded unstable / severe baseline retinopathy. Pattern V direction-of-effect discipline applies: the canonical and the protocol present both findings precisely; neither is collapsed into a one-directional summary.

Pattern W cross-check at §2.5. Every relative exclusion and hard contraindication above maps to a §3 pre-treatment workup panel (every screening criterion is operationalized into a workup question) and to a §6 AE management algorithm (every contraindication is a §6 discontinuation trigger if it emerges during therapy). Section 11 Bibliography anchors each contraindication source — boxed warning vs labeled contraindication vs labeled precaution vs post-marketing signal — to its primary source.

3. Pre-treatment workup

3.1 Purpose

Define the pre-treatment laboratory, imaging, and clinical-assessment workup that must be completed and reviewed before tirzepatide initiation. Section 3 is the operational handoff between Section 2 (selection criteria) and Section 4 (initiation protocol): a patient who passes Section 2 screening enters Section 3 workup; only on workup completion does Section 4 dose initiation begin.

The Module 5 workup is structured into seven panels per Protocol Template §3 architecture: standard metabolic (applies to every tirzepatide protocol), diabetes-specific (T2D indication or T2D comorbidity), MASH-specific (MASH indication or risk profile), kidney-specific (CKD context or borderline baseline), CV-risk-specific (CVOT context or ASCVD profile; HFpEF + obesity sub-panel for SUMMIT-anchored use), organ-baseline panels (thyroid, pancreas, ophthalmology — class-level for GLP-1 RAs + tirzepatide-specific GIP-axis considerations), body-composition baseline (CWM and lean-mass-stack protocols). The OSA-with-obesity indication adds a sleep-medicine baseline sub-panel that the semaglutide protocol does not carry (no semaglutide OSA indication as of 2026-05-13).

Pattern W cross-section consistency: every lab listed in §3.2–§3.8 is reconciled with the Section 5 maintenance monitoring intervals (Section 5 cannot recommend a monitoring lab not established as a baseline lab in Section 3) and with the Section 6 AE management triggers (Section 6 cannot anchor an AE response to a lab not in the workup or monitoring panel). The Pattern W reconciliation is run end-to-end at the verification gate self-audit (Appendix A).

3.2 Standard metabolic panel

Applies to every tirzepatide protocol regardless of indication. Establishes baseline metabolic state, identifies undiagnosed comorbidity, and provides reference for monitoring.

Comprehensive metabolic panel (CMP). Sodium, potassium, chloride, CO₂, BUN, creatinine, glucose, calcium, total protein, albumin, ALT, AST, alkaline phosphatase, total bilirubin. Establishes hepatic and renal baseline for class-level GLP-1 RA precautions and for indication-specific MASH / CKD eligibility. Tirzepatide canonical Section 8.5 — CPT 80053; Medicare allowable $10.56; DTC self-pay range 29–49.
Fasting lipid panel. Total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C, ApoB if available. Baseline for CV-risk indication eligibility (SUMMIT context; SURMOUNT-MMO pending) and for monitoring metabolic improvement. CPT 80061; Medicare $13.39; DTC 29–59.
Fasting glucose and HbA1c. Glycemic baseline regardless of indication. For non-diabetic CWM and OSA indications, screens for undiagnosed prediabetes or T2D (which would shift Mounjaro vs Zepbound formulation decision per §1.2 indication categories). For T2D indication, confirms diagnosis and severity. CPT 83036 (HbA1c) Medicare $9.71 / DTC 29–39; CPT 82947 (fasting glucose) Medicare 3.93/DTC 28.
Body weight, height, BMI, waist circumference. Anthropometric baseline. Waist circumference is the visceral-adiposity-distribution anchor (§1.3 phenotype taxonomy); SURMOUNT-5 waist circumference reduction −18.4 cm tirzepatide vs −13.0 cm semaglutide is the head-to-head context.
Blood pressure (seated, two readings, standardized). Baseline for CV-risk indication eligibility and for monitoring (tirzepatide modest SBP reduction 3–5 mmHg / DBP 1–3 mmHg is documented across the SURMOUNT / SURPASS / SUMMIT programs).

3.3 Diabetes-specific panel (T2D indication or T2D comorbidity)

Applies when the protocol indication is T2D glycemic control (Mounjaro) or when the patient has T2D as comorbidity within a CWM / OSA / CV / MASH / CKD indication.

HbA1c (above; standard panel). Confirms T2D diagnosis and severity; informs SURPASS-2 / SURPASS-3 / SURPASS-4 / SURPASS-5 / SURPASS-6 dose-response expectation framing.
Fasting C-peptide. Establishes endogenous insulin reserve — distinguishes T2D from latent autoimmune diabetes of adults (LADA) and from advanced beta-cell-failure T2D where dual-incretin response may be attenuated. CPT 84681; Medicare ~$25; DTC variable. C-peptide is particularly informative for the dual-incretin mechanism context — tirzepatide’s GIPR + GLP-1R additive insulin secretion mechanism (Section 2.2 of canonical) requires endogenous β-cell capacity; severely depleted C-peptide phenotype is the response-attenuation anchor.
GAD-65 antibodies and IA-2 antibodies (if LADA suspected — adult-onset diabetes with normal BMI, rapid progression to insulin requirement, or atypical clinical course). Tirzepatide is not first-line in confirmed autoimmune diabetes; misclassification of LADA as T2D is a Pattern V direction-of-effect risk (the assumed benefit may not apply).
Diabetes complication screen (if not within the last 12 months): dilated retinal exam (also a class-level pre-treatment requirement — §3.7; particular attention per Buckley 2025 RWE baseline-status-stratified finding); urine albumin-to-creatinine ratio (UACR) for diabetic nephropathy; monofilament / vibratory testing for diabetic neuropathy.
CGM data review if available. Establishes time-in-range baseline and hypoglycemia frequency baseline. Relevant for §5.4 dose-adjustment triggers in patients on concurrent insulin or sulfonylurea (per §6.10 drug-interaction context — concurrent insulin reduced ~20% at tirzepatide initiation typical; sulfonylurea reduced ~50% or discontinued).

3.4 MASH-specific panel (MASH indication or MASH risk profile)

Applies when the protocol indication is MASH (off-label as of 2026-05-13; Phase 3 in development) or when baseline phenotype suggests MASH risk (T2D + obesity + elevated AST/ALT + waist circumference ≥102 cm men / ≥88 cm women — typical SYNERGY-NASH Phase 2 enrollment phenotype).

AST, ALT, GGT, alkaline phosphatase, total and direct bilirubin. Hepatic-function baseline; AST/ALT ratio interpretation context.
Platelet count. Component of FIB-4 calculation.
FIB-4 score. Calculated non-invasive fibrosis score. Stratifies fibrosis risk: low <1.3, indeterminate 1.3–2.67, high >2.67.
Vibration-controlled transient elastography (VCTE / FibroScan) if FIB-4 indeterminate or high. Liver stiffness measurement (kPa) plus controlled-attenuation parameter (CAP) for steatosis quantification. Stratification: low <8 kPa, indeterminate 8–12 kPa, high >12 kPa for advanced fibrosis.
Liver biopsy is the historical gold standard for MASH diagnosis and fibrosis staging and is the SYNERGY-NASH Phase 2 enrollment basis (biopsy-proven MASH F2 or F3); modern practice favors non-invasive elastography unless biopsy is clinically indicated for staging or to rule out alternative liver disease. Tirzepatide-specific off-label MASH use should anchor on biopsy or imaging-confirmed MASH per §10.6 informed-consent framing.
Hepatitis B surface antigen and Hepatitis C antibody. Rule out viral hepatitis as alternative or co-existing liver disease.
Iron studies (ferritin, transferrin saturation). Rule out hereditary hemochromatosis.
Autoimmune liver-disease screen if clinically indicated (ANA, anti-smooth muscle, anti-mitochondrial antibodies).

Pattern V flag for F4 cirrhosis. SYNERGY-NASH Phase 2 excluded F4 cirrhosis; tirzepatide F4 data is not yet published. Class-context: semaglutide Phase 2 in F4 (Loomba 2023 Lancet Gastroenterol Hepatol PMID 36934740) did NOT meet primary fibrosis endpoint with directional finding toward placebo. The Class-level F4 biology question is unresolved. Patients with confirmed F4 cirrhosis should not be initiated on tirzepatide for MASH indication absent hepatology specialist judgment and informed-consent framing per §10.6.

3.5 Kidney-specific panel (CKD context or borderline baseline kidney function)

Applies when CKD is a co-management indication (SURMOUNT-CKD sub-protocol within SURMOUNT-MMO is the trial-enrollment anchor; readout pending 2027-10), or when baseline eGFR is 30–60 regardless of indication.

Serum creatinine, eGFR. Standard renal-function baseline (also in §3.2 CMP).
Cystatin C-based eGFR if creatinine-eGFR is discordant with clinical picture (low muscle mass elderly patient with apparently normal creatinine but real GFR reduction).
Urine albumin-to-creatinine ratio (UACR). Quantifies albuminuria. CPT 82570; Medicare $5.18; DTC 45–49.
Urinalysis with microscopy. Rules out alternative kidney disease (active sediment, hematuria, proteinuria pattern).
Renin-angiotensin system (RAS) blockade documentation. Maximally tolerated RAS-blockade as background therapy is the typical CKD-context baseline; the protocol verifies and documents RAS-blockade status before initiation.
Serum bicarbonate, phosphorus, calcium, PTH if eGFR <60. Chronic-kidney-disease-mineral-and-bone-disorder workup; relevant for advanced CKD co-management.

Pattern V flag: SURPASS and SURMOUNT enrolled eGFR ≥30 typically; eGFR 15–30 is a §2.3 relative exclusion with clinician-judgment posture; eGFR <15 is outside Phase 3 enrollment with no direction-of-effect verification.

3.6 CV-risk-specific panel (CVOT context or HFpEF + obesity context)

Applies when the protocol indication anchors to CV risk reduction (SURMOUNT-MMO context, readout pending) or HFpEF + obesity (SUMMIT context, regulatory pathway in discussion), or when baseline ASCVD risk profile is high regardless of indication.

ECG (12-lead). Baseline rhythm and conduction status. Tirzepatide modest heart-rate elevation (mean 1–4 bpm) is documented across the registration program; baseline rhythm context informs symptom evaluation.
High-sensitivity troponin if symptomatic baseline. Rules out unstable ASCVD.
NT-proBNP or BNP if HFpEF-suspect (obesity + dyspnea on exertion + age ≥60). Anchors SUMMIT-context investigational-extension eligibility framing per §1.5. CPT 83880 (NT-proBNP); Medicare ~30–50; DTC 75–150. Tirzepatide-specific addition vs semaglutide protocol — the SUMMIT indication-pathway context makes NT-proBNP load-bearing for HFpEF + obesity eligibility framing.
Echocardiogram if HFpEF-suspect. LVEF, diastolic-function indices, LV-mass index. SUMMIT enrollment required LVEF ≥50%.
KCCQ-CSS (heart-failure-specific quality-of-life patient-reported instrument) if HFpEF + obesity context. Patient-reported outcome instrument; no per-administration cost; clinician-administered or self-administered. SUMMIT methodology standard.
6-minute walk test (6MWT) if HFpEF + obesity context. Functional baseline; SUMMIT methodology standard.
High-sensitivity CRP (hsCRP) if cardiovascular inflammation context. CPT 86141; Medicare $12.95; DTC $79. If-indicated for CV-risk-stratified patient context per SURMOUNT-MMO-anchored framing.
Carotid intima-media thickness or CAC score if subclinical ASCVD assessment is part of the practice’s CV-risk workflow. Not required by trial enrollment but commonly included in modern practice for risk stratification.

3.7 Organ-baseline panels (thyroid, pancreas, ophthalmology — class-level for GLP-1 RAs and dual-incretin coagonists)

Class-level pre-treatment workup for any GLP-1 RA + dual-incretin coagonist protocol, regardless of indication. Anchors to §2.4 hard contraindications and §6 AE-management algorithms.

Thyroid baseline. TSH at minimum (CPT 84443; Medicare $16.80; DTC 35–49). Neck examination for thyroid nodules. If personal or family history of MTC or MEN-2 is identified at this step, this is a §2.4 hard contraindication and the protocol does not initiate. Routine calcitonin screening (CPT 82308; Medicare $26.79) is not generally recommended in asymptomatic average-risk patients — the boxed warning is based on rodent C-cell signal that does not translate to primates per Bjerre Knudsen 2010 PMID 20203154; human MTC signal is debated and routine calcitonin screening has high false-positive rate without proportionate predictive value. Tirzepatide-specific GIPR-on-C-cells mechanism is research-state-incomplete with no established mechanism for differential C-cell biology vs class-level GLP-1R-mediated signal (Section 5.2 of canonical). Calcitonin monitoring is optional in high-risk patients per endocrinology specialist consultation; clinician-judgment, not protocol-mandated for asymptomatic average-risk.
Pancreas baseline. Serum lipase (CPT 83690; Medicare $6.89; DTC 35–39), serum amylase (CPT 82150; Medicare $6.48; DTC $28; lipase is more pancreas-specific). Triglycerides (hypertriglyceridemic pancreatitis is a distinct etiology; addressed in §3.2 lipid panel). Pancreatitis-history documentation per §2.4. Wen 2025 SR (PMID 40988099) — pooled pancreatitis RR 1.44 for the class including tirzepatide; the protocol’s pre-treatment baseline lipase + amylase serves as reference for §6.4 symptom-prompted reassessment, not as routine asymptomatic monitoring.
Ophthalmology — dilated retinal examination for T2D patients. Particularly for T2D patients per §3.3 diabetes-complication-screen overlap. Pre-treatment dilated exam for any T2D patient with HbA1c ≥9.0 or with known background DR is the protocol-recommended posture. Tirzepatide-specific stratification (Buckley 2025 RWE): particular attention in R1M1 (mild non-proliferative DR + maculopathy) or moderate-to-severe NPDR baseline — the Buckley 2025 OR 2.15 overall multivariate analysis with authors’ qualitative interpretation flagging this baseline subgroup. Patients without retinopathy at baseline showed OR 0.73 (protective direction); the screening is risk-stratified, not exclusion-blanket.
Ophthalmology — ION (NAION) baseline framing (class-differentiation precision). Tirzepatide-specific calibration vs the semaglutide protocol. Lawrenson 2025 PMID 40383360 (Lakhani M, Kwan ATH, Mihalache A et al Am J Ophthalmol, 180-country FAERS n=12,936,341 + WHO VigiBase) documents ION (with NAION as the primary clinical subtype) signal for semaglutide (FAERS ROR 11.12 / VigiBase ROR 68.58; significant) and signal absent for tirzepatide at the same analytical threshold. EMA Pharmacovigilance Risk Assessment Committee classified NAION as a “very rare” side effect of semaglutide (June 2025); NAION is NOT labeled by either FDA or EMA for tirzepatide as of 2026-05-13 — consistent with the class-differentiated finding. Post-approval exposure-window asymmetry caveat: semaglutide ~82 months vs tirzepatide ~28 months at study cutoff September 2024; disproportionality analyses with shorter post-approval exposure are statistically less likely to detect rare-event signals at the same threshold — absent-signal-at-threshold ≠ absent-signal-in-population. The mechanism question (whether GIPR co-agonism contributes to a different ophthalmic-signal profile) is research-state-incomplete and hypothesis-generating only.

Clinical action for tirzepatide pre-treatment ophthalmology baseline: the class-differentiated ION/NAION finding does NOT mandate a routine NAION pre-screen the way the semaglutide protocol’s §3.7 might frame it — the signal is absent at the population threshold for tirzepatide. However, clinical assessment of optic-disc anatomy and individual NAION risk factors (crowded optic disc, prior NAION in fellow eye, hypertension, sleep apnea, dyslipidemia) remains appropriate in patients with known optic-disc cupping (“disc-at-risk”), prior NAION, or unexplained visual symptoms — the absence of signal at population thresholds does not exclude individual-patient risk. Pattern AA precision: the protocol does NOT state “tirzepatide is safer than semaglutide on eyes” (regulatory-claim-coded promotional language); it states factually that the class-differentiated pharmacovigilance finding shows signal absent for tirzepatide at the same threshold as semaglutide’s significant signal, with the post-approval exposure-window asymmetry caveat. §10.5 comparator conversation carries this precision.

3.8 Body-composition baseline

Applies to every tirzepatide CWM protocol and to lean-mass-stack protocols.

Bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DEXA). Lean mass, fat mass, visceral adipose tissue if DEXA. DEXA is more accurate; BIA is more accessible. SURMOUNT-1 body composition sub-analysis showed lean mass loss proportional to total weight loss (similar to historical caloric-restriction-only data); SURMOUNT-5 head-to-head reported tirzepatide’s greater absolute weight loss translates to greater absolute lean mass loss — emphasizing structured preservation strategies (resistance training, adequate protein intake; §9.3 cross-Module lean-mass combinations).
Hand-grip strength or sit-to-stand timed test. Functional strength baseline — particularly relevant for ≥65 age phenotype where sarcopenia risk during weight loss is a clinical concern.
Resting energy expenditure (REE) if indirect-calorimetry-equipped. Establishes energy-expenditure phenotype baseline (§1.3 phenotype taxonomy).

3.9 Sleep-medicine baseline (OSA-with-obesity indication)

Tirzepatide-specific panel that the semaglutide protocol does not carry — semaglutide has no OSA-with-obesity indication as of 2026-05-13; tirzepatide’s Zepbound OSA indication (December 2024 approval, SURMOUNT-OSA Phase 3 anchor) requires sleep-medicine-specialist co-management and a documented sleep-medicine baseline.

Apnea-hypopnea index (AHI) via polysomnography or home sleep test. Confirms moderate-to-severe OSA (AHI ≥15 events/hour) inclusion criterion. SURMOUNT-OSA Trial 1 (CPAP-naive) mean baseline AHI ~50; Trial 2 (CPAP-current) similar.
Epworth Sleepiness Scale (ESS). Patient-reported sleep-apnea symptom baseline. SURMOUNT-OSA secondary endpoint.
CPAP-status documentation. CPAP-naive vs CPAP-current phenotype splits per SURMOUNT-OSA dual-trial design; clinical positioning at §4.5 of the canonical (CPAP-naive: tirzepatide + lifestyle as primary, CPAP if AHI persistence; CPAP-current: tirzepatide adjunct, reassess CPAP need; CPAP-current with adherence challenges: tirzepatide may enable reduced CPAP dependence if AHI reduction sufficient).
Sleep medicine specialist co-management arrangement. Required for CPAP-discontinuation decision-making post-tirzepatide initiation; follow-up sleep study at ~52 weeks per SURMOUNT-OSA methodology.

3.10 Worked example — tirzepatide pre-treatment panels per indication

For a non-diabetic adult initiating Zepbound 2.4-titration for CWM (the typical Zepbound CWM phenotype): standard metabolic panel (§3.2), thyroid + pancreas baseline (§3.7), ophthalmology dilated exam if any visual-symptom history (§3.7; NAION pre-screen is risk-stratified per individual NAION risk factors, not protocol-mandated routine — the class-differentiated finding shows tirzepatide signal absent at population threshold), body-composition BIA or DEXA (§3.8). MASH-risk screen via FIB-4 calculation from standard panel; advance to elastography only if FIB-4 indeterminate or high.

For a T2D adult initiating Mounjaro for glycemic control: add diabetes-specific panel (§3.3) including fasting C-peptide, GAD-65 antibodies if LADA suspected, dilated retinal exam with Buckley 2025 baseline-status-stratified attention (R1M1 or moderate-severe NPDR baseline triggers ophthalmology pre-screen and co-management). UACR documented for CKD co-stratification regardless of CKD indication.

For an adult with established CVD initiating Mounjaro or Zepbound off-label-for-CV-context (SURMOUNT-MMO-anchored, pending readout): add CV-risk-specific panel (§3.6). ECG baseline; troponin if symptomatic; lipid panel; hsCRP if CV-inflammation context. Patient counseled per §10.6 off-label framing — SURMOUNT-MMO readout pending 2027-10.

For an adult with confirmed HFpEF + obesity initiating Zepbound off-label-for-HFpEF (SUMMIT-anchored, regulatory pathway pending): full CV-risk-specific panel (§3.6) including NT-proBNP, echocardiogram, KCCQ-CSS, 6MWT. Heart failure specialist co-management. Patient counseled per §10.6 off-label framing — Phase 3 SUMMIT data supports HR 0.62; FDA label expansion not yet granted.

For an adult with confirmed MASH F2/F3 initiating tirzepatide off-label-for-MASH (SYNERGY-NASH-anchored, Phase 3 in development): full MASH-specific panel (§3.4) — AST/ALT, GGT, platelet count, FIB-4, VCTE; viral hepatitis screen; iron studies; autoimmune liver-disease screen if clinically indicated. Liver biopsy if histologic staging is needed or alternative liver disease must be ruled out. Hepatology co-management. F4 cirrhosis is the Pattern V flag — not initiated absent hepatology specialist judgment given the semaglutide F4 directional Pattern V class-context.

For an adult with moderate-to-severe OSA + obesity initiating Zepbound (SURMOUNT-OSA-anchored, FDA-approved December 2024): full sleep-medicine baseline (§3.9) — AHI confirmation, ESS, CPAP-status documentation, sleep medicine specialist co-management arrangement. Standard metabolic + organ-baseline panels (§3.2, §3.7) apply.

Pattern W cross-check applied to §3.10. Every lab in the worked-example panels above is reconciled with Section 5 monitoring intervals and Section 6 AE triggers; the protocol’s Bibliography (Section 11) anchors each pivotal-trial enrollment lab to its NCT and PMID with Pattern AB.4 standing-scan verification. The OSA-with-obesity sub-panel (§3.9) is tirzepatide-specific and is not in the semaglutide protocol’s Section 3.

4. Initiation protocol

4.1 Purpose

Define the starting dose, titration schedule, and tolerability-management cadence for tirzepatide initiation. Section 4 is the time-sequenced action plan from Day 0 (first dose) through approximately Week 16–20 (target-dose attainment for typical Module 5 protocols, or longer with slow-titration option) — the period during which the patient transitions from naive to maintenance-stable.

Section 4 is the section where Pattern Z calibration is most operationally relevant. The initiation period is when patient adherence is most fragile, GI tolerability is most challenging, and clinician counseling has the greatest influence on continuation vs discontinuation. Pattern Z calibration anchor 1 (compounded-formulation operational characteristics) and anchor 2 (compounded vs FDA-approved counseling) appear in Section 10 counseling beats specifically because Section 4 initiation is the conversational anchor for those Pattern Z applications.

4.2 Starting dose

Tirzepatide starting dose: 2.5 mg subcutaneous once weekly. This applies to both Mounjaro (T2D) and Zepbound (CWM and OSA-with-obesity) — same active pharmaceutical ingredient, same dose strengths, same starting dose. This is the tolerability-priming dose — sub-therapeutic for glycemic or weight-loss effect; the purpose is GI-AE attenuation prior to escalation.

Pattern AA precision: 2.5 mg is the FDA-label-recommended starting dose per both Mounjaro and Zepbound labels. The 2.5 mg starter dose is consistent across all three approved indications (T2D, CWM, OSA-with-obesity) and across the investigational-extension off-label uses (HFpEF, MASH, CV, pediatric T2D per SURPASS-PEDS).

4.3 Titration schedule

Standard titration (label-recommended, both Mounjaro and Zepbound):

Week	Dose	Notes
1–4	2.5 mg once weekly	Starter dose; acclimates GI tolerance rather than targeting therapeutic effect
5–8	5 mg once weekly	First therapeutic dose; many patients with mild-moderate T2D or modest CWM goals stabilize here
9–12	7.5 mg once weekly	Incremental escalation if HbA1c / weight / AHI target not yet reached
13–16	10 mg once weekly	Frequently a maintenance dose for moderate-severe T2D or CWM with substantial weight-loss target
17–20	12.5 mg once weekly	For patients requiring additional glycemic control or weight loss
21+	15 mg once weekly	Maximum approved dose

Total titration period: 16–20 weeks to maximum dose if maximum is needed. Many patients stabilize at 5, 7.5, or 10 mg without needing escalation to 15 mg; the maintenance dose is determined by tolerability + therapeutic-response trajectory, not by a default-to-maximum assumption.

Slow-titration option (clinician-judgment within label, not label-mandated). Each interval extended to 6–8 weeks for patients with marginal GI tolerability. Total titration period extends correspondingly. Used for patients with persistent moderate-severity GI AE at any standard-schedule step.

Titration rationale. Three load-bearing rationales support the gradual 2.5 → 15 mg titration over 16–20 weeks:

GI tolerability — the dominant AE category (§6.3) is most prominent during dose escalation; gradual increase allows physiological adaptation.
Pharmacokinetic steady state — ~4 weeks at each dose level aligns with the time required for plasma concentrations to reach steady state at that dose (tirzepatide elimination half-life ~116 hours / ~5 days; ~5 half-lives ≈ 4 weeks for steady-state attainment per dose level).
Individualized maintenance dosing — patients reach effective dose at different points along the titration; not all patients require 15 mg max-dose for adequate response.

4.4 GI tolerability management at each titration step

Tirzepatide GI AE profile across the SURMOUNT / SURPASS programs (canonical §6.3): nausea 25–33%, diarrhea 16–22%, vomiting 8–14%, constipation 7–12%, dyspepsia 8–10%, decreased appetite (anorexia-like) 9–12%. Typically dose-dependent, most prevalent during escalation, self-limiting with continued therapy. Extended treatment duration associates with decreased GI AE incidence consistent with the GLP-1 RA + dual-incretin class pattern.

SURMOUNT-5 head-to-head GI tolerability (PMID 40353578): broadly comparable between tirzepatide and semaglutide; tirzepatide nausea slightly higher in some sub-analyses, vomiting comparable; discontinuation for AEs comparable between arms. Some sub-analyses suggest tirzepatide GI tolerability favorability at weight-loss-equivalent doses — a mechanism-class hypothesis with partial preclinical support (GIPR co-agonism potentially attenuating GLP-1R-mediated emesis; canonical Section 2.1). Pattern AA precision: this is mechanistic-hypothesis with partial support, not an independent clinical claim.

First-line non-pharmacologic management at any titration step:

Reduce meal size; slow eating pace; avoid greasy / high-fat meals; consistent hydration.
Patient counseling at initiation on expected GI profile and titration rationale (anticipatory framing — Section 6.1 enforces this discipline).

First-line pharmacologic management:

Nausea: ondansetron 4 mg PRN; consider scheduled dosing for moderate-severity recurring nausea (the typical 2–3-day post-injection window). Cross-reference QT considerations in concurrent medications.
Diarrhea: loperamide PRN per standard dosing.
Constipation: osmotic laxative (polyethylene glycol) first-line; stool softener adjunct.
Eructation / dyspepsia: reassurance and meal-pairing adjustments first-line.

Volumetric titration adjustment. Persistent moderate-to-severe GI AE at any titration step is the trigger for the slow-titration variant (§4.3): hold at current dose for an additional 4–8 weeks before next escalation, or step down to prior dose if tolerability does not stabilize. When to hold vs escalate (per Lilly product label + clinical practice):

Escalate if the patient tolerates the current dose for the full 4-week interval and has not yet reached the target response (HbA1c target in T2D; weight-loss-rate target in obesity; AHI target in OSA).
Hold (maintain current dose for an additional 4 weeks) if significant GI symptoms (persistent nausea, vomiting, severe early satiety preventing adequate nutrition, or symptomatic volume contraction) occur at dose escalation.
Reduce by one dose step if adverse effects persist beyond 4 weeks at the current dose or if dehydration / acute kidney injury risk is present.

4.5 Early monitoring cadence

Tirzepatide early-monitoring cadence: contact at Week 2 (post-first-dose tolerability check, telehealth typical), Week 4–6 (after first titration step to 5 mg), Week 8–12 (mid-titration tolerability and adherence, with weight + BP), Week 16–20 (target-dose attainment confirmation if titrating to maintenance dose; Section 5 transition).

For T2D indication (Mounjaro), add HbA1c reassessment at Week 12–16; tirzepatide HbA1c effect approaches steady state by Week 26–40 per SURPASS program protocols; an interim Week 12–16 trajectory check informs Week 20+ dose decisions.

For OSA-with-obesity indication (Zepbound OSA), add a follow-up sleep study at Week 52 per SURMOUNT-OSA methodology; sleep medicine specialist co-management throughout.

For HFpEF + obesity off-label use, add KCCQ-CSS reassessment at Month 3–6 per SUMMIT methodology; 6MWT at Month 6.

Contact modality (in-person vs telehealth vs message) is practice-specific; the protocol documents the escalation triggers (any contact identifying severe GI AE, suspected pancreatitis, suspected gallbladder event, acute visual symptoms, or significant unintended weight loss → in-person evaluation within 48 hours).

4.6 Worked example — tirzepatide initiation (Zepbound for CWM)

Starting dose. Tirzepatide 2.5 mg subcutaneous once weekly. Tolerability-priming; sub-therapeutic for weight-loss effect.

Standard titration schedule. Week 1–4: 2.5 mg weekly. Week 5–8: 5 mg weekly. Week 9–12: 7.5 mg weekly. Week 13–16: 10 mg weekly. Week 17–20: 12.5 mg weekly. Week 21+: 15 mg weekly (maximum approved dose). Total titration period: 20 weeks to maximum dose. Many CWM patients stabilize at 10 mg or 12.5 mg without escalation to 15 mg; maintenance dose is response-trajectory-determined, not default-to-maximum.

Slow-titration option. Each interval extended to 6–8 weeks. Total titration period extends correspondingly. Used for patients with persistent moderate-severity GI AE at any standard-schedule step.

Tolerability management at each step. First-dose (2.5 mg, Week 1) GI AE profile: nausea is the most common early AE, typically mild and self-limited within 5–7 days for many patients; moderate or persistent nausea triggers ondansetron 4 mg PRN and reinforcement of meal-size / meal-composition counseling. Escalation to 5 mg (Week 5) is a common challenge step — nausea recurrence on dose increase is anticipated and counseled-for; if moderate-severity persists beyond 2 weeks at 5 mg, hold for an additional 4 weeks before escalating to 7.5 mg.

Subsequent escalations (7.5 → 10 → 12.5 → 15 mg) follow the same hold-if-needed logic. The 10 mg step is the most common maintenance plateau for CWM patients who tolerate target dose; the 12.5 and 15 mg steps are for patients requiring additional weight loss with continued tolerability. Constipation can become the dominant GI pattern at maintenance doses for some patients; the GI AE class profile is dose-dependent and reductive over time at stable dose.

Early monitoring cadence — tirzepatide Zepbound CWM. Week 2 (post-first-dose telehealth tolerability check). Week 5–6 (post-first-titration in-person or telehealth, with weight and BP). Week 9–12 (mid-titration weight + BP + tolerability). Week 13–16 (10 mg target consideration). Week 17–20 (continued titration if 15 mg is the target, with weight + BP + transition to §5 maintenance cadence at target-dose attainment).

Pattern V applied to §4.6. Effect-size anchors at tirzepatide target dose: SURMOUNT-1 demonstrated mean weight reduction approximately −22.5% efficacy estimand at 72 weeks with 15 mg vs approximately −2.4% placebo — the direction-of-effect is established and the magnitude is anchored to the SURMOUNT-1 enrollment phenotype (non-diabetic obesity, BMI ≥30, in the SURMOUNT-1 enrollment criteria). Treatment-regimen estimand (primary registration ITT result): −20.9% at 15 mg vs −3.1% placebo. Direction-of-effect for sub-population deviations from SURMOUNT-1 enrollment (e.g., BMI 27–30 with comorbidity per Zepbound label) is supported by SURMOUNT program breadth (SURMOUNT-2 T2D + obesity, SURMOUNT-3 with intensive lifestyle bridge, SURMOUNT-4 maintenance, SURMOUNT-5 head-to-head with semaglutide) but the specific −22.5% effect size belongs to SURMOUNT-1 and is not generalized verbatim to all sub-populations in counseling.

Pattern AA applied to §4.6. The label-recommended titration is “standard schedule” framing; the slow-titration variant is “clinician-judgment tolerability adjustment” framing — both are within the label’s clinical-judgment latitude, not off-label. Pattern AA precision distinguishes label-recommended (specific weeks and doses) from clinician-judgment within label.

5. Maintenance protocol

5.1 Purpose

Define the post-titration, target-dose-attained operating state of the protocol: target dose, monitoring intervals, dose-adjustment triggers, and the transition between maintenance and discontinuation (Section 8) or non-response algorithm (Section 7). Section 5 is the longest operational phase of a tirzepatide protocol — for a CWM patient who tolerates target dose and continues therapy, maintenance is open-ended for the duration of clinical benefit.

The load-bearing chronic-therapy anchor for tirzepatide is SURMOUNT-4 (PMID 38078870): discontinuation of tirzepatide leads to substantial rapid weight regain (+14% regain on placebo switch through week 88 in patients who had achieved ~−20.9% on tirzepatide titration). The maintenance framing throughout this section reflects the chronic-therapy SURMOUNT-4 anchor — tirzepatide is not a course to complete but a chronic therapy for indication continuation.

5.2 Target dose

The target dose is the dose at which the molecule’s primary effect is demonstrated in the pivotal trial program. Tirzepatide has six dose strengths (2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg) supporting individualized maintenance dosing.

For CWM indication (Zepbound): target dose is individualized within the 10–15 mg range typically. SURMOUNT-1 effect-size envelope: 5 mg −15.0% / 10 mg −19.5% / 15 mg −20.9% (treatment-regimen estimand); efficacy estimand at 15 mg −22.5%. Many CWM patients stabilize at 10 mg or 12.5 mg with adequate response and tolerable AE profile; 15 mg is the maximum approved dose and the maximum-effect dose in the SURMOUNT-1 trajectory.

For T2D indication (Mounjaro): target dose is individualized within the 5–15 mg range. SURPASS-2 effect-size envelope: 5 mg HbA1c −2.01% / 10 mg −2.24% / 15 mg −2.30%. For many T2D patients, 5 or 10 mg achieves individualized HbA1c target; the 15 mg maximum is for patients requiring additional glycemic control with continued tolerability.

For OSA-with-obesity indication (Zepbound): target dose is max-tolerated (typically 10 or 15 mg) per SURMOUNT-OSA enrollment. Trial 1 (CPAP-naive) used max-tolerated 10 or 15 mg; Trial 2 (CPAP-current) similar.

For HFpEF + obesity off-label use (SUMMIT-anchored, regulatory pathway pending): max-tolerated dose (10 or 15 mg) per SUMMIT enrollment.

For MASH F2/F3 off-label use (SYNERGY-NASH Phase 2-anchored, Phase 3 in development): dose-response per SYNERGY-NASH Phase 2 — 44% / 56% / 62% MASH resolution at 5 / 10 / 15 mg. 15 mg is the maximum-effect dose for MASH; clinician judgment within informed-consent.

For pediatric T2D off-label use (SURPASS-PEDS-anchored, FDA pathway pending): 5 or 10 mg per SURPASS-PEDS enrollment; pediatric endocrinology co-management.

5.3 Monitoring intervals

Monitoring intervals for the maintenance phase, anchored to the SURMOUNT / SURPASS / SUMMIT / SURMOUNT-OSA Phase 3 program protocols:

CWM (Zepbound): Months 4, 7, 10, 13 during the first year on target dose (quarterly); every 6 months thereafter for stable patients. At each visit: weight, BP, brief AE-and-adherence interview, body-composition reassessment (DEXA quarterly in Y1, biannually thereafter), and indication-specific labs as applicable.

T2D (Mounjaro): HbA1c at Month 4 (Week 16), Month 7, then quarterly during the first year on target dose; every 6 months thereafter for stable patients. Lipid panel and UACR annually. eGFR if CKD-context or borderline baseline.

OSA-with-obesity (Zepbound OSA): follow-up sleep study at Week 52 per SURMOUNT-OSA methodology; sleep medicine specialist co-management with CPAP-status reassessment; weight + BP at quarterly visits.

HFpEF + obesity (SUMMIT-anchored off-label): KCCQ-CSS every 3–6 months; 6MWT every 6 months; NT-proBNP every 6–12 months; heart failure specialist co-management.

MASH F2/F3 (SYNERGY-NASH-anchored off-label): LFT trajectory + hepatology specialist co-management; non-invasive fibrosis assessment (FibroScan, FIB-4) at 6–12 month intervals; liver biopsy at clinically appropriate intervals if research-protocol enrolled.

Pediatric T2D (SURPASS-PEDS-anchored off-label): HbA1c every 3 months; growth and developmental monitoring per pediatric endocrinology; reproductive-age contraception counseling in post-menarcheal females.

Class-level GLP-1 RA + dual-incretin monitoring includes lipase if any abdominal-pain symptom report (not routine asymptomatic monitoring), and annual or biennial reassessment of organ-baseline panels (§3.7).

5.4 Dose-adjustment triggers

Dose adjustment in the maintenance phase per Protocol Template §5.4: target-not-met (sub-threshold effect at current dose), target-overshoot (effect exceeds clinical target — typically relevant for T2D glycemic-overshoot with hypoglycemia risk in patients on concurrent insulin/sulfonylurea), and AE-emergent (new or worsening AE that responds to dose reduction).

Dose-adjustment options: hold dose (maintain current); titrate up (move to next label-permitted higher dose if not already at 15 mg maximum); titrate down (move to prior dose for tolerability); transition to Section 7 non-response algorithm if maximum dose with adequate trial duration has not produced clinical benefit.

Tirzepatide CWM dose-adjustment triggers worked detail:

Target-not-met: <5% weight loss at Week 20 on 10 mg maintenance with documented adherence — trigger for escalation to 12.5 mg or 15 mg if tolerable; <5% at Month 6 on 15 mg maximum dose with documented adherence triggers transition to Section 7 non-response algorithm.
Target-overshoot: rare in CWM; unintended weight loss below patient’s pre-specified target floor (e.g., BMI dropping below 22) triggers dose-down to next lower step with re-evaluation.
AE-emergent: persistent moderate-severity GI AE on current dose that does not respond to symptomatic management is the most common dose-down trigger — reduce by one dose step with reassessment at Month 3 (whether the lower dose maintains adequate weight-loss effect for the patient).

Tirzepatide T2D dose-adjustment triggers worked detail:

Target-not-met: HbA1c above individualized target at Month 6 on 5 mg triggers escalation to 7.5 mg or 10 mg consideration; persistent above-target HbA1c at 15 mg maximum dose triggers transition to Section 7 non-response algorithm (consider SGLT-2 add per §9.2 within-Module combinations; or transition to a different agent — though within-class transition options are limited as tirzepatide is the most efficacious approved dual-incretin / GLP-1 class agent for T2D HbA1c per SURPASS-2 head-to-head).
Target-overshoot: hypoglycemia risk on concurrent insulin or sulfonylurea is the most common overshoot pattern; protocol typically titrates down the concurrent agent rather than down-titrating tirzepatide (§6.7 hypoglycemia AE class management).

Tirzepatide OSA-with-obesity dose-adjustment triggers worked detail:

Target-not-met: AHI not significantly reduced at Week 52 follow-up sleep study on max-tolerated dose with documented adherence — sleep medicine specialist reassessment; consider CPAP intensification; transition to Section 7 non-response algorithm if max-tolerated tirzepatide does not produce AHI improvement.
Target-met with CPAP-current phenotype: consider CPAP-modification or discontinuation per sleep medicine specialist + follow-up polysomnography. Tirzepatide does NOT replace CPAP for all patients with OSA — patients with persistent OSA on tirzepatide should continue CPAP.

5.5 Worked example — tirzepatide maintenance scenarios

A non-diabetic adult on Zepbound 15 mg for CWM, Month 12 on target dose, has lost 18 kg (~17% of starting weight, on-trajectory for SURMOUNT-1 effect-size at 15 mg). Maintenance per §5.3 — quarterly visits Y1, biannual thereafter; weight, BP, brief AE-and-adherence interview at each visit; body-composition reassessment (DEXA biannually after Y1); lipid panel annually. SURMOUNT-4 (PMID 38078870) chronic-therapy framing is the counseling beat (§10.7 discontinuation conversation): if discontinuation is considered, the +14% regain trajectory through week 88 is the operational counseling content; re-initiation pathway available per §8.6 if regain occurs and warrants re-treatment.

A T2D adult on Mounjaro 10 mg, Month 6 on target dose, HbA1c reduced from 8.4 to 6.8 (on-trajectory for SURPASS-2 effect-size at 10 mg). HbA1c target met; maintenance dose continues at 10 mg. Quarterly HbA1c trajectory tracking; UACR annually; lipid panel annually. If patient is also on concurrent insulin or sulfonylurea, §6.7 hypoglycemia management applies — concurrent insulin typically reduced ~20% at tirzepatide initiation; further reduction if HbA1c reaches individualized target.

An adult with moderate-severe OSA + obesity on Zepbound 15 mg, Month 6 on max-tolerated dose, has lost 14% of starting weight. Follow-up sleep study scheduled at Week 52 per SURMOUNT-OSA methodology. Sleep medicine specialist co-management. If AHI is reduced below the moderate-OSA threshold (AHI <15) and the patient is CPAP-naive, sleep medicine specialist may reassess CPAP need; if patient is CPAP-current, CPAP-modification or discontinuation decision is sleep-medicine-specialist-led with follow-up polysomnography. Patients with persistent OSA on tirzepatide should continue CPAP.

Pattern W cross-check at §5.5. The monitoring intervals above are reconciled with the §3 pre-treatment panel (every monitoring lab is established as a baseline lab) and with the §6 AE-management algorithms (every AE-trigger lab is in the monitoring schedule). The protocol explicitly states: lipase is monitored on symptom-prompted basis (abdominal pain), not on scheduled-interval basis, per the AC2-26-class system-observations precedent on not screening with low-specificity labs absent symptom.

6. Side-effect management

6.1 Purpose

Define the anticipatory framing and clinician response algorithms for the adverse-event categories that apply to tirzepatide. Section 6 is the AE-by-AE-class operational reference for the practice — what to expect, when to escalate, when to discontinue. The section is structured by AE class (GI, gallbladder, pancreatitis, ophthalmology including the NAION class-differentiation precision, injection site, hypoglycemia-in-T2D-with-concurrent-agent, immunogenicity) with each AE class addressed in a standard sub-structure: anticipatory framing, identification, severity grading, first-line management, escalation triggers, discontinuation triggers.

Pattern R enforcement at this section: each AE-class sub-block opens with anticipatory framing — what the AE is, why it occurs, how common it is in the trial program — before management. Opening with discontinuation triggers would steer clinicians (and through training materials, patients) toward fear-framed AE response rather than expectation-anchored AE response.

Pattern V enforcement at this section: when an AE-class signal is post-marketing or under evaluation, the protocol documents the signal status precisely (post-marketing pharmacovigilance vs labeled warning vs labeled contraindication) and does not generalize signal direction beyond what is established. The ION/NAION class-differentiation at §6.5 is the load-bearing Pattern V + Pattern AA precision point in this section.

6.2 Class-level safety profile (per Lilly Mounjaro / Zepbound product labels)

Discontinuation rates due to adverse events: 6–10% across registration trials, primarily GI-driven. Serious adverse events occur at rates similar to placebo overall; the differential AE signature is dominated by GI category.

Black box warning: personal or family history of MTC or MEN-2 (class-level precaution shared with other GLP-1 RAs and the dual-incretin coagonist class).

Contraindications: known hypersensitivity to tirzepatide or any product excipients; history of severe gastroparesis (per Lilly product labels).

Relative contraindications: history of pancreatitis; severe gastrointestinal disease; pregnancy (Category X-equivalent labeling — §6.8 + §8.4).

Class-level safety topics per product label: hypoglycemia risk when co-administered with insulin or sulfonylureas (§6.7); acute kidney injury risk in setting of severe GI volume contraction (counseling on hydration; titration pause if symptomatic); hypersensitivity reactions (rare); acute pancreatitis (§6.4); cholelithiasis and acute cholecystitis (§6.3 secondary; canonical Section 6.5).

6.3 GI AE class — the dominant AE class for tirzepatide

Anticipatory framing. Tirzepatide’s dual-incretin mechanism — delayed gastric emptying (GLP-1R-dominant), central appetite-pathway modulation (both receptors), direct GI-motility effects — produces a characteristic AE profile: nausea, vomiting, diarrhea, constipation, dyspepsia, eructation, abdominal pain. The AE profile is typically peak-at-dose-escalation and attenuates within 2–4 weeks at stable dose. Pooled SURMOUNT / SURPASS prevalence: nausea 25–33%, diarrhea 16–22%, vomiting 8–14%, constipation 7–12%, dyspepsia 8–10%, decreased appetite 9–12%. Discontinuation due to GI AE: 6–10% of tirzepatide arms across SURMOUNT registration program.

SURMOUNT-5 head-to-head GI tolerability (PMID 40353578): broadly comparable between tirzepatide and semaglutide; tirzepatide nausea slightly higher in some sub-analyses, vomiting comparable; discontinuation for AEs comparable between arms. The mechanism-class hypothesis (GIPR co-agonism potentially attenuating GLP-1R-mediated emesis at weight-loss-equivalent doses) has partial preclinical support and partial clinical-tolerability sub-analysis support; Pattern AA precision: this is mechanistic-hypothesis with partial support, not an independent clinical claim.

Identification. Patient-reported during early-monitoring contacts (§4.5) and maintenance visits (§5.3). Standardized severity grading via CTCAE: Grade 1 (mild, intervention not indicated), Grade 2 (moderate, minimal intervention indicated), Grade 3 (severe, hospitalization indicated), Grade 4 (life-threatening). Most protocol-relevant GI AEs are Grade 1–2.

First-line management. Non-pharmacologic: meal-size reduction, slow eating pace, low-fat / non-greasy meal composition, hydration emphasis. Pharmacologic: ondansetron 4 mg PRN for nausea (consider scheduled dosing for moderate-severity recurring nausea); loperamide PRN for diarrhea; osmotic laxative (polyethylene glycol) for constipation; reassurance and meal-pairing adjustments for eructation / dyspepsia.

Escalation triggers. Grade 3 severity at any step. Persistent Grade 2 severity beyond 4 weeks at stable dose. Vomiting with severe abdominal pain → assess for pancreatitis (§6.4). Significant unintended weight loss exceeding the protocol’s target trajectory.

Discontinuation triggers. Grade 3 GI AE that does not resolve with dose-down. Patient preference (a tolerable but unpleasant Grade 2 profile is a Pattern Z calibration point — the protocol does not override patient preference for discontinuation by framing tolerability as obligation).

6.4 Gallbladder AE class

Anticipatory framing. Cholelithiasis and acute cholecystitis: ~0.6–1.5% in SURMOUNT-1 and across the SURMOUNT / SURPASS programs — consistent with the known GLP-1 RA + dual-incretin class signal. Mechanism: rapid weight loss elevates gallstone risk through cholesterol supersaturation in bile. Higher tirzepatide dose and faster weight-loss trajectory associate with higher gallbladder event rate.

Identification. Symptom-prompted — right upper quadrant pain, post-prandial colicky pain, fever-and-pain combination. Ultrasound is the first-line imaging study; HIDA scan if functional cholecystitis suspected without stones.

First-line management. Symptomatic gallstones with confirmed cholelithiasis and biliary colic: surgical consultation, typical management trajectory is laparoscopic cholecystectomy. Protocol decision: temporary hold during peri-operative window; resume at maintenance dose post-cholecystectomy if no other contraindication has emerged.

Escalation triggers. Acute cholecystitis with systemic signs (fever, leukocytosis, sepsis). Choledocholithiasis suspected (LFT pattern + dilated CBD on imaging) requires urgent ERCP or surgical consultation.

Discontinuation triggers. Recurrent symptomatic gallstones post-cholecystectomy with bile-acid-related pattern: clinician judgment for protocol continuation vs alternative-molecule transition. A single uncomplicated cholecystitis episode with cholecystectomy is not a permanent contraindication. Gallbladder-mediated AE class is distinct from gallbladder cancer signal — class-level 2026 SR (PMID 41359966) characterizes gallbladder cancer in low-certainty “may have little or no effect” tier; the gallstone-mediated mechanism for gallbladder AE is rapid-weight-loss-mediated cholesterol supersaturation, mechanism-distinct from cancer biology.

6.5 Ophthalmologic AE class — NAION class-differentiation precision + diabetic retinopathy stratification

The Section 6.5 framing for tirzepatide is class-differentiation-precise per Pattern AA, NOT the semaglutide-protocol §6.5 framing. Two distinct ophthalmologic findings require differentiated discussion:

6.5.a NAION (non-arteritic anterior ischemic optic neuropathy) — class-differentiation finding

Anticipatory framing — the class-differentiation precision. ION (ischemic optic neuropathy, with NAION as the primary clinical subtype) class-level signal: Lawrenson 2025 PMID 40383360 (Lakhani M, Kwan ATH, Mihalache A et al Am J Ophthalmol 277:148–168) — 180-country FAERS (n=12,936,341 reports) + WHO VigiBase pharmacovigilance study. Key class-differentiation findings:

Compound	FAERS ROR (ION)	VigiBase ROR (ION)	Signal status
Semaglutide	11.12 (95% CI 8.15–15.16)	68.58 (95% CI 16.75–280.67)	Significant ION association
Tirzepatide	Not significant at same threshold	Not significant at same threshold	No ION signal at same threshold

Class-differentiated finding: ION (NAION primary subtype) signal is specific to semaglutide at the analytical thresholds Lakhani 2025 applied; signal absent for tirzepatide at the same thresholds. EMA Pharmacovigilance Risk Assessment Committee classified NAION as a “very rare” side effect of semaglutide (June 2025); NAION is NOT labeled by either FDA or EMA for tirzepatide as of 2026-05-13. FDA has not updated semaglutide US labels for NAION as of 2026-05-13 (US/EU labeling divergence on this axis).

Post-approval exposure-window asymmetry caveat. Semaglutide ~82 months (FDA approval December 2017 through study cutoff September 2024) vs tirzepatide ~28 months (FDA approval May 2022 through September 2024). Disproportionality analyses with shorter post-approval exposure are statistically less likely to detect rare-event signals at the same threshold. Absent-signal-at-threshold ≠ absent-signal-in-population. The class-differentiated finding is real at the analytical threshold Lakhani 2025 applied; the inference to underlying-population signal patterns is exposure-window-limited.

Additional converging evidence on the semaglutide-NAION axis (cited for class-context completeness; tirzepatide-absent-signal is the load-bearing differentiation):

Hathaway et al 2024 JAMA Ophthalmol PMID 38958939 — single-center matched cohort; HR 4.28 (95% CI 1.62–11.29) in T2D + obesity; HR 7.64 (95% CI 2.21–26.36) in overweight/obese — semaglutide-exposed, not tirzepatide.
Grauslund et al 2024 Int J Retina Vitreous PMID 39696569 — Danish nationwide 5-year longitudinal cohort n=424,152 T2D — HR 2.19 (95% CI 1.54–3.12) for NAION in semaglutide-exposed; tirzepatide exposure not analyzed due to limited Danish tirzepatide uptake during the period.
Cheng et al 2026 J Endocrinol Invest PMID 41021211 — multi-database FAERS + VigiBase pharmacovigilance confirming semaglutide-NAION signal.

Mechanism hypotheses for the class-differentiation: tirzepatide’s GIPR co-agonism may produce a different ophthalmic-signal profile via different downstream mechanisms — hypothesis-generating only; no established mechanism for the differential. Tirzepatide’s distinct biased-affinity profile at GLP-1R (~5-fold lower affinity than native GLP-1 per Coskun 2018 PMID 30473097) may produce different downstream signaling at vascular / optic-disc tissues. Different patient populations and prescription patterns between the two compounds may produce different observable populations. Reporting bias differences between compounds at the time of pharmacovigilance database analysis (though Lakhani 2025 attempted to control for this). Mechanism is research-state-incomplete and hypothesis-generating only — Pattern AA discipline: the protocol does NOT claim tirzepatide is “safer than semaglutide on eyes” (regulatory-claim-coded promotional language); it states factually that the class-differentiated pharmacovigilance finding shows ION signal absent for tirzepatide at the same threshold as semaglutide’s significant signal, with the post-approval exposure-window asymmetry caveat.

Identification. Acute monocular vision loss, typically painless, often altitudinal visual field defect. Optic disc edema on exam in the acute phase. Differential includes giant cell arteritis (arteritic AION, separate entity), retinal vascular occlusion, optic neuritis.

First-line management. Urgent ophthalmology evaluation. Discontinue tirzepatide pending evaluation. Cross-reference with ESR / CRP to rule out arteritic etiology.

Escalation triggers. Confirmed NAION → permanent tirzepatide discontinuation; ophthalmology co-management; consideration of contralateral-eye risk (NAION recurrence in fellow eye is the established ophthalmology-counseling beat post-event).

Discontinuation triggers. Confirmed NAION → permanent tirzepatide discontinuation regardless of indication continuation. Transition to non-tirzepatide Module 5 alternative if Module 5 indication continues — within the GLP-1 RA + dual-incretin coagonist class, the class-differentiated finding does not categorically generalize to “no GLP-1 RA / dual-incretin agent should be used in NAION-recovery context” but the within-class direction-of-effect is not yet established for cross-compound transition (Pattern V flag); semaglutide is the documented-signal compound and is contraindicated post-NAION; other class members are clinician-judgment with informed-consent for the post-NAION context.

Clinical action for tirzepatide pre-treatment ophthalmology counseling (Pattern AA + Pattern Z precision). Standard ophthalmologic counseling at tirzepatide initiation includes the class-differentiated NAION finding: the signal is documented for semaglutide but absent for tirzepatide at the same pharmacovigilance thresholds (post-approval exposure-window asymmetry caveat applies). Particular attention in patients with known NAION risk factors (crowded optic disc, prior NAION in fellow eye, hypertension, sleep apnea, dyslipidemia) — the absence of signal at population thresholds does not exclude individual-patient risk; clinical assessment of optic-disc anatomy and risk factors is appropriate. §10.5 comparator conversation carries the multi-dimensional fact-based comparison with semaglutide including this class-differentiation precision per Pattern Z calibration anchor 4.

6.5.b Diabetic retinopathy progression — class-level + baseline-status-stratified findings

Anticipatory framing. Diabetic retinopathy worsening with rapid glycemic improvement is a class-level GLP-1 RA observation (most clearly documented in semaglutide SUSTAIN-6). Within the SURPASS clinical trial program (Phase 3), no increased risk of DR progression was observed in the controlled-trial population — Popovic et al 2024 Diabetes Obes Metab Letter PMID 38456523 (commentary on SURPASS retinopathy data; publication type = Letter, not pooled meta-analysis; commentary-tier evidence); the underlying SURPASS controlled-trial-population pooled retinopathy data anchor is Rosenstock 2023 Diabetes Care. The controlled-trial population excluded patients with unstable or severe baseline retinopathy.

Real-world evidence presents a more nuanced baseline-status-stratified picture. Buckley et al 2025 Diabetologia PMID 40637847 — retrospective matched cohort study; n=6,869 (3,435 tirzepatide-exposed matched 1:1 with 3,434 tirzepatide-unexposed individuals; matching on sex, diabetes duration, retinopathy status, HbA1c, retinal screening episodes, glucose-lowering medications):

Overall multivariate analysis (adjusted for established risk factors): OR 2.15 (95% CI 1.24–3.74) for new-onset proliferative diabetic retinopathy on tirzepatide. Authors’ qualitative interpretation: signal “particularly evident” in R1M1 (mild non-proliferative DR + maculopathy) or moderate-to-severe NPDR baseline.
In patients without retinopathy at baseline: OR 0.73 (95% CI 0.62–0.86) — reduced odds of new-onset retinopathy on tirzepatide.

Pattern V direction-of-effect discipline: the canonical and the protocol present both findings precisely. The elevated-OR finding (OR 2.15) is from the overall multivariate analysis with authors’ qualitative subgroup interpretation; the no-baseline-retinopathy subgroup shows the opposite direction of effect (OR 0.73, protective). The protocol does NOT summarize the Buckley 2025 RWE as a one-directional “retinopathy risk” finding.

Mechanism for retinopathy progression in moderate-severe baseline subgroup. Rapid glycemic improvement-mediated worsening — hypothesized as the dominant mechanism, consistent with the class-level SUSTAIN-6 observation for semaglutide and the broader insulin / intensification-of-glycemic-control retinopathy progression literature. Tirzepatide produces faster and larger glycemic improvement than comparator antidiabetes therapies in T2D + retinopathy patients, which may explain higher progression rates in the moderate-severe baseline subgroup.

Identification. Ophthalmologic baseline at initiation (§3.7 + §3.3 diabetes-complication screen). Routine retinal screening per ophthalmology specialist co-management; HbA1c trajectory monitoring at quarterly maintenance visits.

First-line management. Ophthalmology pre-treatment evaluation in patients with known retinopathy or long-standing T2D. Gradual titration to mitigate rapid glycemic improvement-mediated worsening (the standard 4-week step schedule is the rapid-improvement-mitigation default; slow-titration variant for high-risk DR baseline). Ophthalmology co-management where retinopathy is moderate or worse at baseline.

Escalation triggers. Documented progression of retinopathy on serial fundoscopy during tirzepatide therapy — ophthalmology specialist co-management; clinician judgment for tirzepatide continuation, dose-down, or transition. The retinopathy concern is mechanistically distinct from the ION/NAION signal at §6.5.a — retinopathy worsening is hypothesized as glycemic-improvement-mediated; NAION is a direct optic-disc-vasculature signal.

Discontinuation triggers. Severe progression of proliferative diabetic retinopathy attributable to rapid glycemic improvement may trigger temporary discontinuation or slow-titration restart with ophthalmology co-management. This is clinician-judgment-driven, not protocol-mandated discontinuation.

6.6 Pancreatitis AE class

Anticipatory framing. Wen 2025 SR (PMID 40988099) — class-level meta-analysis of 62 GLP-1 RA RCTs (n=66,232) including tirzepatide. Pooled RR 1.44 (95% CI 1.09–1.89, P=0.009) for acute pancreatitis across the class. Modest relative increase; absolute event rates <1–2% per year. Authors frame as “slightly increased risk, likely minimal.” Pattern V direction-of-effect anchor: the canonical and the protocol present Wen 2025 accurately — modest pooled-RR-elevated finding per authors’ framing, not null/protective.

Tirzepatide-specific pancreatitis data within Wen 2025: the SURPASS and SURMOUNT registration trials contributed to the pooled analysis; tirzepatide-specific pancreatitis subgroup analyses do not show differentiation from the class-level pattern. The Section 2.4 framing — severe prior pancreatitis history as labeled relative contraindication / precaution — is the screening-criterion anchor; the §6.6 framing is the during-therapy AE response.

Identification. Symptom-prompted — persistent severe upper abdominal pain radiating to back, often with vomiting, often worse with food. Differential: GI AE class (§6.3) typically does not produce severe persistent localized pain — protocol differentiates “GI AE expected at titration” from “pancreatitis-suspect abdominal pain” via persistence, severity, localization, and lipase.

First-line management. Acute persistent severe abdominal pain with vomiting → immediate evaluation, lipase + amylase + CMP + CBC + lipid panel (rule out hypertriglyceridemic pancreatitis), abdominal imaging (CT or MRCP). Discontinue tirzepatide pending evaluation.

Escalation triggers. Confirmed acute pancreatitis (clinical + lab + imaging) → hospitalization, supportive management per pancreatitis standard-of-care. Severity stratification via Ranson / BISAP / APACHE-II.

Discontinuation triggers. Confirmed acute pancreatitis attributable to tirzepatide (excluding alternative etiology — gallstones, hypertriglyceridemia, alcohol) → permanent discontinuation, transition to non-GLP-1 alternative if Module 5 indication continues.

6.7 Injection-site AE class

Anticipatory framing. Injection-site reactions (erythema, induration, pruritus, nodule) occur in approximately 5% of patients on weekly subcutaneous tirzepatide; usually mild and self-resolving. Lipohypertrophy can develop with site-rotation failure.

Identification. Patient-reported or visit-observed. Photograph documentation if reaction is moderate or atypical.

First-line management. Site-rotation reinforcement (abdomen, thigh, upper arm — alternate weekly). Topical hydrocortisone for pruritus. Discontinuation rarely indicated for injection-site AE alone.

Discontinuation triggers. Severe / systemic hypersensitivity reaction is a labeled contraindication (§2.4) and triggers permanent discontinuation.

6.8 Hypoglycemia AE class (T2D indication with concurrent insulin or sulfonylurea)

Anticipatory framing. Tirzepatide monotherapy is not a hypoglycemia-inducing class — the glucose-dependent insulin-secretion mechanism (both GLP-1R and GIPR pathways converge on the glucose-dependent insulin secretory cascade per canonical §2.2) is protective against hypoglycemia in the absence of concurrent hypoglycemia-inducing agents. Hypoglycemia risk emerges when tirzepatide is combined with insulin or sulfonylurea — the typical pivotal-trial protocol was to reduce the concurrent agent at tirzepatide initiation (insulin typically reduced ~20% at tirzepatide initiation; sulfonylurea typically reduced ~50% or discontinued).

Identification. Patient-reported hypoglycemia events; CGM data if available; HbA1c trajectory below individualized target.

First-line management. Reduce concurrent insulin or sulfonylurea dose; reinforce hypoglycemia recognition and treatment counseling.

Discontinuation triggers. Hypoglycemia from tirzepatide is not a discontinuation indication for tirzepatide; it is a dose-adjustment indication for the concurrent agent.

6.9 Drug-drug interaction AE class

Anticipatory framing. Tirzepatide gastric emptying delay alters absorption kinetics for narrow-therapeutic-window co-administered oral drugs. The dominant interaction class derives from gastric emptying delay; mechanism-redundant combinations (DPP-4 inhibitors, other GLP-1 RAs) are avoided.

Specific interaction considerations:

Warfarin — closer INR monitoring during titration and dose changes.
Levothyroxine — thyroid function monitoring; consider dose adjustment with weight loss.
Oral contraceptives — backup non-oral contraception during initiation period due to absorption reduction (§10.4 pregnancy-planning conversation includes this beat for reproductive-age patients on protocol).
Anti-epileptics, immunosuppressants with narrow therapeutic index — closer therapeutic drug monitoring where feasible.
DPP-4 inhibitors — mechanism-redundant (DPP-4 inhibitor preserves endogenous GIP and GLP-1; tirzepatide is exogenous DPP-4-resistant analog); not indicated as combination.
Other GLP-1 RAs / dual-incretin coagonists / triagonists — not indicated (within-class redundant agents); transition between agents, not co-administration (§9.4 contraindicated combinations).

6.10 Immunogenicity AE class

Anticipatory framing. Anti-drug antibody (ADA) formation with tirzepatide is reported but at rates not associated with efficacy loss or hypersensitivity events in registration trials. Coskun 2018 PMID 30473097 and subsequent immunogenicity sub-analyses characterize the ADA profile; ADA cross-reactivity with native GIP and native GLP-1 is limited by sequence modifications (canonical §1.2). ADA cross-reactivity with semaglutide or other GLP-1 RAs has not been characterized at depth; patients switching with ADA history warrant case-by-case clinical evaluation.

Clinical action. Long-term ADA surveillance with chronic therapy continues across the class; no current clinical action required beyond standard hypersensitivity assessment. Hypersensitivity reactions are rare but reported; standard discontinuation if anaphylaxis or severe hypersensitivity.

6.11 Worked example — tirzepatide AE management scenarios

A non-diabetic adult on Zepbound 15 mg for CWM, Month 6 on target dose, presents with persistent moderate nausea (Grade 2, recurring 2–3 days after each weekly injection), early satiety, and 16 kg total weight loss from baseline (~14% of starting weight, on-trajectory for SURMOUNT-1 effect-size at 15 mg).

Protocol response. Anticipatory framing: this is within the trial-program-typical AE profile at the maintenance dose; the recurring 2–3-day post-injection pattern is consistent with the pharmacokinetic profile (Tmax 24–72 hours; flat plasma concentration profile across 7-day dosing interval). First-line management: meal-size and meal-composition reinforcement; scheduled (not just PRN) ondansetron for the 2–3-day-post-injection window. Reassessment at Month 7: if nausea remains Grade 2 and patient is on-trajectory for indication target, continue current dose; if Grade 2 nausea is unacceptable to patient (Pattern Z calibration: patient-preference-anchored, not clinician-override), dose-down to 12.5 mg with Month 9 weight-trajectory reassessment.

A T2D adult on Mounjaro 10 mg, Month 4, presents with acute severe upper abdominal pain radiating to back, vomiting, hospitalized in ED. Lipase elevated to 5× upper limit normal; abdominal CT shows mild peripancreatic fat stranding without necrosis. Triglycerides 220 mg/dL (not severely elevated). No gallstones on imaging. No alcohol history.

Protocol response. Confirmed acute pancreatitis; alternative etiologies (gallstones, severe hypertriglyceridemia, alcohol) ruled out — tirzepatide-attributable acute pancreatitis is the working diagnosis. Discontinue tirzepatide. Supportive pancreatitis management per standard of care. Permanent discontinuation post-recovery; transition to non-GLP-1 T2D regimen (consider SGLT-2 + metformin combination, or pioglitazone — though Pattern V cautions on DPP-4 inhibitors which also carry pancreatitis labeled cautionary use); counsel on T2D-progression context and limited within-class transition options.

A non-diabetic adult on Zepbound 15 mg, Month 4, develops acute painless monocular vision loss in left eye over approximately 24 hours. Ophthalmology urgent evaluation confirms left optic disc edema with altitudinal visual field defect; ESR and CRP normal (excluding GCA). Diagnosis: NAION, left eye.

Protocol response. Discontinue tirzepatide. Confirmed NAION → permanent tirzepatide discontinuation. Ophthalmology co-management for fellow-eye monitoring (post-NAION fellow-eye recurrence is the established counseling beat). Module 5 indication continuation: discuss with patient — the class-differentiated NAION finding (Lawrenson 2025 PMID 40383360) shows tirzepatide signal absent at population thresholds and semaglutide signal present; the case-level NAION event in this patient is an individual-patient event that does not invalidate the population-level class-differentiation but does establish individual-patient sensitivity. Pattern V flag — cross-class transition to non-GLP-1 / non-dual-incretin alternative is the conservative direction post-NAION; alternative GLP-1 RA (semaglutide) is contraindicated post-NAION given the documented signal; alternative dual-incretin coagonist is not currently available; cross-class consideration includes amylin / GLP-glucagon dual / triagonist / GIPR-antagonist + GLP-1R-agonist bispecific class members where the NAION signal direction is not yet established (Pattern V cautions). The patient and clinician decide whether to attempt an alternative class or transition to non-GLP-1 weight-management approach.

A T2D adult on Mounjaro 10 mg, Month 9, with R1M1 baseline retinopathy at initiation, has follow-up ophthalmology exam showing progression to moderate-severe NPDR. Per Buckley 2025 RWE finding, R1M1 baseline is the subgroup where the OR 2.15 overall multivariate analysis signal is most evident per authors’ qualitative interpretation. Mechanism: rapid HbA1c improvement on tirzepatide (HbA1c reduced from 9.2 to 6.5 over 9 months). Ophthalmology specialist co-management. Clinical decisions: ophthalmology specialist-led — may include retinal laser, intravitreal anti-VEGF therapy, or other interventions depending on progression characteristics. Tirzepatide continuation vs dose-down vs slow-glycemic-improvement strategy: clinician judgment with ophthalmology co-management; the HbA1c target may need to be re-evaluated to a less aggressive trajectory.

Pattern AA precision in §6.11. “Pancreatitis-attributable to tirzepatide” is precise (alternative etiologies ruled out, temporal association). The labeled framing for tirzepatide pancreatitis is “labeled relative contraindication / precaution,” not “labeled contraindication” — but post-event, permanent discontinuation is the clinical judgment standard. “NAION class-differentiation finding” is precise — Lawrenson 2025 PMID 40383360 pharmacovigilance shows signal absent for tirzepatide at the same threshold as semaglutide’s significant signal, with the post-approval exposure-window asymmetry caveat; the individual-patient case-level NAION event does not invalidate the population-level class-differentiation. “Retinopathy progression in R1M1 baseline subgroup” is precise per Buckley 2025 baseline-status-stratified RWE finding.

7. Plateau and non-response algorithm

7.1 Purpose

Define the structured clinical-decision approach when tirzepatide’s primary effect has not met its target (non-response) or has stalled below a clinically meaningful endpoint (plateau). Section 7 is the diagnostic-and-decision branch point: distinguish pseudo-plateau (apparent stall within normal trajectory variation) from true plateau (legitimate response stall requiring intervention) and from non-response (insufficient initial effect from the start).

7.2 Pseudo-plateau vs true plateau vs non-response — diagnostic distinctions

Pseudo-plateau. Apparent stall in weight or HbA1c or AHI that is in fact within normal week-to-week or month-to-month variation, or that reflects body-composition change (lean mass preservation with fat-mass continued loss) rather than total-weight stall, or that occurs in the predictable trial-trajectory pattern (most weight-loss molecules show a deceleration in months 6–9 even on continued effective therapy). Pseudo-plateau is recognized by trajectory-context — comparing the patient’s curve to the trial-program-typical curve (SURMOUNT-1 trajectory for CWM; SURPASS-2 trajectory for T2D HbA1c; SURMOUNT-OSA Trial 1 or 2 trajectory for OSA) and identifying that the apparent stall is in fact on-trajectory.

True plateau. Legitimate response stall — patient was responding, then response flattens or reverses. True plateau is recognized by trajectory inflection plus an adequate observation window (typically 2–3 months at stable dose to confirm the inflection is not pseudo-plateau).

Non-response. Insufficient initial effect from the start. Recognized at Month 3–6 on target dose with effect substantially below the trial-program-typical effect for the patient’s phenotype.

7.3 Set-point reset framing

Weight-regulation physiology operates on a defended set-point that the body actively resists changes from. SURMOUNT-4 (PMID 38078870) is the load-bearing chronic-therapy anchor for the set-point framing — discontinuation produces +14% regain through week 88 across patients who had achieved ~−20.9% on tirzepatide titration. Weight loss into a new set-point window typically requires sustained pharmacologic and behavioral intervention; loss beyond the body’s defended range tends to recruit counter-regulatory responses (increased hunger signals, decreased energy expenditure — adaptive thermogenesis). True plateau in CWM context is often the body’s defense at a new set-point — not therapeutic failure but biological-equilibrium attainment. The protocol framing in counseling (Section 10) does not pathologize plateau but reframes it as biological-equilibrium and as the decision point for continuation, intensification, or maintenance-at-new-set-point.

7.4 Decision tree for plateau / non-response

Confirm adherence. Missed doses, injection-technique issues, salt-form variability (if patient is using compounded tirzepatide with tirzepatide sodium vs tirzepatide base per pharmacy specification — the salt-form difference produces different molar dose at the same mass dose; §8.3.2 of the canonical) are the most common pseudo-non-response causes. Confirm via patient interview and via prescription-refill audit.
Confirm trajectory-context. Plot the patient’s curve against the trial-program-typical curve for their phenotype. If the curve is on-trajectory, pseudo-plateau — continue current dose, reassess at next interval.
Confirm dose attainment. Is the patient on max-tolerated dose? If not, complete titration to max-tolerated (typically 10 / 12.5 / 15 mg depending on tolerability); reassess at Month 3 on max-tolerated dose.
Reassess phenotype. Does the patient’s clinical picture support a phenotype the trial program enrolled, or is the patient in an under-represented or out-of-trial phenotype? Pattern V direction-of-effect — for under-represented phenotypes, expected effect-size may be smaller, recalibrate target.
If true plateau / non-response confirmed at adequate observation window:
- CWM context. Tirzepatide is the highest-effect approved single-agent anti-obesity medication as of 2026-05-13 (SURMOUNT-5 head-to-head superiority over semaglutide at max-tolerated doses; cross-trial superiority over single GLP-1 RAs across the class). Non-response transition options are limited within the approved single-agent class. Within-class transition to semaglutide is generally not the right move (cross-trial expected effect smaller). Cross-class consideration includes retatrutide (Phase 3 readout pending — TRIUMPH program with TRIUMPH-4 topline showing −28.7% at 12 mg per Lilly investor disclosure December 11, 2025; not yet FDA-approved); MariTide bispecific GIPR-antagonist + GLP-1R-agonist (MARITIME Phase 3 active; once-monthly SC; not yet FDA-approved); CagriSema fixed-combination amylin + GLP-1 RA (REDEFINE Phase 3 readout reported; FDA submission status — check current). Adjunct intensification: structured behavioral / nutritional / activity program intensification — SURMOUNT-3 (intensive lifestyle bridge protocol) demonstrated additive efficacy: lifestyle intervention + tirzepatide produces greater total weight loss than either alone.
- T2D context. Persistent above-target HbA1c at 15 mg maximum dose triggers SGLT-2 inhibitor add (well-supported by individual-agent CVOT / KOOT data; combination is broadly clinically additive); or insulin add per ADA / EASD progression algorithm. Within-class transition to semaglutide is direction-of-effect-attenuated per SURPASS-2 head-to-head; transition to retatrutide (Phase 3 pending) or MariTide (Phase 3 pending) is currently not an FDA-approved option.
- OSA context. AHI not significantly reduced at follow-up sleep study despite max-tolerated tirzepatide with documented adherence — sleep medicine specialist reassessment; CPAP intensification; consider polysomnography for OSA phenotype characterization (positional vs non-positional, REM-dependent vs non-REM-dependent). Tirzepatide-resistant OSA suggests sleep medicine intervention is the primary pathway.
- MASH context (off-label). SYNERGY-NASH Phase 2 anchored use; non-response transition options are limited. Class-context: semaglutide ESSENCE is the FDA-approved alternative (Aug 2025 approval); resmetirom (Rezdiffra, FDA-approved 2024) is a non-GLP-1 alternative; hepatology co-management for adjunct decisions.
- HFpEF + obesity context (off-label). SUMMIT-anchored use; non-response framing typically not applicable at individual-patient level over short observation windows — primary endpoint is HF event reduction at population level.
- CV-risk context (off-label, SURMOUNT-MMO pending). Similar — CVOT context is event-reduction, not surrogate; individual-patient “non-response” framing is less applicable.

7.5 Worked example — tirzepatide non-responder algorithm

A non-diabetic adult on Zepbound 15 mg, Month 6 on max-tolerated dose, has lost 4.2 kg from baseline (~4% of starting weight) — below the SURMOUNT-1 effect-size anchor of ~−20.9% to −22.5% at 15 mg at 72 weeks and below the 5%-at-Month-6 trajectory marker.

Algorithm walkthrough.

Step 1 — adherence. Patient reports 100% adherence; prescription-refill audit confirms no gaps. No salt-form variability concern (FDA-approved Zepbound pen formulation, not compounded). Adherence-confirmed pseudo-non-response ruled out.

Step 2 — trajectory-context. Patient’s curve at Month 6 (4% loss) is below the SURMOUNT-1 25th percentile trajectory at Month 6. Not on-trajectory.

Step 3 — dose attainment. Patient is on 15 mg max-tolerated dose; no further titration available within tirzepatide labeled dosing.

Step 4 — phenotype reassessment. Patient is a 51-year-old female, BMI 34, no T2D, prior weight-loss attempts including 18 months on phentermine-topiramate with regain to current weight. Per SURMOUNT-1 enrollment, this phenotype is represented (BMI ≥30, no T2D); prior weight-loss-failure with regain is the typical SURMOUNT-1 enrollment phenotype. Phenotype is trial-enrolled and effect-size expectation per SURMOUNT-1 is approximately −20.9% treatment-regimen estimand / −22.5% efficacy estimand; patient’s response at Month 6 is substantially below typical SURMOUNT-1 trajectory.

Step 5 — non-response confirmed; CWM context decision branches.

5a. Adjunct intensification first. SURMOUNT-3 (intensive lifestyle bridge protocol) demonstrated additive efficacy: lifestyle intervention + tirzepatide produces greater total weight loss than either alone. Before within-class or cross-class molecule transition, intensification of behavioral / nutritional / activity program is the conservative first move. Pattern V direction-of-effect: behavioral intensification is effect-additive, not effect-substitutive.

5b. Cross-class transition consideration (with off-label / investigational framing). Within-class transition to semaglutide is direction-of-effect-attenuated (SURMOUNT-5 head-to-head superiority of tirzepatide). Cross-class options pending FDA approval: retatrutide (TRIUMPH program; TRIUMPH-4 topline December 2025 −28.7% at 12 mg; peer-reviewed publication pending; not yet FDA-approved as of 2026-05-13); MariTide (MARITIME Phase 3 active; once-monthly SC; not yet FDA-approved); CagriSema (REDEFINE-1 −20.4% at full adherence; FDA submission status — check current). Pattern AA precision: each of these is investigational pending FDA approval; the conversation per §10.6 frames the off-label / investigational status explicitly.

5c. Bariatric surgery consideration. Metabolic surgery (Roux-en-Y gastric bypass, sleeve gastrectomy) remains the most effective intervention for severe obesity with sustained weight loss in the 25–35% range at 1–2 years. Patient who is a tirzepatide non-responder may benefit from bariatric consultation; pre-bariatric optimization using tirzepatide is an off-label clinical context.

Pattern Z calibration anchor applied at §7.5. The decision among 5a / 5b / 5c is patient-anchored, not clinician-mandated. Counseling beats (Section 10) frame the options without steering — present the trial-program-anchored effect-size estimates for each option (with investigational-pending status precision for 5b options), present the trade-offs (cost, AE-profile, adherence-complexity, surgical risk for 5c), and the clinician-patient decision is patient-preference-driven within the medically reasonable options.

8. Discontinuation and tapering

8.1 Purpose

Define when to stop tirzepatide, how to taper if tapering is indicated, and how to frame post-discontinuation expectations — particularly the weight-regain trajectory in CWM indications per the SURMOUNT-4 chronic-therapy anchor. Section 8 is the symmetric counterpart to Section 4 (initiation): just as initiation has anticipatory framing for AE and adherence, discontinuation has anticipatory framing for the post-discontinuation period and for the patient-and-clinician decision about whether and when to re-initiate.

8.2 When to discontinue — discontinuation triggers

Discontinuation is indicated when one of the following emerges:

Confirmed contraindication discovery (e.g., new MTC diagnosis, new MEN-2 family-history identification, new pregnancy). §2.4 hard contraindications are immediate-discontinuation triggers.
Severe AE attributable to the molecule — confirmed acute pancreatitis (§6.6 worked detail), confirmed NAION (§6.5.a worked detail), severe hypersensitivity reaction (§6.7 / §2.4).
Indication remission or resolution — T2D HbA1c sustained below target with weight stable in some patients; OSA reduced below moderate threshold with sleep-medicine-specialist concurrence (CPAP-modification path; tirzepatide-discontinuation path is less common given the chronic-therapy framing); MASH histologic resolution sustained (rare; pending Phase 3 readout for FDA approval); HFpEF stabilization (rare and clinical-judgment-dependent).
Patient preference. Patient-anchored discontinuation decision is legitimate; the protocol’s role is to inform the post-discontinuation expectations (the SURMOUNT-4 +14% regain trajectory through week 88 is the load-bearing counseling content) and the re-initiation pathway, not to override the patient’s decision.
Cost / access barriers. Particularly for non-T2D Zepbound indication where insurance coverage is more variable. Pattern Z calibration anchor 1+2 (compounded vs FDA-approved) framing applies at §10.3 — present the cost / access reality factually, not as steering. The compounded tirzepatide market has narrower scope post the October 2024 FDA shortage-list removal; clinicians and patients consider current FDA enforcement state for sourcing decisions.
Pre-conception planning for reproductive-age patients: discontinuation with ~25–35-day pharmacokinetic washout arithmetic per §8.4 below. Label-recommended ≥2-month pre-conception planning window is the conservative clinical recommendation. This is anticipatory discontinuation, not reactive.

8.3 How to taper — molecule-specific tapering considerations

For tirzepatide in any indication: pharmacokinetic tapering (step-down dosing) is not pharmacologically required — the half-life-driven pharmacokinetic washout occurs at fixed kinetics regardless of taper schedule (~5-day elimination half-life; ~25 days substantial clearance; ~35 days complete clearance). However, gradual dose reduction is the protocol-recommended pattern for two reasons:

Weight-regain trajectory smoothing. Abrupt discontinuation produces faster weight-regain than gradual reduction; gradual reduction allows behavioral adaptation (the patient’s reduced appetite signal returns gradually, allowing meal-size and meal-composition adaptation in parallel).
AE-class symmetry. Some patients experience appetite-rebound or GI-pattern shifts on abrupt discontinuation; gradual reduction attenuates these.

Typical taper pattern for tirzepatide CWM (Zepbound 15 mg target dose): 15 mg → 10 mg × 4 weeks → 7.5 mg × 4 weeks → 5 mg × 4 weeks → 2.5 mg × 4 weeks → discontinue. Total taper period ~16 weeks. This is clinician-judgment within label, not label-mandated; the FDA label permits abrupt discontinuation. Pattern AA precision: “clinician-judgment within label,” not “label-recommended.”

Tapering modification for patients on doses below 15 mg: step down by 2.5 mg every 4 weeks from current maintenance to 2.5 mg, then discontinue. For pre-conception planning context: §8.4 arithmetic governs the total discontinuation-to-conception window; tapering is folded into the ≥2-month label-recommended pre-conception planning window.

8.4 Pre-conception washout arithmetic — tirzepatide and class considerations

Tirzepatide elimination half-life ~116 hours (~5 days). Approximately 5 half-lives are required for >95% pharmacokinetic clearance — ~25 days for substantial clearance; ~35 days for more complete clearance. The FDA labels for Mounjaro and Zepbound (Category X-equivalent in pregnancy) specify discontinuation at least 2 months before a planned pregnancy. The ~25–35-day arithmetic is the pharmacokinetic minimum; the 8-week label recommendation is the conservative clinical recommendation accounting for pharmacokinetic and pharmacodynamic clearance plus a margin.

Comparison to semaglutide pre-conception arithmetic. Semaglutide elimination half-life ~7 days (1 week); ~5 half-lives ≈ 35 days for >95% clearance. The label-recommended ≥2-month pre-conception window is approximately the same as tirzepatide’s. The tirzepatide ~5-day half-life produces faster pharmacokinetic clearance than semaglutide’s ~7-day half-life — but the label-recommended pre-conception planning window is similar across the class (the conservative recommendation incorporates pharmacodynamic clearance and a margin).

This 8-week pre-conception window is the operational counseling beat for reproductive-age patients on tirzepatide for any indication — §10.4 counseling beats anchor to this arithmetic with Pattern Z calibration anchor 3 precision (research-state-leading; lead with Parker 2025 human pregnancy-exposure data, not PK arithmetic or label-status).

Oral contraceptive interaction. Tirzepatide gastric emptying delay can reduce oral contraceptive absorption efficacy. Patient counseling at initiation includes backup contraception recommendation (non-oral methods — IUD, implant, injection, ring, patch) for women of reproductive potential, particularly during titration when GI effects are most prominent (§6.9 drug-interaction context). This is a tirzepatide-specific counseling beat that is also relevant for the broader GLP-1 RA + dual-incretin class.

8.5 Post-discontinuation weight-regain framing

The trial-program data on post-tirzepatide-discontinuation weight regain anchor to SURMOUNT-4 (Aronne et al 2024 JAMA PMID 38078870): discontinuation after target-dose achievement (participants completed 36-week tirzepatide titration achieving mean ~−20.9%) was followed by +14% weight regain on placebo switch through week 88 — approximately two-thirds of the run-in weight loss regained over the post-discontinuation follow-up. Continued-tirzepatide arm showed additional −5.5% weight loss in the same period.

The mechanism — set-point physiology and the defended-weight biology described in §7.3 — predicts that without pharmacologic support, the body’s counter-regulatory responses re-establish a higher equilibrium. Parallel chronic-therapy evidence from the GLP-1 RA class (semaglutide STEP-1 Extension PMID 35441470 showing two-thirds regain at 52 weeks off therapy; semaglutide STEP-4 randomized withdrawal) is consistent. The combined message across the class is unambiguous: chronic therapy is required; weight and cardiometabolic benefits are sustained with continued therapy.

The protocol framing in counseling (§10.7) does not pathologize weight regain post-discontinuation; it frames the regain trajectory as the expected biological response, the same way pre-treatment counseling framed the appetite-suppression mechanism as the biological intervention. Patients considering discontinuation are counseled on the expected regain trajectory and on the re-initiation pathway if regain occurs and warrants re-treatment.

8.6 Re-initiation pathway

A patient who discontinued and is considering re-initiation: typically re-titration from the 2.5 mg starting dose is the protocol-recommended pattern — the tolerability re-priming is equivalent to initial titration; abrupt re-initiation at the prior target dose is not recommended due to GI AE recurrence risk. Section 4 titration applies. Indication confirmation per Section 1, selection-criteria re-screening per Section 2, and pre-treatment workup refresh per Section 3 if the discontinuation period exceeded approximately 12 months or if any new comorbidity has emerged.

8.7 Worked example — tirzepatide discontinuation scenarios

Scenario A — pre-conception planning. A 33-year-old female on Zepbound 15 mg, Month 14 on target dose, has lost 19 kg (~18% of starting weight, on-trajectory) and is planning conception in approximately 6 months. Counseling beat: discuss the 8-week pre-conception window per Lilly product label; plan taper start approximately 4 months from now (16-week taper period, then ~8-week post-discontinuation pharmacokinetic-and-margin window per label). Pattern Z calibration anchor 3 applies — pregnancy-planning counseling LEADS with Parker 2025 (PMID 40329607) pooled human pregnancy-exposure data (incidence of congenital abnormalities appears relatively low across the GLP-1 RA + dual-incretin class including tirzepatide; sample limited; prospective registry call), then presents the pharmacokinetic facts (~5-day half-life, ~25–35-day clearance, 8-week label recommendation) and the post-discontinuation weight-regain trajectory (SURMOUNT-4 +14% regain) without steering toward continuation or discontinuation; the patient’s reproductive-planning decision is patient-anchored.

Scenario B — patient-preference discontinuation at Month 18. A 59-year-old male on Zepbound 15 mg, has lost 19 kg (~17% of starting weight) and stabilized at the new weight for the last 4 months; reports tolerable but consistent mild GI AE profile and wishes to discontinue. Counseling beat: discuss SURMOUNT-4 trajectory data — approximately two-thirds of lost weight is typically regained over post-discontinuation follow-up; re-initiation pathway is available if regain occurs and is clinically meaningful. Protocol taper: 15 mg → 10 mg × 4 weeks → 7.5 mg × 4 weeks → 5 mg × 4 weeks → 2.5 mg × 4 weeks → off. Post-discontinuation monitoring at Month 3, 6, 12 with weight and BP; re-initiation decision at any monitoring visit if regain warrants and patient agrees.

Scenario C — confirmed acute pancreatitis (per §6.6 case). Permanent discontinuation. No taper — abrupt discontinuation appropriate given the AE-attributable etiology. Transition to non-GLP-1 alternative per indication.

Scenario D — new pregnancy on protocol. A 30-year-old female on Zepbound 15 mg discovers pregnancy at approximately 5 weeks gestation. Both Mounjaro and Zepbound are Category X-equivalent labeled contraindications in pregnancy. Immediate discontinuation. Obstetrics co-management; the pharmacokinetic clearance window (~25–35 days, with first-trimester exposure already occurred) is documented for the obstetrics record. Pattern Z calibration anchor 3 framing — Parker 2025 pooled human pregnancy-exposure data (PMID 40329607) shows incidence of congenital abnormalities appears relatively low in the GLP-1 RA + dual-incretin class including tirzepatide; sample limited; the reassuring early signal is the load-bearing human evidence as of 2026-05-13. Post-pregnancy and post-lactation, re-initiation decision per Section 1 indication and Section 2 selection-criteria reapplication.

Scenario E — confirmed NAION (per §6.5.a case). Permanent tirzepatide discontinuation given the individual-patient case-level NAION event. Cross-class transition consideration per §6.5.a / §6.11 worked detail — within-class transition to semaglutide is contraindicated post-NAION given the documented class signal; cross-class options are clinician-judgment with informed-consent.

Pattern Z calibration anchor 3 precision in §8.7. Pregnancy-planning counseling LEADS with the Parker 2025 human pregnancy-exposure pooled data, then presents the ~5-day pharmacokinetic half-life, the ~5-half-life clearance arithmetic, the 8-week label recommendation, and the post-discontinuation weight-regain trajectory — facts that the patient uses to make her reproductive-and-treatment-planning decision. The protocol does not steer the patient toward continued pharmacotherapy by emphasizing weight-regain risk, nor toward discontinuation by emphasizing pregnancy-exposure risk. Both facts are presented; the patient decides.

9. Combination rules

9.1 Purpose

Define what stacks with tirzepatide, what is contraindicated in combination, and the rationale for each combination category. Section 9 is the protocol’s bridge to Module 5.12 Combination Protocols and to the lean-mass-stack protocols (M5.5 Tesamorelin / AOD-9604; M5.6 Lean Mass / CJC-Ipamorelin / MOTS-c).

The section is structured by combination class — within-Module-5 combinations (tirzepatide + SGLT-2 / insulin / metformin in T2D; no tirzepatide-class combo products in clinical-stage development as of 2026-05-13 per public sources — distinct from the semaglutide CagriSema / IcoSema combo-product context), cross-Module combinations (tirzepatide + lean-mass peptides; tirzepatide + adjunct anti-obesity agents from other classes), and contraindicated combinations.

Pattern W cross-section consistency applies: every combination in this section is reconciled with Section 2 (no patient enters a combination with a contraindicated agent), Section 6 (combination AE-management does not mask or substitute for individual-agent AE-management algorithms), and Section 10 (counseling beats for combinations are Pattern Z calibration-anchor-compliant).

9.2 Within-Module-5 combinations

Tirzepatide + SGLT-2 inhibitor (T2D indication context). Class-additive HbA1c and cardiovascular / kidney benefits; commonly co-prescribed in T2D + CKD or T2D + ASCVD context. Mechanism rationale: SGLT-2 inhibitor adds glucose-osmotic-diuretic and ketogenesis-modulating effects; the combination is broadly supported by individual-agent CVOT and KOOT data and by clinical-practice cohort analyses. Monitoring: eGFR at 2 weeks post-SGLT-2 initiation (typical small reversible eGFR decline expected), then routine quarterly per §5.3.

Tirzepatide + insulin (T2D advanced). Common in T2D with progressed beta-cell failure where tirzepatide monotherapy is insufficient. §6.8 hypoglycemia management applies; concurrent insulin dose typically reduced ~20% at tirzepatide initiation. SURPASS-3 (vs insulin degludec), SURPASS-4 (vs insulin glargine), SURPASS-5 (add-on to basal insulin), SURPASS-6 (vs prandial insulin lispro added to basal) all enroll tirzepatide + insulin contexts and support the combination with appropriate dose adjustment.

Tirzepatide + metformin. Complementary; standard combination in T2D management. SURPASS-2 enrolled tirzepatide + metformin; SURPASS-AP-Combo similar.

Tirzepatide + DPP-4 inhibitor: not indicated. Mechanism redundancy — DPP-4 inhibitor preserves endogenous GIP and GLP-1; tirzepatide is exogenous DPP-4-resistant analog. The combination is not clinically additive. Avoid co-prescribing.

No tirzepatide-class combo products in clinical-stage development as of 2026-05-13 per public sources. Distinct from the semaglutide-combo-product context (CagriSema = cagrilintide + semaglutide; IcoSema = insulin icodec + semaglutide). This is a class-development observation, not a comparative-claim characterization per Pattern AA. Future tirzepatide-class combo products may emerge as the field matures.

9.3 Cross-Module combinations — lean-mass and body-composition stacks

Cross-Module combinations involve adding a peptide outside the GLP-1 RA / amylin / GIP / glucagon metabolic-axis family to address a complementary clinical objective — most commonly lean-mass preservation during weight loss. Tirzepatide’s greater absolute weight-loss magnitude (per SURMOUNT-5 head-to-head vs semaglutide) translates to greater absolute lean-mass loss in body-composition sub-analyses — the lean-mass preservation context is particularly relevant for tirzepatide.

Tirzepatide + CJC-1295 / Ipamorelin (GH secretagogue stack). Mechanism rationale: CJC-1295 (GHRH analog) plus Ipamorelin (GH secretagogue) elevates endogenous GH pulsatility, supporting lean-mass preservation during caloric deficit. Module 5.6 Lean Mass canon documents the M5.6 v3 stack with phenotype targeting, monitoring (IGF-1 anchored), and AE-class considerations. Pattern N.1 applies: CJC-1295 and Ipamorelin are peptides — they belong in the Peptides folder path, not the Small-Molecules folder path.
Tirzepatide + MOTS-c (mitochondrial peptide). Mechanism rationale: MOTS-c is a mitochondrially-encoded peptide with metabolic-regulator activity in preclinical models. Trial-program status: limited human Phase 1/2 data; clinician judgment within Module 5.6 stack framing. Pattern AA precision: do not state “approved” for an investigational peptide.
Tirzepatide + Tesamorelin (FDA-approved for HIV-associated lipodystrophy; off-label for visceral adiposity in non-HIV context). Mechanism rationale: Tesamorelin (GHRH analog) reduces visceral adipose tissue; in combination with tirzepatide-mediated weight loss, visceral-adiposity-targeted effects are additive. Module 5.5 Tesamorelin canon documents trial-program data and off-label clinical use. Pattern AA precision: the off-label-for-non-HIV-visceral-adiposity framing is explicit, not implicit; off-label use is clinician-judgment within informed-consent and primary-source-supported clinical reasoning.
Tirzepatide + GHK-Cu (skin / connective-tissue peptide). Cross-Module — GHK-Cu is a Module 5.7 (skin-elasticity, post-weight-loss skin tone) topical or injectable application. Pattern V direction-of-effect: GHK-Cu trial-program data are limited for the post-weight-loss-skin indication specifically; clinician judgment with patient-anchored expectations. Particularly relevant for tirzepatide given the greater weight-loss-magnitude and corresponding skin-tone concerns at maintenance.

9.4 Contraindicated combinations

Tirzepatide + concurrent semaglutide (avoid; redundant within-class mechanism with additive AE profile and no demonstrated additive benefit; transition between agents, not co-administration). The transition direction is from semaglutide to tirzepatide for non-response context (Section 7); from tirzepatide to semaglutide is rarely the right direction (SURMOUNT-5 / SURPASS-2 head-to-head direction-of-effect favors tirzepatide).
Tirzepatide + other GLP-1 RAs (liraglutide, dulaglutide, exenatide-class — all redundant within-class; not indicated).
Tirzepatide + retatrutide / survodutide / MariTide / orforglipron / aleniglipron (avoid; redundant within-class mechanism; transition between agents, not co-administration). Note: retatrutide, survodutide, MariTide, aleniglipron are all Phase 3 pending and not yet FDA-approved as of 2026-05-13; orforglipron is Phase 3 submitted for obesity / T2D by Lilly. Combination is not indicated regardless of approval status.
Tirzepatide + DPP-4 inhibitor (§9.2 — not contraindicated by safety; contraindicated by lack of additive benefit and by mechanism redundancy).
Tirzepatide + sulfonylurea at full sulfonylurea dose (relative — combination produces excess hypoglycemia risk; sulfonylurea should be reduced or discontinued at tirzepatide initiation per §6.8).
Tirzepatide + agents that severely delay gastric emptying (relative — additive gastric-emptying delay may worsen GI AE profile and may impair absorption of concurrent oral medications).

9.5 Worked example — tirzepatide combination scenarios

Scenario A — tirzepatide 15 mg + CJC-1295 / Ipamorelin stack (M5.6 v3). A 49-year-old male, baseline BMI 38, on Zepbound 15 mg, Month 8 on target dose, has lost 22 kg with DEXA showing approximately 28% of lost mass as lean mass (proportional to total weight loss per SURMOUNT-1 body composition sub-analysis pattern). The absolute lean-mass loss is greater than would have been the case on semaglutide at comparable weight-loss-magnitude trajectory (because tirzepatide achieves greater absolute weight loss). Add M5.6 v3 stack — CJC-1295 + Ipamorelin per the M5.6 stack protocol with IGF-1 monitoring and GH-secretagogue-class AE awareness. Monitoring: DEXA at 3 and 6 months on stack to track lean-mass trajectory; IGF-1 quarterly; resistance training program co-prescription. Pattern Z calibration anchor 5 (off-label / extrapolation transparency) applies — counseling beat states explicitly that CJC-1295 and Ipamorelin are not FDA-approved for this indication and that the combination is supported by mechanism rationale plus M5.6 v3 clinical-practice cohort, not by Phase 3 RCT data.

Scenario B — tirzepatide + SGLT-2 inhibitor (T2D + CKD). A 62-year-old male with T2D + CKD eGFR 44, on Mounjaro 10 mg with HbA1c 7.6 (above individualized target 7.0); add empagliflozin 10 mg daily per ADA / EASD T2D-progression algorithm. Combination is well-supported by individual-agent CVOT / KOOT data and by additive HbA1c reduction. Monitoring: eGFR at 2 weeks post-SGLT-2 initiation (typical small reversible eGFR decline expected), then routine quarterly per §5.3. Pattern V direction-of-effect: combination is effect-additive on HbA1c, on kidney composite, and on CV events per individual-agent data; cross-class combination supported by clinical-practice and by individual-agent trial data, not by head-to-head combination RCT.

Scenario C — tirzepatide + semaglutide concurrent (contraindicated). A patient seeking dual-class metabolic intensification. Counseling beat: combination not indicated — these are within-class redundant agents; transition between them (Section 7 non-response algorithm) is the appropriate decision, not co-administration. Effect-size context: SURMOUNT-5 + SURPASS-2 head-to-head support tirzepatide as the higher-effect within-class agent if semaglutide non-response is the clinical context; transition with appropriate semaglutide discontinuation (per §8 — abrupt discontinuation acceptable in this transition context given immediate replacement with same-class agent) and tirzepatide initiation per §4 initiation protocol.

Scenario D — tirzepatide + tesamorelin (off-label visceral-adiposity stack). A 56-year-old female, baseline BMI 33 with visceral-adiposity-dominant phenotype, on Zepbound 15 mg, Month 12 on target dose, has lost 17 kg with DEXA showing continued visceral adipose tissue residual concern. Add tesamorelin per Module 5.5 canon — off-label for non-HIV visceral adiposity; clinician-judgment with informed-consent framing per §10.6. Pattern AA precision: the tesamorelin FDA-approved indication is HIV-associated lipodystrophy; non-HIV use is explicit off-label.

Pattern W cross-check at §9.5. Each combination above is reconciled with Section 2 (no patient enters a combination with a contraindicated agent), Section 6 (combination AE-management does not mask or substitute for individual-agent AE-management algorithms), and Section 10 (counseling beats for combinations are Pattern Z calibration-anchor-compliant).

10. Patient counseling beats (Pattern Z calibration-anchor-compliant)

10.1 Purpose

Define the protocol’s patient-counseling content for tirzepatide — the conversations the clinician has with the patient at each protocol phase. Section 10 is the operational anchor for Pattern Z (cumulative-tone calibration) and for Pattern R (lead-framing calibration); the counseling beats are the most reader-facing content the protocol produces and are the most vulnerable to drift from “presenting facts” to “steering decisions.”

The five Pattern Z calibration anchors are verbatim examples from the semaglutide v1.0-final canonical (Sections 8.3.2, 12.10-Pattern-2, 6.8, 12.10-Pattern-6, 12.10-Pattern-8), established as the calibration baseline post-iteration-4 verification on 2026-05-11. The canonical source — including verbatim anchor text — is /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md. The Tirzepatide v1.0-final canonical Sections 1.4 + 6.8 + 8.3.2 + 8.7 + 12.5 + 12.10 P2 / P5 / P6 / P8 verify against these anchors with compound-specific translations where compound-specific facts differ. The five anchors referenced throughout this section as Anchors 1–5:

Anchor 1 — Compounded-formulation operational characteristics (verbatim sema §8.3.2; tirzepatide-translated at canonical §8.3.2). Leads with what the compounded option IS (real-world clinical option used by substantial patient population; 503A / 503B pathways); frames operational characteristics neutrally; differences from FDA-approved framed as “factual scope, not deficit framing.” The meta-principle binding all five anchors: lead with what the option IS, never with what it is not. Tirzepatide-specific translation: compounded tirzepatide regulatory landscape has narrower scope post the October 2024 FDA shortage-list removal; salt-form differentiation (tirzepatide base vs tirzepatide sodium per pharmacy specification — distinct chemical entities) is a tirzepatide-specific quality-criteria addition.
Anchor 2 — Compounded vs FDA-approved patient-counseling beat (verbatim sema §12.10 Pattern 2; tirzepatide-translated at canonical §12.10 P2). Affirming open: “Compounded tirzepatide is a real clinical option used by many patients.” Shared-decision-making close: “let’s review the specific compounding pharmacy’s quality practices — sterility testing, certificate of analysis, salt-form transparency, accreditation — and walk through reconstitution training together. That’s how the decision gets made well.” Tirzepatide-specific translation: salt-form transparency beat added; current regulatory state (post-shortage, evolving FDA enforcement, ongoing litigation) flagged as the operational context.
Anchor 3 — Pregnancy section research-state-leading structure (verbatim sema §6.8; tirzepatide-translated at canonical §6.8). LEADS with human pregnancy-exposure data — Parker 2025 PMID 40329607, not PK arithmetic or label-status. The Parker 2025 pooled dataset includes tirzepatide alongside semaglutide, liraglutide, dulaglutide, and class-related compounds — the tirzepatide-translation does not change the lead-with-Parker-2025 discipline. Pharmacokinetic facts (tirzepatide-specific: ~5-day half-life vs semaglutide ~7-day half-life) and label recommendation (≥2-month pre-conception window for both Mounjaro and Zepbound) appear AFTER research-state lead. Animal data + Category-X-equivalent framing relegated to scoped factual context after the human-data lead.
Anchor 4 — Multi-dimensional comparator framing (verbatim sema §12.10 Pattern 6; tirzepatide-translated at canonical §12.10 P6). Tirzepatide-vs-semaglutide counseling presents 8+ dimensions: weight magnitude (SURMOUNT-5 head-to-head PMID 40353578), CV evidence (SELECT done for semaglutide; SURMOUNT-MMO active for tirzepatide), MASH approval (ESSENCE approved for semaglutide; tirzepatide SYNERGY-NASH Phase 3 in development), kidney evidence (FLOW done for semaglutide; SURMOUNT-CKD pending for tirzepatide), ophthalmologic NAION class-differentiation (signal documented for semaglutide per Hathaway 2024 + Grauslund 2024; absent for tirzepatide at same threshold per Lawrenson 2025 PMID 40383360 with post-approval exposure-window asymmetry caveat), OSA approval (tirzepatide approved December 2024; semaglutide research-state), GI tolerability profiles, cost, route, HFpEF + obesity (SUMMIT Phase 3 done for tirzepatide; pooled semaglutide HF analysis comparable class-level). Opens with affirmation of BOTH compounds; closes with shared-decision-making invitation. This is the load-bearing comparator anchor for tirzepatide; the framing leads with affirmation of both compounds, acknowledges tirzepatide’s weight-magnitude advantage explicitly, and presents the NAION class-differentiation precisely.
Anchor 5 — Off-label / extrapolation framing (verbatim sema §12.10 Pattern 8; tirzepatide-translated at canonical §12.10 P8 — microdosing-for-longevity example). Presents trial-population scope as fact (SURMOUNT obesity BMI ≥30 or ≥27 + comorbidity; SURPASS T2D; SUMMIT HFpEF + obesity; SURMOUNT-OSA OSA + obesity); frames extrapolation as research-state-incompleteness, NOT as “no” answer; explicit off-label labeling; informed-consent acknowledgement; closes with shared-decision-making invitation. Tirzepatide-specific translation: the class-differentiated NAION finding for semaglutide does not extend to tirzepatide in pharmacovigilance data (Lawrenson 2025) — this is a substantive class-differentiation that appears in the off-label / longevity discussion.

Compound-specific counseling beats MUST verify against verbatim canonical anchors, not just abstract principles. Each protocol’s Section 10 production includes a verbatim-diff check against the canonical anchor file at PSV iteration 1 — and the tirzepatide canonical’s §12.10 P2 / P5 / P6 / P8 beats have already been verified against the calibration-anchor file (per /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md Stage 4 module audit application).

10.2 Initiation conversation (Section 4 anchor)

The initiation conversation occurs at the pre-treatment workup completion / Section 4 initiation visit. Required counseling beats for tirzepatide:

What the molecule is (Anchor 1): tirzepatide is a once-weekly subcutaneous injection. It is a dual-receptor coagonist — engaging both the GLP-1 receptor (same receptor as semaglutide / Wegovy / Ozempic) and the GIP receptor (additional receptor that single-GLP-1 agonists do not target). Brands: Mounjaro for T2D; Zepbound for chronic weight management or moderate-to-severe OSA with obesity. Same active drug; brand differs by indication.
What it does for the patient’s indication (Anchor 1, Anchor 4): expected effect-size with trial-anchor precision per Section 1.5 and Section 5.2 effect-size envelopes. For CWM: SURMOUNT-1 trajectory at 15 mg ~−20.9% treatment-regimen / −22.5% efficacy estimand at 72 weeks. For T2D: SURPASS-2 HbA1c reductions −2.01% / −2.24% / −2.30% at 5 / 10 / 15 mg vs semaglutide 1 mg −1.86%. For OSA: SURMOUNT-OSA AHI reduction ~−25 events/hour with ~50% achieving AHI <5. Comparator framing per §10.5 if patient has within-class alternatives.
The titration schedule (Section 4): 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg over 16–20 weeks at standard pace; slow-titration option (6–8 week steps) for marginal GI tolerability. The patient is informed that the titration timeline is adjustable to their tolerability — slower is fine; faster is not better. Anchor in the steady-state plasma concentration time (~4 weeks per dose level due to ~5-day half-life).
The AE profile expected at each titration step (Section 6 GI class anticipatory framing): nausea is anticipated, typically attenuates, management strategies — non-pharmacologic first, ondansetron PRN second. Reassurance that AE-emergence is not failure but is anticipated. The pooled trial-program prevalence (nausea 25–33%, diarrhea 16–22%, vomiting 8–14%, constipation 7–12%) gives the patient a calibrated expectation.
The chronic-therapy framing (Section 8 anchor): SURMOUNT-4 (PMID 38078870) showed +14% regain through week 88 on placebo switch after run-in titration. Tirzepatide is chronic therapy for the indication — not a course to complete. Plan for indefinite therapy, or for a maintenance strategy supervised by the clinician if discontinuation is considered later.
The pre-conception planning beat for reproductive-age patients (Anchor 3): research-state-leading with Parker 2025 PMID 40329607 pooled human pregnancy-exposure data; pharmacokinetic washout arithmetic (~25–35 days substantial / complete clearance per ~5-day half-life); 8-week label window; post-discontinuation weight-regain trajectory; re-initiation pathway. Backup non-oral contraception during titration period given oral-contraceptive absorption interaction.
Cost / access realities (Anchor 2): present compounded vs FDA-approved if both are available options for the patient’s situation. Tirzepatide-specific: the compounded tirzepatide regulatory landscape post the October 2024 FDA shortage-list removal is narrower than the semaglutide compounding ecosystem at equivalent point in protocol history; clinicians and patients consider current FDA enforcement state for sourcing decisions.
The NAION class-differentiation precision (Anchor 4 sub-beat per §6.5.a): the ION/NAION signal documented for semaglutide is absent for tirzepatide at the same pharmacovigilance threshold (Lawrenson 2025); post-approval exposure-window asymmetry caveat applies. This is presented as fact, not as a “tirzepatide is safer” steering — see §10.5 comparator conversation for the full multi-dimensional fact-based framing.
What the patient signals back if any concern emerges (escalation pathway): symptoms that warrant in-person evaluation within 48 hours (severe persistent abdominal pain, vomiting blood, acute monocular vision loss or any acute visual change, signs of severe AE).

10.3 Compounded-vs-FDA-approved counseling (Anchors 1 + 2)

The compounded-vs-FDA-approved counseling beat is the most frequently Pattern Z-violation-prone conversation in Module 5 protocols, because the regulatory framing differential between compounded and FDA-approved options can easily slide into steering language. The tirzepatide-specific calibration vs the semaglutide protocol: the compounded tirzepatide regulatory landscape has narrower scope post the October 2024 FDA shortage-list removal.

Pattern Z compliant framing — what compounded tirzepatide IS. Compounded tirzepatide is a real-world clinical option used by a substantial patient population. It emerged during the 2022–2024 FDA-declared shortage period through two regulatory pathways:

503A pathway — state-licensed pharmacies compounding to individual prescriptions; oversight via state boards of pharmacy.
503B pathway — FDA-registered outsourcing facilities compounding for office-stock and patient prescriptions; oversight via FDA cGMP inspection.

Current regulatory state (post October 2024 FDA shortage-list removal). FDA’s shortage declaration ended October 2024 for Eli Lilly’s approved Mounjaro and Zepbound products. FDA has taken enforcement actions against 503A and 503B compounding of products that copy FDA-approved drugs in the absence of a shortage. Litigation between compounding pharmacy interests and FDA has continued into 2026. The regulatory landscape is evolving; clinicians using or prescribing compounded tirzepatide should remain current on FDA enforcement actions and litigation outcomes that may affect compounding pharmacy availability. The narrower current scope vs the broader semaglutide-compounding-ecosystem framing at the equivalent point in protocol history is the compound-specific calibration.

What FDA-approved tirzepatide IS. The Eli Lilly-manufactured products (Mounjaro for T2D; Zepbound for CWM and OSA with obesity) with standardized formulation, manufacturer-validated stability, manufacturer-supported clinical data (the SURPASS / SURMOUNT / SUMMIT / SURMOUNT-OSA / SYNERGY-NASH / SURPASS-PEDS / SURMOUNT-MMO programs), and label-defined indication scope. Pre-filled pen presentations at six dose strengths (2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg).

Pattern Z compliant comparison. Both options deliver tirzepatide. The clinical considerations that differ:

Formulation standardization. FDA-approved: standardized concentration, manufacturer-validated stability, pre-filled pen presentation. Compounded: variable depending on compounding pharmacy quality and protocols; lyophilized vial format requiring reconstitution with bacteriostatic water at point of use. The patient and clinician select a pharmacy with documented quality control. Salt-form differentiation (tirzepatide-specific): some compounding pharmacies prepared tirzepatide as the sodium salt rather than tirzepatide base — a distinct chemical entity from the FDA-approved branded product. The salt-form difference has clinical implications: different molar dose at the same mass dose; different solubility and reconstitution characteristics; potentially different pharmacokinetic profile (research-state; not characterized at clinical-trial depth). Quality criteria for compounding pharmacies should include salt-form transparency in certificate of analysis.
Regulatory framework. FDA-approved: full FDA-label authority; manufacturer adverse-event reporting in FDA pharmacovigilance pipeline. Compounded: regulated under state board of pharmacy + FDA 503A/503B framework; adverse-event reporting pathways vary by jurisdiction. Current regulatory state (post October 2024 shortage-list removal) reflects narrower scope and active FDA enforcement.
Cost and access. Compounded: typically lower out-of-pocket cost; access varies by jurisdiction, by current FDA enforcement state, and by litigation outcomes. FDA-approved: typically higher cost; insurance coverage variable for non-T2D Zepbound indication; Lilly direct-pay programs exist for some patient situations.
Clinical-data anchor. Both formulations deliver tirzepatide; the trial-program effect-size data (SURMOUNT, SURPASS, SUMMIT, SURMOUNT-OSA, SYNERGY-NASH, SURPASS-PEDS) were generated with the manufacturer formulation. Compounded effect-size expectations are extrapolated from manufacturer-formulation trial data with the formulation-variation considerations above plus the salt-form variability.

Quality criteria clinicians evaluate when selecting a compounding pharmacy:

Sterility testing per USP <797> (sterile compounding) and <800> (hazardous drugs) standards
Certificate of analysis per batch (peptide content, purity, residual solvents, endotoxin)
Salt-form identification (tirzepatide base vs tirzepatide sodium) — tirzepatide-specific quality criterion
State-licensure (for 503A) or FDA registration (for 503B) verification
Cold-chain shipping documentation
Clinical reputation and pharmacist accessibility

Patient-counseling beat (Anchor 2 verbatim-mirror with tirzepatide-specific salt-form addition): “Compounded tirzepatide is a real clinical option used by many patients. The operational differences from Mounjaro or Zepbound are real — different format that requires reconstitution, different oversight pathway, different storage. Costs are typically lower, and the patient self-administration is similar to insulin self-injection. Some compounded preparations use the sodium-salt form rather than tirzepatide base; that’s a different chemical and matters for dose comparison. If you’re considering it, let’s review the specific compounding pharmacy’s quality practices — sterility testing, certificate of analysis with salt-form, accreditation — and walk through reconstitution training together. That’s how the decision gets made well.”

What Pattern Z compliance does NOT mean. It does not mean presenting compounded as equivalent to FDA-approved in every dimension; it does not mean presenting FDA-approved as exclusively legitimate. It means presenting both as factual categories with their respective trade-offs, allowing the patient and clinician to make a choice anchored to the patient’s circumstances (cost, access, regulatory comfort, formulation comfort, current FDA enforcement state for tirzepatide compounded supply specifically). Pattern Z compliance also does not mean presenting compounded tirzepatide and compounded semaglutide as identical regulatory contexts — the tirzepatide compounded ecosystem post the October 2024 FDA shortage-list removal has narrower scope than semaglutide’s at the equivalent point.

10.4 Pregnancy-planning conversation (Anchor 3)

For reproductive-age patients on tirzepatide for any indication. The conversation LEADS with human pregnancy-exposure research-state data, not with PK arithmetic or label recommendation — this lead-framing discipline is the core of canonical Anchor 3. Required counseling beats:

Human pregnancy-exposure data — Parker 2025 (PMID 40329607). Pooled review of unplanned pregnancies from FDA- and EMA-submitted GLP-1 RA + dual-incretin coagonist regulatory clinical trials — the pooled dataset includes tirzepatide alongside semaglutide, liraglutide, dulaglutide, and class-related compounds. Incidence of congenital abnormalities appears relatively low in this pooled dataset; sample size limited; exposures from unplanned-pregnancy contexts. Prospective planned-pregnancy exposure data is research-state-incomplete; authors call for prospective pregnancy registries.
Pharmacokinetic facts (post-research-state-lead). Tirzepatide elimination half-life ~5 days (~116 hours); ~5 half-lives ≈ 25 days for substantial clearance, ~35 days for more complete clearance. (Compare to semaglutide ~7-day half-life — tirzepatide produces faster pharmacokinetic clearance than semaglutide.)
Label recommendation. Discontinue at least 2 months (8 weeks) before planned conception per Mounjaro / Zepbound labels (Category X-equivalent labeling in pregnancy). Both formulations carry the same pregnancy contraindication.
Oral contraceptive interaction. Tirzepatide gastric emptying delay can reduce oral contraceptive absorption efficacy. Backup non-oral contraception (IUD, implant, injection, ring, patch) is recommended during initiation period, particularly during titration when GI effects are most prominent. This is a tirzepatide-specific counseling beat that is also relevant for the broader GLP-1 RA + dual-incretin class.
Animal data context. Reproductive toxicity studies in animals supported the Category X-equivalent contraindication. Animal data does not always translate to human teratogenicity profile. Parker 2025 human pooled data including tirzepatide is the load-bearing human evidence as of 2026-05-13.
Post-discontinuation weight-regain trajectory. SURMOUNT-4 (PMID 38078870) — approximately +14% regain through week 88 across patients who had achieved ~−20.9% on tirzepatide titration. The biological expectation is well-characterized.
The patient’s reproductive-planning decision is patient-anchored. Some patients on protocol will plan conception within the next 1–2 years; some will plan conception within the next decade; some are not planning conception at all but want awareness of the protocol-discontinuation arithmetic in case planning changes. The counseling beat presents the facts; the timing decision is patient-anchored.
Re-initiation pathway. Post-pregnancy and post-lactation, re-initiation per §8.6 if indication and selection criteria are met. Re-titration from 2.5 mg starting dose is the protocol-recommended pattern.

10.5 Comparator conversation (Anchor 4) — multi-dimensional fact-based comparison with semaglutide

For patients with within-class alternatives (semaglutide is the primary comparator; cross-class alternatives like retatrutide / MariTide / CagriSema are Phase 3 pending and addressed separately under off-label / investigational framing per §10.6). Canonical Anchor 4 requires multi-dimensional fact presentation across 8+ dimensions — single-dimension comparison (weight magnitude alone) is the canonical pre-patch anti-anchor that steered patients away from tirzepatide’s actual head-to-head superiority and that the protocol must NOT reproduce. Required counseling beats:

Weight-loss magnitude (Pattern V trial-anchored). SURMOUNT-5 head-to-head (Aronne et al 2025 NEJM PMID 40353578; n=751; max-tolerated-dose comparison at week 72; obesity without T2D): tirzepatide −20.2% (95% CI −21.4 to −19.1) vs semaglutide −13.7% (95% CI −14.9 to −12.6) — ~6.5 percentage-point difference favoring tirzepatide; P<0.001. Waist circumference reduction: −18.4 cm tirzepatide vs −13.0 cm semaglutide. Cross-trial context (separate trials, indirect): SURMOUNT-1 tirzepatide 15 mg achieved −22.5% (efficacy estimand) in obesity without T2D; STEP UP semaglutide 7.2 mg (Wegovy HD, FDA-approved March 19, 2026, Wharton et al 2025 PMID 40961952) achieved −18.7% — closes the gap with tirzepatide max-dose but is not head-to-head. No head-to-head Wegovy 7.2 mg vs Zepbound 15 mg trial exists as of 2026-05-13.
T2D glycemic comparison. SURPASS-2 head-to-head T2D (Frias et al 2021 NEJM PMID 34170647; n=1,879): tirzepatide HbA1c reductions −2.01% / −2.24% / −2.30% (5 / 10 / 15 mg) vs semaglutide 1 mg −1.86% at Week 40 — superior at all three tirzepatide doses. Weight reductions superior at all three doses. The comparator note: semaglutide 1 mg was the maximum approved Ozempic T2D dose at the time of SURPASS-2; subsequent semaglutide 2.0 mg Ozempic and the obesity-dose semaglutide 2.4 mg Wegovy / 7.2 mg Wegovy HD were not the comparator in SURPASS-2. The obesity-dose head-to-head is SURMOUNT-5.
Cardiovascular outcomes evidence base. Semaglutide SELECT (PMID 37952131; n=17,604; 39.8 months; HR 0.80 for 3-point MACE in BMI ≥27 + established CVD without T2D) — completed; semaglutide-anchor for CV outcomes in non-diabetic obesity + CVD. Tirzepatide SURMOUNT-MMO (NCT05556512; Phase 3 ACTIVE_NOT_RECRUITING; primary completion 2027-10) — pending readout; the analogue trial for tirzepatide. Pattern AA precision: SURMOUNT-MMO is pending, NOT “promising” or “emerging.”
HFpEF + obesity evidence base. SUMMIT (Packer et al 2025 NEJM PMID 39555826; HR 0.62 for CV death or worsening HF events in HFpEF + obesity) — completed; tirzepatide-anchor for HFpEF + obesity. Pooled semaglutide HF analysis (Kosiborod et al 2024 Lancet PMID 39222642; 4-trial pooled across SELECT + FLOW + STEP-HFpEF + STEP-HFpEF DM, n=3,743; HR 0.69) — comparable class-level evidence. Both compounds are class-supportive for HFpEF + obesity as a disease-modifying indication.
MASH approval status. Semaglutide FDA-approved August 2025 for MASH F2/F3 per ESSENCE Phase 3 (PMID 40305708) — completed and approved. Tirzepatide SYNERGY-NASH Phase 2 (PMID 38856224) demonstrated comparable MASH resolution magnitudes (62% at 15 mg) but Phase 3 program is in development; tirzepatide not yet FDA-approved for MASH as of 2026-05-13.
Kidney outcomes evidence base. Semaglutide FLOW (PMID 38785209; T2D + CKD; primary kidney composite HR 0.76 at median 3.4 years) — completed; semaglutide-anchor for kidney outcomes in T2D + CKD. Tirzepatide SURMOUNT-CKD sub-protocol within SURMOUNT-MMO — pending readout.
OSA-with-obesity approval status. Tirzepatide FDA-approved December 2024 (Zepbound OSA indication) — first FDA approval of a pharmacological agent for OSA with obesity. Semaglutide OSA is research-state without a dedicated FDA-approved indication as of 2026-05-13. This is a tirzepatide-specific approval that the semaglutide protocol does not have.
Ophthalmologic class-differentiation (NAION) — LOAD-BEARING for tirzepatide comparator framing. Lawrenson 2025 PMID 40383360 (Lakhani M et al Am J Ophthalmol, 180-country FAERS + WHO VigiBase pharmacovigilance) — semaglutide ION (NAION primary subtype) signal documented (FAERS ROR 11.12 / VigiBase ROR 68.58); signal absent for tirzepatide at the same threshold (post-approval exposure-window asymmetry caveat: semaglutide ~82 months vs tirzepatide ~28 months at study cutoff September 2024). EMA labeled semaglutide for NAION as “very rare” (June 2025); tirzepatide is NOT labeled by either FDA or EMA for NAION. This is a class-differentiation finding, not a class-wide finding — Pattern AA precision. Mechanism research-state-incomplete and hypothesis-generating only (potential GIPR co-agonism contribution, biased-affinity profile contribution, or other compound-specific factors).
GI tolerability profile. Both have GI-dominant AE profile; SURMOUNT-5 head-to-head reported broadly comparable GI tolerability with some sub-analyses favoring tirzepatide at weight-loss-equivalent doses (mechanism-class hypothesis with partial preclinical support — GIPR co-agonism potentially attenuating GLP-1R-mediated emesis); both within-class typical patterns.
Route / platform availability. Tirzepatide: SC injection only as of 2026-05-13 (Mounjaro / Zepbound pen formulations); oral tirzepatide is early-stage development. Semaglutide: SC injection (Wegovy / Ozempic) + oral (Rybelsus, plus oral Wegovy 25 mg approved 2025). Semaglutide has the oral platform; tirzepatide does not. This is a meaningful patient-preference differentiation for patients with strong preference for oral administration.
Cost and access. Patient-specific; both compounds with cash list prices ~1, 000–1,300/month and substantial commercial-payer coverage variation; insurance coverage realities vary by indication and jurisdiction.
Comparator framing precision (Pattern V). Effect-size differentials are anchored to specific trials and specific enrollments. The differential observed in trial populations may or may not generalize to the patient’s specific phenotype; the patient and clinician make the comparator decision with the trial-anchored estimates as one input, not the only input.

Patient-counseling beat (Anchor 4 verbatim-mirror with tirzepatide-specific dimensions): opens with affirmation of both compounds, acknowledges tirzepatide’s weight-magnitude advantage explicitly, closes with shared-decision-making invitation.

“Both compounds are evidence-based weight-management options. SURMOUNT-5 head-to-head showed tirzepatide produced about 6.5 percentage points more weight loss at max-tolerated doses. Beyond that, the compounds differ on cardiovascular and other-outcome evidence bases — semaglutide has the completed SELECT trial showing 20% MACE reduction; tirzepatide’s equivalent trial SURMOUNT-MMO is still active with readout 2027. Semaglutide is approved for MASH per ESSENCE; tirzepatide’s MASH trial is in development. Semaglutide has the FLOW kidney trial completed; tirzepatide’s kidney sub-protocol is part of SURMOUNT-MMO. Tirzepatide is FDA-approved for sleep apnea with obesity per SURMOUNT-OSA; semaglutide isn’t. Tirzepatide has SUMMIT Phase 3 in HFpEF with obesity; semaglutide has a comparable pooled HF analysis. The eye-nerve signal NAION has been documented for semaglutide in pharmacovigilance studies covering 180 countries; the same studies looked at tirzepatide at the same threshold and didn’t find a signal — a real class-differentiation, though the shorter post-approval exposure for tirzepatide means absent-signal-at-threshold doesn’t equal absent-signal-in-population. GI side effects are broadly comparable. Semaglutide has an oral form available; tirzepatide is injection-only. Insurance coverage and cost vary. Here are the facts on each dimension; let’s discuss which factors matter most for your situation.”

10.6 Off-label / extrapolation conversation (Anchor 5)

For uses outside FDA-approved indications — e.g., tirzepatide for HFpEF + obesity (off-label as of 2026-05-13; SUMMIT Phase 3 supports HR 0.62; regulatory pathway in active discussion), tirzepatide for MASH F2/F3 (off-label; SYNERGY-NASH Phase 2 supports 62% resolution at 15 mg; Phase 3 in development), tirzepatide for CV-risk reduction in obesity (off-label; SURMOUNT-MMO Phase 3 active, readout pending 2027-10), tirzepatide for pediatric T2D ages 10–17 (off-label; SURPASS-PEDS supports; FDA pathway pending), or microdosing-for-longevity / metabolic-health context outside the SURMOUNT trial-population scope. Required counseling beats:

Explicit off-label framing. “This use is off-label” — stated, not implied.
Primary-source rationale. Trial data supporting the off-label use — e.g., SUMMIT Phase 3 for HFpEF + obesity rationale; SYNERGY-NASH Phase 2 for MASH rationale; SURPASS-PEDS Phase 3 for pediatric T2D rationale; M5.6 v3 stack data for CJC-Ipamorelin lean-mass-stack rationale.
Informed-consent acknowledgement. Patient understands the use is off-label and consents to clinician judgment within informed-consent standards.
Re-evaluation if labeled indication emerges. If FDA approval for the indication is subsequently granted (e.g., HFpEF expansion if regulatory pathway concludes; MASH expansion post Phase 3 completion; CV expansion post SURMOUNT-MMO readout), the use transitions from off-label to label-supported; the counseling beat re-anchors at that transition.

Patient-counseling beat for microdosing-for-longevity / lean-population extrapolation (Anchor 5 verbatim-mirror with tirzepatide-specific dimensions including the NAION class-differentiation):

“Here’s what the trials studied and what they showed: SURMOUNT enrolled people with obesity (BMI ≥30) or overweight with weight-related comorbidities. SURPASS enrolled T2D patients. SUMMIT enrolled people with heart failure plus obesity. SURMOUNT-OSA enrolled people with sleep apnea plus obesity. Your question is about extrapolating to a different population — lean, no obesity, possibly seeking microdose ‘longevity’ use. That extrapolation isn’t tested in trials. The known side-effect profile is GI effects, gallbladder events, pancreatitis signal — those apply whether the patient is in the studied population or not. The class-differentiated NAION finding for semaglutide doesn’t extend to tirzepatide in pharmacovigilance data at the same threshold, but the shorter post-approval exposure for tirzepatide means absent-signal-at-threshold doesn’t equal absent-signal-in-population. Whether the cardiovascular or metabolic benefit extrapolates to lean populations is research-state-incomplete; SURMOUNT-MMO is active in obesity + CV risk factors but not in lean populations. Let’s discuss what you’re hoping to achieve, what the evidence does and doesn’t tell us about your specific situation, and what monitoring would matter if you decided to proceed.”

10.7 Discontinuation conversation (Section 8 anchor)

For patient-preference, indication-resolution, or AE-driven discontinuation. Required counseling beats:

Reason for discontinuation framing. Patient-preference (legitimate; protocol’s role is to inform, not override); indication-resolution (rare in CWM; in T2D with sustained HbA1c target achievement is possible but the chronic-therapy framing predominates; in OSA may apply with sleep-medicine-specialist concurrence); AE-attribution (clinical decision; protocol-mandated where applicable per §6 — confirmed pancreatitis, confirmed NAION, severe hypersensitivity).
Taper schedule (per §8.3): 15 mg → 10 mg × 4 weeks → 7.5 mg × 4 weeks → 5 mg × 4 weeks → 2.5 mg × 4 weeks → off (for tirzepatide Zepbound CWM 15 mg target dose). Total taper period ~16 weeks. Patient-judgment within taper if accelerated discontinuation preferred. Abrupt discontinuation is FDA-label-permitted but not protocol-preferred for the regain-trajectory-smoothing and AE-symmetry rationales.
Post-discontinuation weight-regain framing (per §8.5): SURMOUNT-4 trajectory data — approximately two-thirds of lost weight is typically regained over the post-discontinuation period; the +14% regain through week 88 is the load-bearing trial-anchor. Not pathologized; framed as expected biological response.
Re-initiation pathway (per §8.6): available if regain occurs and warrants re-treatment; titration restarts at 2.5 mg starting dose, not at prior target dose.

10.8 Pattern Z self-audit on Section 10 counseling beats

The five Anchors above are also the self-audit checklist for Section 10 counseling-beat language. A protocol’s Section 10 is Pattern-Z-violation-positive if any of the following appear:

Compounded tirzepatide framed as default-suspect (e.g., “Compounded tirzepatide is not FDA-approved and should be approached with caution” — Anchor 2 violation; opens with what it is not).
Pregnancy-planning framed with weight-regain-pathway emphasized vs pregnancy-exposure-pathway de-emphasized, or vice versa (Anchor 3 violation; steering through asymmetric emphasis). The Parker 2025 human pooled data must lead, not the Category X-equivalent labeling.
Comparator framing with verbatim trial effect-sizes generalized to the patient’s phenotype without trial-enrollment qualification (Anchor 4 violation; Pattern V cross-fail).
Comparator framing that under-presents the NAION class-differentiation OR over-presents it as a “tirzepatide is safer” steering (Anchor 4 + Pattern AA cross-fail). The precise framing: signal absent for tirzepatide at the same threshold as semaglutide’s significant signal, with post-approval exposure-window asymmetry caveat, mechanism research-state-incomplete.
Off-label use embedded in counseling as if labeled (Anchor 5 violation; Pattern AA cross-fail). MASH, HFpEF, CV-risk-in-obesity, pediatric T2D, microdosing-for-longevity are all off-label as of 2026-05-13.

The Section 10 production agent runs the five-Anchor self-audit before handoff to the verification gate (Appendix A).

11. Source citations

11.1 Purpose

Define the bibliography format, the evidence-hierarchy tiers, and the PMID-anchor / NCT-anchor / DOI-anchor identifier-integrity discipline for the tirzepatide protocol. Section 11 is the protocol’s evidentiary spine — every effect-size claim, every dose threshold, every contraindication, every counseling-beat fact-anchor traces to a Section 11 citation entry. The protocol’s Bibliography references the canonical’s Bibliography at /Process/Tirzepatide/Tirzepatide - Bibliography.md (3,481 verified PMIDs across 204 PubMed E-utilities queries + 22 Phase 2.5 supplement + 143 ClinicalTrials.gov NCT records, per the canonical’s audit trail).

Pattern AB.1 / AB.2 / AB.4 standing scans operate at this section. Every PMID and NCT in §11.5 below has been content-verified through the canonical’s PSV iterations 1 and 2 (Phase 10.5; HALT #8 fired at iteration 1 with 11 discrepancies caught + 5 cascade-5+ identifier-cascade corrections; iteration 2 clean post-patch with 0 new findings per the canonical’s audit trail at /Process/Tirzepatide/Tirzepatide - Primary-Source-Verification-v2.md).

11.2 Bibliography format

Each citation entry contains: first author last name + et al; title; journal + year + volume + pages; PMID; DOI if available; NCT for trial reports; effect-size summary; citation context (protocol sections citing this source).

11.3 Evidence hierarchy tiers

Tier 1 — pivotal Phase 3 RCT with FDA-label-supporting trial-program inclusion. Examples for tirzepatide: SURMOUNT-1, SURMOUNT-2, SURMOUNT-5, SURPASS-2, SURMOUNT-OSA, SUMMIT, SURPASS-PEDS.
Tier 1.5 — Phase 3 head-to-head RCT comparing within-class alternatives. Examples: SURPASS-2 (tirzepatide vs semaglutide 1 mg in T2D); SURMOUNT-5 (tirzepatide vs semaglutide at max-tolerated obesity doses).
Tier 2 — Phase 2 RCT, large Phase 3 extension / open-label, large meta-analysis, pivotal mechanism paper. Examples: SYNERGY-NASH Phase 2 (PMID 38856224); SURMOUNT-3 lifestyle-bridge protocol; SURMOUNT-4 randomized withdrawal; Coskun 2018 medicinal chemistry (PMID 30473097); Ko et al 2026 Annals Intern Med cancer SR (PMID 41359966); Wen 2025 pancreatitis SR (PMID 40988099).
Tier 3 — post-marketing pharmacovigilance, observational cohort, retrospective analysis, case series. Examples: Lawrenson 2025 / Lakhani et al Am J Ophthalmol ION class-differentiation (PMID 40383360); Buckley et al 2025 Diabetologia retinopathy RWE (PMID 40637847); Parker et al 2025 pooled pregnancy-exposure (PMID 40329607).

The protocol does not invert tiers — a Tier 3 case series does not override a Tier 1 trial-program finding; a Tier 1 trial finding can be contextualized by a Tier 3 post-marketing signal but the directional-of-effect anchor remains the Tier 1 source.

11.4 Identifier-integrity discipline — Pattern AB.1 / AB.2 / AB.4

Every PMID, NCT, and DOI in this protocol’s Bibliography has been verified by content, not by existence — abstract retrieval matching title / authors / journal / year / study-type / intervention / population for PMIDs; ClinicalTrials.gov entry retrieval matching sponsor / intervention / indication / phase / status for NCTs. The canonical’s PSV iteration 1 (HALT #8) caught 11 discrepancies with 5 cascade-5+ corrections; the protocol-specific subset below inherits the verified chain.

Pattern AB.4 standing scan: when any identifier is corrected in the canonical, every occurrence in this protocol AND in cross-referenced canon / system-observations / process files is updated in the same commit. The NCT05608252 cascade (mis-attributed as TRIUMPH-1 in the AC2-26 system-observations log) is the failure mode this verification prevents.

11.5 Tirzepatide protocol bibliography subset

Tier 1 — pivotal Phase 3 RCT, indication-anchored.

Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205-216. PMID 35658024. NCT04184622. SURMOUNT-1; CWM-indication anchor in obesity without T2D; treatment-regimen estimand −15.0% / −19.5% / −20.9% at 5 / 10 / 15 mg vs −3.1% placebo; efficacy estimand −22.5% at 15 mg vs −2.4% placebo at 72 weeks. Cited in §1.5, §2.5, §4.6, §5.2, §5.4, §7.5, §10.5.
Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet 2023;402:613-626. PMID 37385275. NCT04657003. SURMOUNT-2; obesity-with-T2D anchor; −12.8% (10 mg) / −14.7% (15 mg) vs −3.2% placebo at 72 weeks. Cited in §1.5, §5.2.
Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024;331:38-48. PMID 38078870. NCT04660643. SURMOUNT-4; randomized-withdrawal anchor; +14% regain on placebo switch through week 88 vs continued tirzepatide additional −5.5%. Load-bearing chronic-therapy anchor. Cited in §1.5, §5.1, §7.3, §8.5, §10.7.
Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med 2025;393:26-36. PMID 40353578. NCT05822830. SURMOUNT-5; direct head-to-head vs semaglutide max-tolerated doses in obesity without T2D at week 72; tirzepatide −20.2% vs semaglutide −13.7%, P<0.001; ~6.5 percentage-point difference favoring tirzepatide; waist circumference −18.4 cm vs −13.0 cm. Cited in §1.5, §3.10, §10.5.
Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021;385:503-515. PMID 34170647. NCT03987919. SURPASS-2; head-to-head vs semaglutide 1 mg in T2D inadequately controlled on metformin; tirzepatide HbA1c reductions −2.01% / −2.24% / −2.30% at 5 / 10 / 15 mg vs semaglutide 1 mg −1.86% at 40 weeks; superior at all three tirzepatide doses; weight reductions superior at all three doses. Cited in §1.5, §5.2, §10.5.
Hannon TS, Kelsey MM, Jadhav AP, et al. Once-weekly tirzepatide in adolescents with type 2 diabetes (SURPASS-PEDS). Lancet 2025;406(10511):1484-1496. PMID 40975112. SURPASS-PEDS; Phase 3 youth-onset T2D ages 10–17; n=99; HbA1c −2.23% vs +0.05% placebo at week 30. FDA pediatric T2D indication pathway pending. Cited in §1.5, §2.2, §5.2.
Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193-1205. PMID 38912654. NCT05412004 / NCT05215574. SURMOUNT-OSA; dual-trial Phase 3 in moderate-to-severe OSA + obesity; AHI reduction −25.3 events/hour (Trial 1 CPAP-naive) and −29.3 events/hour (Trial 2 CPAP-current); ~50% achieving AHI <5. Supported December 2024 FDA Zepbound OSA approval — first FDA approval of pharmacological agent for OSA with obesity. Cited in §1.5, §2.5, §3.9, §5.2.
Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med 2025;392:427-437. PMID 39555826. NCT04847557. SUMMIT; Phase 3 in HFpEF + obesity; HR 0.62 for CV death or worsening HF events; KCCQ-CSS improvement; 6MWT improvement. Regulatory pathway in active discussion; not yet FDA-labeled for HFpEF as of 2026-05-13. Cited in §1.5, §3.6, §5.2.

Tier 2 — Phase 2 RCT, large meta-analysis, pivotal mechanism paper.

Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab 2018;18:3-14. PMID 30473097. Tirzepatide medicinal chemistry; native-GIP backbone with substitutions enabling GLP-1R co-binding; C20 fatty diacid at Lys20 via γGlu-2xOEG linker. Cited in §1.2 (canonical) + scaffold + §6.10 (immunogenicity) + protocol §1.3, §3.7, §6.5.a.
Loomba R, Sanyal AJ, Kowdley KV, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med 2024;391(4):299-310. PMID 38856224. NCT04166773. SYNERGY-NASH Phase 2; biopsy-proven MASH F2/F3; n=190; MASH resolution without worsening fibrosis 44% / 56% / 62% at 5 / 10 / 15 mg vs 10% placebo; fibrosis improvement 55% / 51% / 51% vs 30% placebo at 52 weeks. Phase 3 program in development; FDA submission anticipated post-Phase 3 completion. Cited in §1.5, §3.4, §5.2.
Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Nat Med 2024. SURMOUNT-3; intensive lifestyle bridge protocol; n=579; additional −18.4% on tirzepatide vs +2.5% on placebo after 12-week lead-in; total ~25% weight loss from baseline. Cited in §1.5, §7.5.
Ko C-J, Tsai S-J, Lin S-Y, et al. GLP-1 Receptor Agonists and the Risk of Cancer: A Systematic Review and Meta-analysis. Ann Intern Med 2026. PMID 41359966. Definitive 2026 cancer SR; n=94,245 across 48 RCTs including tirzepatide and other GLP-1 RAs; 11 cancer types + multiple myeloma + meningioma; moderate-certainty “little or no effect” on thyroid / pancreatic / breast / kidney; low-certainty “may have little or no effect” on colorectal / esophageal / liver / gallbladder / ovarian / endometrial / multiple myeloma / meningioma; very uncertain on gastric. Cited in canonical §5 + protocol §2.3, §2.5, §6.4 (gallbladder context).
Wen Y, Zhang Q, Liu X, et al. Pancreatic Adverse Events Associated with GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis. 2025. PMID 40988099. Wen 2025 pancreatitis SR; 62 GLP-1 RA + dual-incretin RCTs n=66,232 including tirzepatide; pooled RR 1.44 (95% CI 1.09–1.89, P=0.009) for acute pancreatitis; modest signal, “slightly increased risk, likely minimal” per authors. Cited in §2.3, §6.6.
Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010. PMID 20203154. Rodent C-cell tumor signal mechanism paper; species-specific to rodents in available primate data; anchor for FDA boxed warning for MTC / MEN-2. Cited in §2.4, §3.7.

Tier 3 — post-marketing pharmacovigilance, observational cohort, retrospective analysis.

Lakhani M, Kwan ATH, Mihalache A, et al. Tirzepatide and Semaglutide Use and Ischemic Optic Neuropathy: A Pharmacovigilance Study. Am J Ophthalmol 2025;277:148-168. PMID 40383360. Lawrenson 2025 (Lakhani et al as primary authors; “Lawrenson 2025” is the editorial-context shorthand in the calibration brief); 180-country FAERS (n=12,936,341) + WHO VigiBase pharmacovigilance; semaglutide FAERS ROR 11.12 (95% CI 8.15–15.16) / VigiBase ROR 68.58 (95% CI 16.75–280.67) significant ION association; tirzepatide signal absent at same threshold; class-differentiated finding. Post-approval exposure-window asymmetry caveat: semaglutide ~82 months vs tirzepatide ~28 months at study cutoff September 2024. Cited in scaffold calibration notes, §3.7, §6.5.a, §10.1 Anchor 4, §10.5, §10.6.
Buckley AJ, Conaglen JV, Lipschitz JD, et al. Tirzepatide use and new-onset diabetic retinopathy: a matched retrospective cohort study. Diabetologia 2025. PMID 40637847. Buckley 2025 RWE; retrospective matched cohort n=6,869 (3,435 tirzepatide-exposed matched 1:1 with 3,434 unexposed); overall multivariate analysis OR 2.15 (95% CI 1.24–3.74) for new-onset PDR, signal “particularly evident” per authors in R1M1 / moderate-severe NPDR baseline; in patients without retinopathy at baseline OR 0.73 (95% CI 0.62–0.86) protective. Baseline-status-stratified Pattern V direction-of-effect finding. Cited in §2.3, §3.3, §3.7, §6.5.b.
Parker CH, Jeffery RM, Yousefi S, et al. Maternal and fetal outcomes associated with GLP-1 receptor agonist exposure during pregnancy: a pooled analysis. Diabetes Obes Metab 2025;27(8):4102-4108. PMID 40329607. Parker 2025; pooled review of unplanned pregnancies from FDA- and EMA-submitted GLP-1 RA + dual-incretin coagonist regulatory trials including tirzepatide; incidence of congenital abnormalities appears relatively low; sample limited; authors call for prospective pregnancy registries. Pattern Z anchor 3 load-bearing human pregnancy-exposure data. Cited in §8.4, §8.7, §10.1 Anchor 3, §10.4.
Popovic DS, Papanas N, Pantea Stoian A. Tirzepatide and diabetic retinopathy: a perspective from SURPASS clinical trial program. Diabetes Obes Metab 2024;26(6):2497-2500. PMID 38456523. Popovic 2024; Letter / commentary on SURPASS retinopathy data; commentary-tier evidence (publication type = Letter, not pooled meta-analysis); the underlying SURPASS controlled-trial-population pooled retinopathy data anchor is Rosenstock 2023 Diabetes Care. Cited in §2.3, §6.5.b.
Hathaway JT, Shah MP, Hathaway DB, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol 2024;142:732-739. PMID 38958939. Hathaway 2024; single-center matched cohort; HR 4.28 in T2D + obesity / HR 7.64 in overweight/obese — semaglutide-exposed, not tirzepatide. Class-context for the NAION class-differentiation conversation at §6.5.a + §10.5. Cited in §6.5.a, §10.5.
Grauslund J, Hindkjær KK, Hansen JR, et al. Semaglutide-associated nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes — a 5-year nationwide cohort study. Int J Retina Vitreous 2024. PMID 39696569. Grauslund 2024; Danish nationwide 5-year longitudinal cohort n=424,152 T2D; HR 2.19 (95% CI 1.54–3.12) for NAION in semaglutide-exposed; tirzepatide exposure not analyzed due to limited Danish tirzepatide uptake during the period. Cited in §6.5.a.
Cheng X, Liu Y, Hu Y, et al. Semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: a multi-database pharmacovigilance study. J Endocrinol Invest 2026;49(2):425-433. PMID 41021211. Cheng 2026; multi-database FAERS + VigiBase pharmacovigilance confirming semaglutide-NAION signal. Cited in §6.5.a.
Bezin J, Pariente A, Faillie J-L, et al. GLP-1 receptor agonist exposure and risk of suicidality: a French case-time-control study. EClinicalMedicine 2025. PMID 39844933. Bezin 2025; French nationwide case-time-control GLP-1 RA use and suicide / suicide attempt; OR 0.62 (95% CI 0.51–0.75) protective direction; DPP-4 inhibitor negative-control OR 0.75; authors’ conclusion “reassurance about the short-term psychiatric safety of GLP-1 RA.” Cited in canonical §12.6; class-level context for the protocol’s suicidality framing in counseling.

Class-context and comparator citations (subset for §10.5 multi-dimensional comparator framing):

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221-2232. PMID 37952131. NCT03574597. SELECT; semaglutide CV outcomes in non-diabetic obesity + CVD; HR 0.80 for 3-point MACE. Cited in §10.5 (semaglutide comparator).
Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121. PMID 38785209. NCT03819153. FLOW; semaglutide kidney outcomes in T2D + CKD; primary kidney composite HR 0.76. Cited in §10.5 (semaglutide comparator).
Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med 2025;392:2089-2099. PMID 40305708. NCT04822181. ESSENCE; semaglutide MASH F2/F3 anchor; FDA-approved August 15, 2025. Cited in §10.5 (semaglutide comparator MASH approval).
Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in Patients With Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med 2024;390:1394-1407. PMID 38587233. STEP-HFpEF DM; semaglutide HFpEF + obesity + T2D. Class-context for §10.5 HFpEF comparator (alongside the 4-trial pooled analysis below).
Kosiborod MN, Verma S, Borlaug BA, et al. Effects of semaglutide on heart failure outcomes in obesity with and without type 2 diabetes: a pooled analysis of four randomised trials. Lancet 2024. PMID 39222642. Pooled 4-trial semaglutide HF analysis (SELECT + FLOW + STEP-HFpEF + STEP-HFpEF DM, n=3,743); HR 0.69 for CV death or worsening HF. Class-context comparator to SUMMIT for HFpEF + obesity. Cited in §1.5, §10.5.
Wharton S, Pi-Sunyer X, Davies M, et al. Once-weekly semaglutide 7.2 mg for weight management in adults with overweight or obesity (STEP UP): a randomised, double-blind, placebo-controlled phase 3b trial. Lancet Diabetes Endocrinol 2025. PMID 40961952. STEP UP semaglutide 7.2 mg (Wegovy HD) trial; n=1,407; −18.7% at week 72. FDA approved Wegovy HD March 19, 2026. Cited in §10.5 (cross-trial context).

SURMOUNT-MMO (active, readout pending):

NCT05556512. Tirzepatide for cardiovascular outcomes in obesity (SURMOUNT-MMO). Phase 3 ACTIVE_NOT_RECRUITING. Primary completion: 2027-10. SURMOUNT-MMO; CV outcomes trial in obesity + CVD or CV risk factors; analogue to semaglutide SELECT for tirzepatide. Readout pending per Pattern AA precision. Cited in §1.5, §3.6, §10.5.

Pattern AB.4 standing-scan applied to §11.5. Every PMID and NCT in this representative subset has been content-verified by abstract retrieval (PMID) or ClinicalTrials.gov entry retrieval (NCT) at the canonical’s PSV iteration 1 and 2. The cascade-failure pattern (NCT05608252 mis-attributed as TRIUMPH-1 in the AC2-26 system-observations log) is the failure mode this verification prevents.

12. Clinical decision tree

12.1 Purpose

Define a phenotype-guided decision tree that integrates Sections 1–11 into a single navigable clinical-workflow reference for tirzepatide. Section 12 is the operational summary that a clinician reaches for at point-of-care: should this patient be on tirzepatide, at what indication and brand (Mounjaro vs Zepbound), what is the starting and target dose, what is the monitoring cadence, what are the off-ramps.

Section 12 is rendered as a markdown decision matrix (table-based) plus an ASCII flowchart for the high-level decision branches. The decision tree is not authority — it summarizes the authoritative content in Sections 1–11; if the decision tree and a Section 1–11 sub-block disagree, the Section 1–11 content is canonical.

12.2 High-level decision flowchart (ASCII)

                  PATIENT PRESENTS
                         |
                         v
              [Section 1] Indication scope
              - T2D / CWM / OSA-with-obesity / HFpEF / MASH / CV / CKD / pediatric T2D?
              - Brand: Mounjaro (T2D) or Zepbound (CWM, OSA-with-obesity)?
                         |
                         v
              [Section 2] Selection criteria
              - Inclusion criteria met?   --> NO  --> Out of protocol
              - Relative exclusion?       --> Clinician judgment
              - Hard contraindication?    --> YES --> Out of protocol
                         |
                         v (Inclusion met, no contraindication)
              [Section 3] Pre-treatment workup
              - Standard metabolic + indication-specific panels
              - Organ-baseline (thyroid, pancreas, ophthalmology)
              - Body composition baseline (CWM); sleep-medicine baseline (OSA)
              - NAION individual-risk-factor assessment (not population-routine)
                         |
                         v
              [Section 4] Initiation
              - 2.5 mg starting dose; 4-week steps to max-tolerated
              - Standard pace (16-20 weeks to 15 mg) OR slow-titration (6-8 week steps)
              - Early monitoring cadence; GI tolerability management
                         |
                         v (Target dose attained)
              [Section 5] Maintenance
              - Target dose held; quarterly Y1, biannual thereafter
              - SURMOUNT-4 chronic-therapy framing
              - Indication-specific monitoring panel
                         |
                         v
              [Section 6/7/8] Branch points
              - AE emerges? --> Section 6 AE-class algorithm
                (NAION confirmed = permanent discontinuation; pancreatitis confirmed = permanent)
              - Plateau / non-response? --> Section 7 algorithm
                (within-class transition options limited; cross-class options Phase 3 pending)
              - Discontinuation trigger? --> Section 8 taper / framing
                (~16-week taper; SURMOUNT-4 +14% regain trajectory framing)
                         |
                         v
              [Section 9] Combination decisions
              - Within-Module-5 (SGLT-2 in T2D; insulin reduction at initiation)
              - Cross-Module (lean-mass stacks M5.5/M5.6; tesamorelin off-label)
              - Contraindicated: within-class concurrent agents avoided
              - No tirzepatide-class combo products available
                         |
                         v
              [Section 10] Counseling beats
              - Pattern Z 5-anchor compliance at every conversation
              - NAION class-differentiation precision in comparator conversation
              - Compounded tirzepatide narrower-scope post Oct 2024 regulatory context
                         |
                         v
              [Section 11] All claims source-anchored
              - Tier 1 / 1.5 / 2 / 3 evidence hierarchy
              - Pattern AB.4 identifier-integrity standing scan
                         |
                         v
              [Appendix A] Verification gate self-audit
              - §6.5 + §10.5 NAION class-differentiation precision check
              - §11 PMID/NCT verified against canonical's PSV chain
              - §3 panels vs §6 AE triggers Pattern W reconciliation

12.3 Phenotype-guided decision matrix

Phenotype dimension	Pattern	Tirzepatide fit	Within-class alternatives	Cross-class additions
Indication = T2D, HbA1c 7.0–9.0	SURPASS-2 anchored	Mounjaro 5–15 mg titration	Semaglutide if oral platform preferred or NAION-risk-context	SGLT-2 if CKD/CV; pioglitazone if MASH co-indication
Indication = T2D + CKD, eGFR 25–75	SURMOUNT-CKD pending; FLOW class-context	Mounjaro 5–15 mg + SGLT-2 (well-supported additive)	Semaglutide if FLOW-anchor preferred	RAS blockade maximally tolerated
Indication = T2D + ASCVD	SURMOUNT-MMO pending; SUMMIT class-context	Mounjaro 5–15 mg	Semaglutide if SELECT-anchor preferred	SGLT-2 for additive CV; statins, antiplatelets standard
Indication = CWM, non-diabetic, BMI ≥30	SURMOUNT-1 / SURMOUNT-5 anchored	Zepbound titration to 15 mg	Semaglutide 2.4 mg / 7.2 mg if patient prefers (lower expected weight loss per SURMOUNT-5)	Lean-mass stack M5.6 if lean-mass-loss concern
Indication = CWM, BMI 27–30 + comorbidity	SURMOUNT-1 sub-population	Zepbound titration	Semaglutide 2.4 mg / 7.2 mg	Behavioral / IBT intensification (SURMOUNT-3 additive)
Indication = CWM, intensive lifestyle bridge	SURMOUNT-3 anchored	Zepbound 10–15 mg post-lead-in	Semaglutide post-IBT (cross-trial extrapolation)	Intensive lifestyle intervention (foundational)
Indication = OSA, moderate-severe + obesity	SURMOUNT-OSA anchored	Zepbound — first FDA-approved pharmacological agent for OSA + obesity (December 2024)	Semaglutide is research-state for OSA, no FDA-approved OSA indication	Sleep medicine specialist co-management; CPAP continued unless AHI resolution per follow-up sleep study
Indication = HFpEF + obesity	SUMMIT anchored (off-label; regulatory pathway pending)	Zepbound off-label; heart-failure specialist co-management	Semaglutide STEP-HFpEF / pooled HF analysis class-context	KCCQ-CSS, 6MWT, NT-proBNP monitoring
Indication = MASH F2/F3	SYNERGY-NASH Phase 2 anchored (off-label; Phase 3 in development)	Tirzepatide off-label; hepatology co-management	Semaglutide ESSENCE F2/F3 approved (Aug 2025) — FDA-approved alternative	Resmetirom (Rezdiffra, FDA-approved 2024) — non-GLP-1 alternative
Indication = CV risk, BMI ≥27 + CVD	SURMOUNT-MMO active (off-label pending readout 2027-10)	Tirzepatide off-label; informed consent	Semaglutide SELECT-anchored is FDA-approved alternative	Standard-of-care CV management (statins, RAS, antiplatelet)
Indication = pediatric T2D ages 10–17	SURPASS-PEDS anchored (off-label; FDA pathway pending)	Tirzepatide off-label; pediatric endocrinology co-management	Semaglutide off-label adolescent T2D	Reproductive-age contraception counseling (post-menarcheal females)
Phenotype: severe gastroparesis	Hard contraindication per label	OUT OF PROTOCOL	Non-GLP-1 alternative (SGLT-2, metformin)	Behavioral / surgical bariatric pathway
Phenotype: MTC / MEN-2 personal/family hx	Hard contraindication — FDA boxed warning	OUT OF PROTOCOL	Non-GLP-1 alternative	Per indication; behavioral / bariatric pathway
Phenotype: pre-conception planning	Anchor 3 framing	Mounjaro/Zepbound with 8-week pre-conception washout per label	Same arithmetic for all GLP-1 RAs + dual-incretin coagonists	Pre-pregnancy counseling pathway; backup non-oral contraception
Phenotype: reproductive-age + active pregnancy	Hard contraindication (Category X-equivalent)	Immediate discontinuation, OB co-management	Same — all class members pregnancy-contraindicated	Pre-pregnancy / post-pregnancy reinitiation per §8.6
Phenotype: lean-mass concern (older adult, athletic)	M5.6 stack consideration	Zepbound 10–15 mg + CJC-Ipamorelin per M5.6 v3	Semaglutide + M5.6 (cross-trial)	Resistance training program co-prescription
Phenotype: cost / access barrier — compounded tirzepatide	Anchor 1+2 framing; narrower-scope post Oct 2024	Compounded tirzepatide where current regulatory state permits; salt-form transparency (base vs sodium)	Compounded semaglutide (broader regulatory scope; verify current FDA state)	Insurance-pathway counseling; Lilly direct-pay programs
Phenotype: prior semaglutide non-response	Section 7 transition	Tirzepatide is the within-class higher-effect transition target (SURMOUNT-5 + SURPASS-2 head-to-head superiority)	Cross-class options (retatrutide / MariTide / CagriSema) Phase 3 pending	IBT intensification (SURMOUNT-3 additive)
Phenotype: prior tirzepatide non-response at 15 mg	Section 7 algorithm	Out of tirzepatide; cross-class transition	Semaglutide is direction-of-effect-attenuated per head-to-head; not the right move typically	Cross-class Phase 3 pending; behavioral / bariatric pathway
Phenotype: NAION risk factors (disc-at-risk; prior NAION)	§6.5.a clinical-judgment	Tirzepatide signal absent at population threshold per Lawrenson 2025; individual-patient risk assessment per ophthalmology	Semaglutide is contraindicated post-NAION given documented class signal	Non-GLP-1 alternative if individual risk substantial
Phenotype: R1M1 / moderate-severe NPDR baseline T2D	§3.7 + §6.5.b clinical-judgment	Ophthalmology pre-screening + co-management per Buckley 2025 RWE; clinician judgment	Semaglutide similar class-level retinopathy concern	Gradual titration to mitigate rapid HbA1c improvement

12.4 Worked example — tirzepatide phenotype-guided decision tree application

A 53-year-old female presents with BMI 36, T2D (HbA1c 8.6), known ASCVD (prior MI 4 years ago, on statin and antiplatelet), moderate OSA (AHI 22) on CPAP with good adherence, mild non-proliferative diabetic retinopathy without maculopathy on recent ophthalmology exam, eGFR 64, UACR 120 mg/g, no MTC / MEN-2 family history, no pancreatitis history, no gastroparesis, no active pregnancy, not planning conception (post-menopausal).

Decision-tree walkthrough.

Step 1 — Indication scope. Multiple tirzepatide indications apply: T2D (HbA1c 8.6 above target — Mounjaro); CWM (BMI ≥27 with comorbidities — Zepbound); OSA-with-obesity (moderate OSA on CPAP — Zepbound OSA indication); off-label CV risk reduction in obesity (SURMOUNT-MMO pending — clinical-judgment with informed consent per §10.6). This is a polycondition phenotype. Brand selection: Mounjaro is the T2D-indication-labeled brand; Zepbound is the CWM and OSA-with-obesity-labeled brand. Practical prescribing depends on payer policy and indication priority — for a polycondition T2D + obesity + OSA patient, the prescriber selects per primary indication and per coverage; both deliver the same tirzepatide active drug.

Step 2 — Selection criteria. Inclusion criteria met for T2D, CWM, OSA-with-obesity indications. No hard contraindications. Relative consideration: R1M1-baseline-stratified retinopathy concern per Buckley 2025 RWE — patient has mild NPDR without maculopathy (not R1M1; the lower-risk DR stratum). Ophthalmology pre-treatment and gradual-titration are protocol-recommended; not exclusion.

Step 3 — Pre-treatment workup. Full panel: standard metabolic (§3.2), diabetes-specific (§3.3) including HbA1c, fasting C-peptide, dilated retinal exam (HbA1c 8.6 → exam confirmation; mild NPDR documented), UACR documented (already noted), CV-risk panel (§3.6) including ECG and lipid panel, kidney baseline (§3.5) — RAS-blockade documentation; if patient is on RAS-blockade at maximally tolerated dose, this is satisfied. Sleep-medicine baseline (§3.9) — AHI confirmed, ESS, CPAP-status documented (CPAP-current per Trial 2 SURMOUNT-OSA phenotype). Organ-baseline (§3.7) — TSH, lipase, ophthalmology pre-screen for NAION risk factors (patient does not have known optic-disc cupping, prior NAION, or unexplained visual symptoms — NAION risk assessment per individual-risk-factor approach, not population-routine). Body-composition baseline (§3.8) — DEXA.

Step 4 — Initiation. Mounjaro selected for T2D + polycondition mix at this practice (clinician judgment within label; both Mounjaro and Zepbound deliver tirzepatide for this polycondition phenotype). Starting 2.5 mg weekly per §4.6 titration schedule; standard pace given good baseline tolerability profile and absence of severe GI risk factors.

Step 5 — Maintenance. Target dose individualized within 10–15 mg range; for T2D + obesity polycondition, 10 or 12.5 mg is the typical maintenance plateau. Quarterly Y1, biannual thereafter. HbA1c at Month 4, 7, 10, 13 in Y1. UACR annually. eGFR quarterly Y1. Lipid panel annually. Weight + BP at every visit. Follow-up sleep study scheduled at Week 52 per SURMOUNT-OSA methodology for OSA-context AHI reassessment; sleep medicine specialist co-management for CPAP-modification decision if AHI improves.

Step 6 — Branch points. Anticipated AE profile per §6.3 — manage as standard. Particular attention to retinopathy progression in the mild-NPDR-baseline subgroup per §6.5.b — ophthalmology specialist co-management with serial fundoscopy. The class-differentiated NAION finding per Lawrenson 2025 per §6.5.a — tirzepatide signal absent at population threshold; individual NAION risk factors absent in this patient; standard ophthalmology baseline.

Step 7 — Combination decisions. Patient should also be on RAS-blockade (already confirmed) and statin (already confirmed). Consider adding SGLT-2 inhibitor for additive CV and kidney benefit per §9.2; SGLT-2 + tirzepatide combination is well-supported. CPAP continues unless follow-up sleep study supports modification.

Step 8 — Counseling beats. Initiation conversation per §10.2. Comparator conversation per §10.5 — present semaglutide as within-class alternative; multi-dimensional fact-based framing including SURMOUNT-5 head-to-head + the additional dimensions (SELECT done for semaglutide; SURMOUNT-MMO pending for tirzepatide; FLOW done for semaglutide; SURMOUNT-CKD pending for tirzepatide; ESSENCE MASH approved for semaglutide; SUMMIT HFpEF + obesity done for tirzepatide; SURMOUNT-OSA OSA approved for tirzepatide; NAION class-differentiation absent for tirzepatide at same threshold with post-approval exposure-window caveat). Pregnancy-planning conversation not applicable (post-menopausal). Compounded-vs-FDA-approved conversation per practice convention with the narrower-scope post-October-2024 regulatory context.

Step 9 — Source citations. All claims above traced to §11.5 Bibliography subset: SURMOUNT-1, SURMOUNT-5, SURPASS-2, SURMOUNT-OSA, SUMMIT, Buckley 2025, Lawrenson 2025, Parker 2025 (PK arithmetic context for pre-conception not applicable here but counseling framework is anchored). Effect-size anchors precise per Pattern V; PMID/NCT verified per Pattern AB.4.

Step 10 — Verification gate. Per Appendix A self-audit, this protocol application passes the §6.5 + §10.5 NAION class-differentiation precision check; §11 PMID/NCT verified against canonical’s PSV chain; §3 panels vs §6 AE triggers Pattern W reconciliation passes.

Pattern Z calibration self-audit at §12.4. The decision-tree walkthrough presents the patient’s options factually with trial-anchored effect-size estimates; the polycondition phenotype is anchored to multiple FDA-approved tirzepatide indications without inflating cross-indication benefit; the SGLT-2 + tirzepatide combination is presented as standard polycondition regimen (Pattern Z compliant — what the combination IS for this phenotype); the comparator framing presents semaglutide as an alternative with multi-dimensional fact-based comparison including the NAION class-differentiation precision without steering toward or away from tirzepatide; the off-label / extrapolation transparency is not triggered for the primary indications (T2D, CWM, OSA-with-obesity all FDA-labeled) but the CV-context counseling notes SURMOUNT-MMO pending.

Appendix A. Verification gate self-audit findings

Per the calibration brief verification-gate task list, this Appendix documents the self-audit findings the production agent ran on protocol completion.

A.1 §10 framing-discipline diff against canonical Anchors 1–5

Anchor 1 (compounded operational characteristics — what the option IS). §10.3 opens with “Compounded tirzepatide is a real-world clinical option used by a substantial patient population.” Verbatim-mirror of the canonical §8.3.2 lead. Operational characteristics (lyophilized vial format, reconstitution, salt-form variability) framed as “factual scope, not deficit framing.” PASS — verbatim-mirror of canonical anchor with tirzepatide-specific salt-form translation.

Anchor 2 (compounded vs FDA-approved patient-counseling beat). §10.3 patient-counseling beat: “Compounded tirzepatide is a real clinical option used by many patients. The operational differences from Mounjaro or Zepbound are real — different format that requires reconstitution, different oversight pathway, different storage. Costs are typically lower, and the patient self-administration is similar to insulin self-injection. Some compounded preparations use the sodium-salt form rather than tirzepatide base; that’s a different chemical and matters for dose comparison. If you’re considering it, let’s review the specific compounding pharmacy’s quality practices — sterility testing, certificate of analysis with salt-form, accreditation — and walk through reconstitution training together. That’s how the decision gets made well.” PASS — verbatim-mirror with tirzepatide-specific salt-form transparency addition; affirming open + shared-decision-making close preserved.

Anchor 3 (pregnancy section research-state-leading structure). §10.4 LEADS with “Human pregnancy-exposure data — Parker 2025 (PMID 40329607).” Pharmacokinetic facts (~5-day half-life), label recommendation (8-week pre-conception window), animal data context (Category X-equivalent), post-discontinuation weight-regain trajectory (SURMOUNT-4) appear AFTER the research-state lead. PASS — research-state-leading structure preserved; Parker 2025 leads; PK + label + animal-data follow in scoped factual context.

Anchor 4 (multi-dimensional comparator framing). §10.5 presents 10+ dimensions: weight magnitude (SURMOUNT-5 head-to-head; SURMOUNT-1 cross-trial; STEP UP 7.2 mg cross-trial), T2D HbA1c (SURPASS-2 head-to-head), CV outcomes (SELECT done for sema; SURMOUNT-MMO active for tirz), HFpEF + obesity (SUMMIT done for tirz; pooled semaglutide HF comparable class-level), MASH approval (ESSENCE approved for sema; SYNERGY-NASH Phase 3 in development for tirz), kidney outcomes (FLOW done for sema; SURMOUNT-CKD pending for tirz), OSA approval (tirzepatide approved December 2024; semaglutide research-state), NAION class-differentiation (Lawrenson 2025 PMID 40383360 signal absent for tirz at same threshold as sema’s significant signal; post-approval exposure-window asymmetry caveat; mechanism research-state), GI tolerability, route / platform (semaglutide has oral; tirzepatide does not), cost / access. Patient-counseling beat opens with affirmation of both compounds, acknowledges tirzepatide’s weight-magnitude advantage explicitly, closes with shared-decision-making invitation. PASS — multi-dimensional fact presentation with NAION class-differentiation precision; verbatim-mirror with tirzepatide-specific dimensions (OSA approval, SUMMIT HFpEF, NAION class-differentiation, route).

Anchor 5 (off-label / extrapolation framing). §10.6 presents trial-population scope as fact (SURMOUNT obesity; SURPASS T2D; SUMMIT HFpEF + obesity; SURMOUNT-OSA OSA + obesity); frames extrapolation as research-state-incompleteness, not as “no” answer; explicit off-label labeling; informed-consent acknowledgement; shared-decision-making invitation close. The microdosing-for-longevity counseling beat includes the NAION class-differentiation precision (the class-differentiated NAION finding for semaglutide doesn’t extend to tirzepatide at the same threshold, with post-approval exposure-window caveat). PASS — research-state-incompleteness framing preserved; tirzepatide-specific dimensions added.

Every PMID and NCT in §11.5 was content-verified through the canonical’s PSV iteration 1 (HALT #8; 11 discrepancies caught + 5 cascade-5+ corrections applied) and iteration 2 (clean post-patch with 0 new findings). Key verified identifiers in this protocol’s subset:

PMID 35658024 (SURMOUNT-1) — verified
PMID 37385275 (SURMOUNT-2) — verified
PMID 38078870 (SURMOUNT-4) — verified
PMID 40353578 (SURMOUNT-5) — verified
PMID 34170647 (SURPASS-2) — verified
PMID 40975112 (SURPASS-PEDS) — verified
PMID 38912654 (SURMOUNT-OSA) — verified
PMID 39555826 (SUMMIT) — verified
PMID 30473097 (Coskun mechanism) — verified
PMID 38856224 (SYNERGY-NASH Phase 2) — verified
PMID 41359966 (Ko 2026 cancer SR) — verified
PMID 40988099 (Wen 2025 pancreatitis SR) — verified
PMID 40383360 (Lawrenson 2025 / Lakhani et al ION class-differentiation) — verified
PMID 40637847 (Buckley 2025 retinopathy RWE) — verified
PMID 40329607 (Parker 2025 pooled pregnancy-exposure) — verified
PMID 38456523 (Popovic 2024 SURPASS retinopathy Letter) — verified
PMID 38958939 (Hathaway 2024 semaglutide NAION) — verified
PMID 39696569 (Grauslund 2024 Danish nationwide cohort) — verified
PMID 41021211 (Cheng 2026 multi-database FAERS+VigiBase) — verified
PMID 39844933 (Bezin 2025 GLP-1 + suicidality) — verified
PMID 37952131 (SELECT) — verified
PMID 38785209 (FLOW) — verified
PMID 40305708 (ESSENCE) — verified
PMID 38587233 (STEP-HFpEF DM) — verified
PMID 39222642 (4-trial pooled semaglutide HF) — verified
PMID 40961952 (STEP UP semaglutide 7.2 mg) — verified
NCT05556512 (SURMOUNT-MMO) — verified

PASS — all PMIDs and NCTs in protocol §11.5 inherit the canonical’s verified chain.

A.3 §3 panels vs §6 AE triggers reconciled (Pattern W)

Pattern W cross-section consistency check ran end-to-end. Reconciliation pairs:

Thyroid: §3.7 TSH baseline + neck exam ↔︎ §2.4 MTC / MEN-2 contraindication ↔︎ §6.2 class-level black box. Reconciled.
Pancreas: §3.7 lipase + amylase baseline ↔︎ §2.3 pancreatitis history relative exclusion ↔︎ §6.6 pancreatitis AE class symptom-prompted reassessment. Reconciled.
Ophthalmology — NAION: §3.7 individual-risk-factor assessment ↔︎ §6.5.a NAION class-differentiation precision ↔︎ §10.5 comparator conversation NAION dimension. Reconciled.
Ophthalmology — diabetic retinopathy: §3.3 + §3.7 dilated retinal exam in T2D + R1M1 / moderate-severe NPDR baseline attention ↔︎ §6.5.b Buckley 2025 RWE baseline-status-stratified finding ↔︎ §2.3 relative exclusion for rapid-HbA1c-improvement risk. Reconciled.
Renal: §3.2 CMP + §3.5 kidney-specific panel ↔︎ §2.3 eGFR <15 relative exclusion ↔︎ §5.3 quarterly eGFR monitoring in CKD context. Reconciled.
Hepatic / MASH: §3.4 MASH-specific panel ↔︎ §10.6 MASH off-label framing ↔︎ §5.3 LFT + non-invasive fibrosis monitoring in MASH context. Reconciled.
Cardiovascular / HFpEF: §3.6 CV-risk panel including NT-proBNP, echocardiogram, KCCQ-CSS, 6MWT ↔︎ §10.6 HFpEF off-label framing ↔︎ §5.3 KCCQ-CSS + 6MWT + NT-proBNP monitoring in HFpEF context. Reconciled.
Sleep medicine / OSA: §3.9 sleep-medicine baseline (AHI, ESS, CPAP-status) ↔︎ §1.5 SURMOUNT-OSA indication framing ↔︎ §5.3 follow-up sleep study at Week 52. Reconciled.
GI / pancreatitis differentiation: §3.7 lipase baseline ↔︎ §6.3 GI AE class anticipatory framing + §6.6 pancreatitis identification (severity, persistence, localization differentiate from GI AE). Reconciled.

PASS — Pattern W cross-section consistency verified end-to-end.

A.4 NAION class-differentiation correctness: signal-absent precision in §6.5 + §10.5

The class-differentiation precision was checked verbatim across the three protocol locations:

Scaffold calibration notes — class-differentiation finding (signal-presence semaglutide, signal-absence tirzepatide at same threshold; post-approval exposure-window asymmetry caveat; mechanism research-state-incomplete) — PASS.
§3.7 ophthalmology pre-screen — NAION pre-treatment framing: class-differentiated finding does not mandate routine population NAION pre-screen; clinical assessment of individual NAION risk factors remains appropriate; Pattern AA precision — does NOT claim “tirzepatide is safer than semaglutide on eyes.” PASS.
§6.5.a NAION AE class — full class-differentiation table (semaglutide FAERS ROR 11.12 / VigiBase ROR 68.58 significant; tirzepatide not significant at same threshold; signal-absent precision); post-approval exposure-window asymmetry caveat (semaglutide ~82 mo vs tirzepatide ~28 mo at September 2024 cutoff); absent-signal-at-threshold ≠ absent-signal-in-population; mechanism hypotheses (GIPR co-agonism, biased-affinity profile, other compound-specific factors) framed as research-state-incomplete and hypothesis-generating only. PASS.
§10.5 comparator conversation — NAION class-differentiation dimension precisely framed; counseling beat: “The eye-nerve signal NAION has been documented for semaglutide in pharmacovigilance studies covering 180 countries; the same studies looked at tirzepatide at the same threshold and didn’t find a signal — a real class-differentiation, though the shorter post-approval exposure for tirzepatide means absent-signal-at-threshold doesn’t equal absent-signal-in-population.” PASS.
§10.6 off-label / extrapolation conversation — microdosing-for-longevity counseling includes “the class-differentiated NAION finding for semaglutide doesn’t extend to tirzepatide in pharmacovigilance data at the same threshold, but the shorter post-approval exposure for tirzepatide means absent-signal-at-threshold doesn’t equal absent-signal-in-population.” PASS.

PASS — class-differentiation precision verbatim-consistent across §3.7, §6.5.a, §10.5, §10.6, and scaffold calibration notes.

A.5 Compound-specific calibration items

Dual GIP/GLP-1 mechanism framing: verified throughout scaffold, §1.3, §2.2, §3.7 (GIP-axis-specific organ-baseline framing), §6.5.a NAION mechanism hypotheses, §6.7 hypoglycemia, §6.10 immunogenicity, §10.1 Anchor 4. Mechanism-precision-driven section architecture, not single-receptor-template-borrowed. PASS.
MASH / CV development pipeline framing: SURMOUNT-MMO labeled “Phase 3 ACTIVE_NOT_RECRUITING, primary completion 2027-10, readout pending” throughout — NOT “approved-pending” or “promising/emerging.” SYNERGY-NASH Phase 2 → Phase 3 in development. HFpEF + obesity regulatory pathway in active discussion; not yet FDA-labeled. Pattern AA precision preserved. PASS.
Compounding ecosystem calibration: narrower scope post October 2024 FDA shortage-list removal; salt-form differentiation (base vs sodium); active FDA enforcement + ongoing litigation context. Distinct from semaglutide’s broader compounding-ecosystem framing. PASS.
Route precision: SC injection only; no oral platform as of 2026-05-13; §10.5 comparator conversation flags this dimension explicitly. PASS.
Pattern N.1 (peptide path, not small-molecule path): file located at /Protocols/ under the peptides folder structure; scaffold frames Pattern N.1 explicitly. PASS.

Appendix B. Pattern discipline summary

The full Pattern discipline audit (Protocol Template Appendix B) applied to this tirzepatide protocol:

Pattern R / R.1 / R.2: every section opens with research-state content (Section 1 indication scope leads; Section 2 inclusion criteria lead; Section 6 anticipatory framing leads); section ordering design-time-locked; framing discipline applied at design step. PASS.
Pattern V: every effect-size claim has primary-source anchor and population qualification — SURMOUNT-1 −22.5% efficacy estimand qualified to non-diabetic obesity BMI ≥30 enrollment; SURMOUNT-2 −14.7% qualified to obesity + T2D; SURMOUNT-5 −20.2% qualified to non-diabetic obesity head-to-head; SURPASS-2 HbA1c reductions qualified to T2D inadequately controlled on metformin; SUMMIT HR 0.62 qualified to HFpEF + obesity; SURMOUNT-OSA AHI reductions qualified per CPAP-naive vs CPAP-current; SYNERGY-NASH Phase 2 MASH resolution qualified to F2/F3; Buckley 2025 OR 2.15 vs OR 0.73 qualified per baseline-retinopathy stratification; Lawrenson 2025 ION signal qualified to FAERS/VigiBase pharmacovigilance with post-approval exposure-window asymmetry caveat. PASS.
Pattern W: structural-count claims reconciled end-to-end (§3 panels vs §5 monitoring vs §6 AE triggers — Appendix A.3 audit); seven workup panels + tirzepatide-specific sleep-medicine baseline (§3.9) for OSA-with-obesity indication; three FDA-approved indications + five investigational extensions (§1.2). PASS.
Pattern Z: §10 self-audit against 5 anchors complete (Appendix A.1); cumulative-tone scan non-steering across §10.3 compounded conversation + §10.4 pregnancy conversation + §10.5 comparator conversation + §10.6 off-label conversation. Compound-specific translations (salt-form, narrower-scope compounding ecosystem, NAION class-differentiation, OSA approval) preserve the verbatim framing-discipline. PASS.
Pattern AA: every regulatory claim precise — three FDA-approved indications (T2D Mounjaro May 2022; CWM Zepbound November 2023; OSA-with-obesity Zepbound December 2024); investigational extensions (HFpEF, MASH, CV, CKD, pediatric T2D) labeled “in development” / “readout pending” / “regulatory pathway in active discussion”; class-level FDA boxed warning vs labeled contraindication vs labeled precaution vs post-marketing signal each labeled precisely; NAION class-differentiation framed as signal-absent at threshold + post-approval exposure-window asymmetry caveat + mechanism research-state — NOT “tirzepatide is safer than semaglutide on eyes.” PASS.
Pattern AB.1 / AB.2 / AB.4: PMID and NCT verification inherited from canonical’s PSV iterations 1+2 (Appendix A.2); standing scan complete; no cascade corrections identified for the protocol-specific subset beyond the canonical’s already-resolved cascades. PASS.
Pattern N.1: tirzepatide is a peptide (large molecule, SC); file path /Protocols/Tirzepatide Protocol.md under the peptides folder structure (parallel to canonical at /Peptides/Tirzepatide.md); NOT at /Small-Molecules/. PASS.

Appendix C. Items deferred to Dr. Gross verification gate

The following items are flagged for senior clinical-judgment review at the Dr. Gross verification gate (Protocol Template Appendix A Step 4) per the calibration brief’s verification-gate task list:

Tirzepatide brand-vs-formulation prescribing convention. This protocol’s §1.2 + §10.5 + §12.3 distinguishes Mounjaro (T2D) from Zepbound (CWM and OSA-with-obesity) per FDA label. For polycondition patients (e.g., the §12.4 worked example with T2D + obesity + ASCVD + OSA), the brand-selection decision in practice depends on payer policy, indication-priority, and access pathway. Dr. Gross verification gate: clinician-judgment-tier framing for the brand-selection decision in polycondition phenotypes — is the protocol’s framing (clinician selects per primary indication and per coverage; both deliver the same tirzepatide active drug) the right operational framing, or does it need refinement for practice-level clarity?
Slow-titration option timing in T2D + DR baseline subgroup. §4.3 slow-titration variant (6–8 week intervals) is framed as clinician-judgment within label for marginal GI tolerability. §6.5.b Buckley 2025 RWE retinopathy progression in R1M1 / moderate-severe NPDR baseline is hypothesized as rapid-HbA1c-improvement-mediated. Should the slow-titration variant be the protocol-recommended default for T2D + R1M1 / moderate-severe NPDR baseline patients (mitigation strategy), or is the standard titration with ophthalmology co-management sufficient? Dr. Gross verification gate: clinical-judgment review on the slow-titration default vs standard-titration-with-co-management decision for the R1M1 baseline phenotype.
NAION individual-risk-factor assessment depth in §3.7 pre-treatment. §3.7 frames NAION pre-treatment as individual-risk-factor assessment (not population-routine) given the class-differentiated signal-absent finding for tirzepatide. The individual risk factors enumerated (crowded optic disc / “disc-at-risk,” prior NAION in fellow eye, hypertension, sleep apnea, dyslipidemia) are standard ophthalmologic risk factors. Dr. Gross verification gate: is this individual-risk-factor screening depth appropriate for tirzepatide pre-treatment, or should the protocol be more or less aggressive on this dimension given the post-approval exposure-window asymmetry caveat?
F4 cirrhosis Pattern V class-context for tirzepatide. §2.3 + §3.4 reflect the class-context Pattern V flag from semaglutide Loomba 2023 F4 directional finding toward placebo (PMID 36934740); tirzepatide F4 data is not yet published. SYNERGY-NASH Phase 2 excluded F4. The protocol’s framing: F4 cirrhosis “not initiated absent hepatology specialist judgment given the class-context Pattern V flag.” Dr. Gross verification gate: is this appropriate caution, or should the framing be more permissive of clinical-judgment-driven F4 use given that the mechanism class is GLP-1/GIP coagonist (mechanistically distinct from single GLP-1R agonism that produced the Loomba directional finding)? The mechanism question is unresolved per canonical §4.8.
OSA-with-obesity counseling on CPAP-modification timing. §1.5 + §5.4 + §10.7 frame CPAP-modification or discontinuation as sleep-medicine-specialist-led decision based on follow-up sleep study + clinical assessment, with the protocol’s caveat that “tirzepatide does NOT replace CPAP for all patients with OSA.” Dr. Gross verification gate: is the protocol’s framing (which preserves CPAP as the default and flags tirzepatide as adjunct) the right operational framing for sleep-medicine-specialist co-management, or does it need refinement?
Cross-class transition options under §7.5 / §10.6 (retatrutide / MariTide / CagriSema) — investigational framing. Retatrutide TRIUMPH-4 topline (December 2025; −28.7% at 12 mg) is investor-disclosure pending peer-reviewed publication; MariTide Phase 3 active; CagriSema REDEFINE Phase 3 reported. None are FDA-approved as of 2026-05-13. The protocol’s framing: each is labeled “Phase 3 pending” or “Phase 3 readout reported, FDA submission status — check current” per Pattern AA precision. Dr. Gross verification gate: as readout dates approach and FDA actions occur during the protocol’s deployment lifecycle, the §7.5 / §10.6 framing should be re-validated against current FDA / regulatory state at each protocol-version revision; this is the standing-review-item that the gate verifies on each protocol revision.
Compounded tirzepatide salt-form transparency operational practice. §8.3.2 (canonical) and §10.3 (protocol) flag salt-form (tirzepatide base vs tirzepatide sodium) as a tirzepatide-specific quality-criterion for compounded supply. The certificate-of-analysis-with-salt-form expectation is in the patient-counseling beat. Dr. Gross verification gate: clinician-judgment-tier review on whether the salt-form transparency expectation in the counseling beat is operationally realistic for the current 503A / 503B compounding marketplace, or whether the framing should be modified to reflect what patients can actually obtain from compounding pharmacies in current FDA-enforcement state.
Section 12 decision matrix completeness. §12.3 phenotype-guided decision matrix has ~20 phenotype-row entries. Dr. Gross verification gate: review for completeness vs the typical practice patient panel — are there phenotype dimensions or polycondition combinations that should be added or refined? Adolescent CWM (pediatric obesity Phase 3 not yet published; not in matrix) is one specific item — should the matrix flag adolescent CWM as a “wait for Phase 3 readout” off-protocol entry, or omit entirely?

The above eight items represent the senior-clinician-judgment review surface area. The agent layers (production-agent draft per Appendix A.2 + PSV per A.3 + IAR per A.4) have prepared the protocol; the Dr. Gross gate authorizes delivery per Protocol Template Appendix A.5.

Tirzepatide Protocol